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Abstract: 
Five platinum-based compounds Cisplatin，Oxaliplatin, [Pt(DMC)(NH3)2], 
[ P t ( D M C ) ( N H 2 C H 3 ) 2 ] and [Pt(DMC)(i?,i?-DACH)] are used in this drug combination 
study. In combination with Demethylcantharidin (DMC), synergisms are 
demonstrated in both hepatocarcinoma (HCC) and Colorectal Cancer (CRC) cell 
lines. Combination Index (CI) and Dose Reductive Index (DRI) are employed to 
evaluate the efficiency of the drug combinations. All simultaneous and sequential 
drug combinations show synergism (CI < 1，DRI > 1) in both cancer cell lines. 
In both sensitive HCT116 colorectal cancer cell, platinum pretreated with DMC 
is the most effective drug combination. Similarly, in oxaliplatin-resistant (8 folds 
resistant) HCTl 16，platinum pretreatment produces the best synergistic effect. For 
sensitive SK-Hepl liver cancer cell, pretreatment with platinum concentration is the 
most effective treatment. However, in cisplatin-resistant SK-Hepl (15 folds resistant), 
concurrent treatment demonstrates the best synergistic effect. 
In combination with platinum drug, DMC can enhance the cytotoxic effect of 
platinum drug, i.e. toxic platinum drug dose can be reduced. In sensitive SK-Hepl, 
cisplatin and oxaliplatin can be reduced by 20- and 15-folds respectively. 
DMC-containing compound [Pt(DMC)(NH3)2]，[Pt(DMC)(NH2CH3)2] and 
[Pt(DMC)(/?,/?-DACH)] can also be reduce up to 16, 31 and 88 folds respectively. In 
cisplatin-resistant SK-Hepl, DMC enhances the cytotoxicity of platinum drugs by 2-
to 9- folds. In oxaliplatin-resistant HCTl 16，DMC effectively reduces the platinum 
dose by 2- to 7- folds. 
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1.1 A General Introduction to the Development and Clinical Activities of 
Platinum Drugs 
Cancer causes millions of deaths all over the world each year (Parkin et al 
2005). Over the last decades, extensive efforts had been devoted to the search of 
novel therapeutic methods or agents to combat against malignant disease. However, 
no complete success has ever been achieved. 
Chemotherapy is nowadays the core treatment for metastatic cancer. Clinically 
used chemotherapeutic drugs included alkylating agent (busulfan, cisplatin, 
cyclophosphamide, dacarbazine), antimetabolites (5-fluorouracil, mercaptopurine, 
methotrexate), antibiotics (doxorubicin, mitoxantrone), tubulin-active antimitotic 
agents (paclitaxel), advancing in the treatment of leukemia, lymphomas, breast 
cancer and ovarian cancer. In late 1970’s，cisplatin was found to have the broadest 
activity spectrum towards tumor and thus is widely used in cancer chemotherapy 
from then on, being particularly advance in the therapy of testicular cancer and solid 
tumor. In combination with other approved drugs such as bleomycin, doxorubicin or 
5-fluorouracil, cisplatin is used worldwide in the therapy of ovarian, cervical, head 
and neck cancer (Canetta et a/1987). However, toxicity issues arise and cancer recur 
with aggressive drug resistance. On the basis of the knowledge on cisplatin, 
alternative platinum-based antitumor drugs are synthesized. The most successful 
platinum-based derivative is carboplatin (lower toxicity) and oxaliplatin (higher 
potency). The former is used to treat patients with ovarian carcinoma recurrent after 
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prior cisplatin chemotherapy and the latter is applied in combination with 
5-fluorouracil or leucovorin to treat metastatic colorectal cancer recurrent. In spite of 
this significant progress in chemotherapeutic platinum drugs, patients with liver and 
lung cancer are mostly fatal, with only 10% survival according to statistics prepared 
in 2002 (Parkin etal 2005). 
Upon the limitations of the existing drugs, chemists aimed to synthesize novel 
drugs by improving the old one and clinicians attempted to optimize the antitumor 
effect of the existing drugs through synergistic drug combinations. Combinational 
chemotherapy was first introduced clinically in mid-20^'' century 
(leucovorin/5-fIuorouracil) as a palliative treatment for patients with advanced 
colorectal cancer. Instead of using single drugs, combinational drug therapy can: 1) 
increase therapeutic efficacy; 2) decrease toxicity or unwanted side effects; 3) 
minimize or delay the development of drug resistance; and 4) achieve selective 
synergism. In this way, optimized drug action can be accompanied with manageable 
toxicity. 
The purpose of this work has to investigate the potential synergistic 
combinations of various platinum-based compounds with demethylcantharidin 
(DMC, CgHgOs). Several platinum-based compounds were used in this study 
including two clinically used drugs cisplatin and oxaliplatin, and three 
platinum-based compounds with DMC: [Pt(DMC)(NH3)2]’ [Pt(DMC)(NH2CH3)2] 
and [Pt(DMC)(/?,i?-DACH)] that were synthesized by our group previously (Ho et al 
2001). All of the newly synthesized compounds were composed of a DMC ligand 
and a platinum moiety, endothalate (the dianion form of DMC, 
7-Oxabicyclo(2,2,1 )heptane-2,3-dicarboxylic acid) would be dissociated upon 
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hydrolysis, in which it could exert its own cellular activity in addition to that induced 
by the activated platinum moiety. Drug combinations with the highest efficacy and 
the lowest toxicity were determined in this study and the potential clinical 
combination protocol discussed. It is possible that these combination regimens may 
play an important part in chemotherapy. 
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1.1.1 Platinum Drugs used in a Clinical Setting 
Cisplatin, a5-diamminedichloroplatinum(II), was the first platinum-based 
antitumor drug to be introduced in cancer chemotherapy. It was first discovered first 
time as a chemical compound in 1845 (Peyrone M. et al 1845). Its biological activity 
was unraveled accidentally in an electrical experiment in 1965, where cisplatin was 
formed as an electrolysis product from a platinum electrode, and the compound was 
found to inhibit mitosis in bacteria Escherichia coli. Later in 1969, cisplatin was 
demonstrated to induce tumor regression in sarcoma 180 and leukemia L1210 
implanted in mice (Rosenberg et al 1965, 1969). It was then introduced into clinical 
practice in 1972 where cisplatin became the foundation of curative regimens in 
testicular and ovarian cancers, and showed significant activity against cancers of the 
lung, head and neck, esophagus, bladder, cervix and endometrium. Furthermore, for 
patients who were no longer amenable to surgical or radiation therapy, cisplatin 
would be the choice. From fatal metastatic cancer to curable disease, cisplatin has 
made a remarkable improvement to the prognosis of solid tumors. 
C I \ p , N H 3 V y _ o , � N H 3 
C | Z � N H 3 O 
Figure 1.1.1 Cisplatin Figure 1.1.2 Carboplatin 
Carboplatin, d«y-diammine(l，1 -cyclobutanedicarboxylato)platinum(II), an 
analogue of cisplatin, was introduced into clinical trial in 1981 and has lower toxicity 
than cisplatin. Subsequently, it replaced cisplatin in the initial regimen of advanced 
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ovarian cancer or ovarian cancer recurrent since late 1990's. Unlike cisplatin, 
carboplatin had lowered both nephrotoxicity and ototoxicity, however, it caused 
substantial adverse myelosuppresive effects. The side effect induced by 
myelosuppression, unexpectedly, had been turned into something beneficial. 
Carboplatin had been used in treating acute myeloblastic leukemia or chronic 
myeloid leukemia (Meyer et al 1989, Dutcher et al 1998). Nonetheless, some may 
found that the myelosuppressive activity was more prominent than that of the 
remedial antiproliferative effect in leukemia (Su et al 2003). 
In recent years, oxaliplatin, [trans-{ 1 R,2R)-cyclohexane-1,2-diamine] 
oxalatoplatinum(II), has been approved in Europe, Asia, and Latin America for the 
treatment of metastatic colorectal cancer that is unresponsive to 5-fluorouracil based 
therapy. It has superior activity towards cisplatin resistant cancer and much lower 
toxicity. Its antitumor activity is different from that of cisplatin. Mismatch Repair 
(MMR) deficiency cells showed reduced cytoxicity with cisplatin but remained 
sensitive to oxaliplatin. 
Pt 
Figure 1.1.3 Oxaliplatin 
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1.1.2 Platinum Drugs under Clinical TVials 
Other potential platinum drugs were synthesized and successfully progressed to 
the clinical trials. Nedaplatin, cw-diamine(glycolato)platinum (II) was approved in 
Japan for the treatment of testis, head and neck, bladder, ovary, oesophagus and 
cervix cancer in 1995. In Korea, another platinum analogue, SKI 2053R was shown 
to overcome cisplatin resistance with reduced nephrotoxicity, which was now 
undergoing phase II clinical trial in stomach cancer. A platinum racemate, 
Cycloplatam was found to circumvent cisplatin resistant without observable 
neurotoxicity and nephrotoxicity, which was in phase II trial in the treatment of 
ovarian and breast cancer in former Soviet Union. In Europe, Lobaplatin remained 
sensitive to cisplatin resistant cancer in the absence of significant organ toxicity, now 
in phase III trial for the treatment of esophagus cancer (Lebwohl et al 1998). All 
these compounds had superior activity over cisplatin in terms of potency and 
cytotoxicity with far lower level of side effects. 
N H 3 \ / 0 丫 ^ ) 
/ P t / O ^ ^ N H ^ O ^ 
N H 3 / 、 。 〉 w 。 
Figure 1.1.4 Nedaplatin Figurel.1.5 SKI2053R 
O 门 , � � � � � � N \ H 2 / V 
II 一 Pt 
H s N 、 O - ^ ^V-oVh)。八。 
f V - N H ^ o V O H Q V I 
Figure 1.1.6 Cycloplatam Figure 1.1.7 Lobaplatin racemate 
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1.1.3 Platinum Compounds with Dual Mechanisms 
Some cisplatin derivatives targeted liver cancer by combining bile acids or their 
analogs with platinum moiety chemically, Bamet-R2 
(c/5-diamminechlorocholyglycinate platinum(II)) and Bamet-UD2 
(cw-diamminebis-ursodeoxycholate platinum(II)). Bile acids are circulated back and 
forth from the liver to the intestine. Hence it can act as a drug carrier by transferring 
the platinum moiety to the target tissues located in the enterohepatic circulation. By 
this strategy, active platinum drug can be retained in the target sites and harmfiil 
effects to other healthy tissues can be minimized. These derivatives were proved to 
have antitumor activity comparable to cisplatin but with lower in vivo toxicity 
(Criado et al 1997，2000, Marin et al 1998). 
H \ / N H , 
f Y OH o 
p 
OH 
Figure 1.1.8 cw-diamminechlorocholyglycinate platinum(II) (Bamet-R2) 
严 2 
OH 
Figure 1.1.9 cw-diamminebis-ursodeoxycholate platinum(II) (Bamet-UD2) 
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Another novel concept in designing platinum drugs is to combine the platinum 
moiety with biological active ligand/ligands. As a pioneer to test this novel idea, 
several compounds with different platinum moiety were chemically bound to the 
potential antitumor compound DMC. It was thought that the designated drug could 
kill cancer cells through dual mechanism individually exerted by platinum and DMC 
(Ho etalim). Three of which, [Pt(C8H805)(NH3)2]，[PKCgHsOsXNHzOHb)?] and 
[Pt(C8H805)(尺i?-DACH)] are analyzed and discussed here in the drug combination 
study. 
O O 
r / " W ^ � \ , 3 /NH^Me 
O Pt\ O Pt\ 
^ - J y ^ S ^ d N^Hg NHjMe 
0 O 





1.2 Platinum Drug Antitumor Mechanism 
In conventional cancer chemotherapy, cisplatin was administrated through 
intravenous injection. Once injected into the body, cisplatin was stabilized by the 
-O.IM chloride ion in the blood. After passing through the cell membrane with 
unknown mechanism, it reaches the cytoplasm where there is a drastic decrease in 
chloride ion concentration to 4 mM. It allowed the cisplatin to be hydrolysed into 
reactive diaquated species with two chloride ligands dissociated (Legendre et al 
2000). The faster rate of hydrolysis rendered cisplatin ten times more cytotoxic than 
carboplatin, the main reason was attributed to the higher aquation rates in which the 
activated species generated could interact with DNA more readily. (Knox et al 1986， 
Micetich etaimS) 
H P 厂 1+ H^ O 
C l \ ,NH3 I H p NH3 V . H2O NH3 
c|Z、nh3 a cr NH3 ) Hp NH3 
L. -J L _ 
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Figure 1.2.1 Equation for Hydrolysis of Cisplatin 
Once the platinum drug got into the cell and was chemically transformed to its 
active diaquated species. Platinum reacted with several kinds of sulphur-containing 
biomolecules in the cell before it encountered DNA. Plaitnum-binding biomolecules 
included amino acids Z-methionine and Z-cysteine, proteins glutathione and 
metallothionein, DNA nucleobases and their analogues. 
I-methionine and Z-cysteine are amino acids.丄-methionine possesses a 
thioether and Z-cysteine has a thiol as the sulphur-containing functional group. The 
Page 9 
former one is present as the free amino acid in the blood while the latter is mainly 
found in proteins, enzymes and small biomolecules, such as glutathione and 
metallothionein. GSH, figure 1.2.4，is one of the primary defense lines against toxins 
and oxidants in the cell. It can deactivate platinum drugs through irreversible binding 
(Eastman 1987). Cisplatin was found bind to four cysteine residues of 
metallothionein with other ligands removed (Pattanaik et al 1992). 
/ S o O 
NH3+ NH3+ 




人 - o 
Figure 1.2.4 Glutathione (GSH) 
DNA is the target of platinum drugs in which the main biological effect can be 
brought out. Studies in cisplatin show that it binds preferentially to the nitrogen-7 
position of the nucleosides guanine and adenine on DNA, with very little binding to 
thymine and cytosine (Eastman 1987b). 
NH2 o N H , O 
、丄—、丄— N H 2 6、人。6、人 
Adenine (A) Guanine (G) Cytosine (C) Thymine (T) 
Figure 1.2.5 DNA nucleobases 
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Cisplatin cross-links could occur on the same strand of DNA or on adjacent 
points between the two strands within 280 pm. Adjacent guanine-guanine or 
adenine-guanine bases were the primary binding sites for bifunctional cisplatin 
(Pinto et al 1985). The major lesions were d(GG) and d(AG) 1,2-intrastrand 
cross-links, representing 65% and 25% of the total adducts, respectively. The 
interstrand cross-links represented a minor portion, less than 10% of the total adducts 
{review by Lemaire et al 1991). Note that not all the guanines were platinated. The 
binding of cisplatin was sequence and conformation specific. By binding to DNA, 
cisplatin-crosslinks induced widening of the minor groove and a considerable bend 
towards the major groove. The platinum-DNA adducts induced by cisplatin and 
carboplatin have the same degree of conformational change (Knox et al 1986，de 
Boer et al 1992, Schmidt et al 1993). Oxaliplatin was less reactive towards DNA, 
less DNA-platinum adducts was formed. Though that, it exhibited a higher rate of 
DNA elongation inhibition, rendering it more cytotoxic than cisplatin (Woynarowski 
et al 2000). 
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1.3 Limitations of Platinum Drugs 
Cancer chemotherapy can be either advantageous or detrimental to human. 
Apart from therapeutic activity, cisplatin also induce harmful side effects, including 
myelosuppression, nephrotoxicity, neurotoxicity, ototoxicity, emetogenesis and mild 
alopecia, which potentially limits its use in clinical practice. 
1.3.1 Toxicity 
Myelosuppression 
Alkylating agents generally induce leucopenia (low level of leukocytes), 
thrombocytopenia (low level of blood platelets) and neutropenia (low level of 
neutrophil granulocytes). Cisplatin caused milder myelosuppresion than that of 
carboplatin, one fourth of the patient encountered myelosuppression upon 
carboplatin treatment. Only 5% to 6 % suffered the same side effect in case of 
cisplatin treatment (Von Hofife^ al 1979). 
Nephrotoxicity 
Cisplatin induced oxidative stress in kidney cells, leading to severe renal 
damage. In mice at the maximum tolerated dose, cisplatin caused glycosurea, 
proteinurea and decreased glomerular filtration rate (Daugaard et al 1989). Cisplatin 
was found to cause renal tubular epithelial necrosis, adequate hydration and diuresis 
should be used to prevent excessive renal damage (Kintzel et al 1995). Amifostine is 
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a thiol-containing compounds used to reduce the cumulative renal toxicity. 
Carbonium ions generated by alkylating agents were inactivated by these compounds. 
However, the binding of thiol-containing compounds may lower the antitumor 
activity of cisplatin (Kemp et al 1996，Schiller et al 1996). 
Neurotoxicity 
Neurotoxicity is the main dose-limiting toxicity to the therapeutic treatment. 
Neuropathy was irreversible and occured in approximately 85% of patients with a 
cumulative dose greater than 300mg/m^ (Cersosimo et al 1989). Neurotoxicity was 
found to correlate with concentration of cisplatin deposited in peripheral nervous 
system. It was thought that cisplatin accumulated in the lipid-rich dorsal root ganglia 
of the peripheral sensory nerve cells in the form of platinum-DNA adduct. These 
binding potentially reduced the velocity of signal transduction in sensory nerve 
(Poirier et al 1992, Gregg et al 1992). It was shown recently that deposition of 
platinum drug in the peripheral nervous system did not directly correlate with the 
neurotoxicity. Instead, it correlated with hydrophilicity of platinum drugs and the rate 
of formation of electrophilic platinum species.(Screnci et al 2000). However, it is 
still unclear whether platinum binding on or outside the sensory neurons is involved 
in the mechanism of peripheral neurotoxicity (Van der Vygh et al 1986). 
Oxaliplatin had been shown to have prominent neurotoxicty in clinical trials 
(Misset et al 1998). Symptoms of neurotoxicity were generally reversible within 
several months after the chemotherapy regimen has been completed. 
Damage to the auditory sensory nerve induced severe ototoxicity, the high 
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frequency hearing loss. Ototoxicity was found to be caused by damage to the outer 
hair cells in the organ of Corti (Stadnicki et al 1975). Unfortunately, there is no 
effective remedy to avoid this side effect so far. 
Emetogenesis 
Nausea and vomiting was severe under cisplatin chemotherapy. Prophylactic 
antiemetics drug such as ondansetron, granisetron together with corticosteroids had 
to be taken to relieve these side effects. 
Alopecia 
Cancer chemotherapy generally caused hair loss from slight thinning to 
complete loss of hair. After completion of therapy, hair regrowth usually occurs in 
two months time. 
Page 14 
1.3.2 Drug Resistance and Cross Resistance 
Neoplastic cancer recurred with drug resistance. Resistance mechanisms include 
reduced cellular drug accumulation by changing the profile of drug efflux or uptake, 
cytosolic drug inactivation by cellular thiols, enhancement of DNA repair to 
platinum-DNA adducts, increased tolerance to DNA damage and failure of cell to 
undergo apoptosis. 
Some mechanisms of resistance are common to cisplatin, carboplatin and 
ZD0473: decreased drug uptake, increased glutathione and metallothionein, loss of 
the DNA mismatch repair MLHl, increased Bcl-2 levels. Resistance to one of these 
drugs may induce resistance to another, i.e. these drugs are cross-resistant to each 
other. 
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1.3.2.1 Reduced Drug accumulation or increased drug efflux 
Cisplatin enters the cells through both passive diffusion and active transport. 
Passive diffusion is an automatic downhill transport process which does not involve 
energy while active transport utilizes energy from adenosine triphosphate (ATP) to 
do uphill transport. Reduction in the intracellular drug accumulation can be induced 
either by impaired influx or enhanced efflux. JM216, a lipophilic platinum (IV) 
complex, was shown to circumvent cisplatin-resistance by increasing the drug uptake 
through passive diffusion (Sharp et al 1995). 
By restricting the energy supply to the cell membrane, unwanted molecules can 
be restricted from entering into the cells. In human cisplatin-resistant ovarian cell 
lines, decreased carboplatin accumulation was resulted from reduced 
energy-dependent uptake (Shen et al 2000). Increased drug efflux was also found in 
cisplatin-resistant cell lines of human hepatoma (Johnson et al 1996). Cisplatin 
resistance was found to be linked to copper transport directly (Komutsu et al 2000). 
Further evidence indicated that copper influx transporter {CTRl), a transmembrane 
protein, controlled the accumulation of cisplatin in Saccharmyces cerevisiae. 
C77?7-deficient cells also demonstrated impaired accumulation of the cisplatin 
analogs carboplatin, oxaliplatin and ZD0473 (Lin et al 2002). Apart from defection 
in drug influx, there is some evidence to suggest that an active drug efflux system 
was responsible for the reduced cisplatin accumulation in cisplatin-resistant cancer 
cell (Fujii et al 1994). Overexpression of the copper transporting P-type adenosine 
triphosphatase (ATP7B) in human epidermoid carcinoma causes resistance to both 
cisplatin (8.9 fold) and copper (2.0 fold). ATP7B mediated cisplatin resistance by 
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actively pumping cisplatin out of the cell via the same channel devoted to copper 
(Komatsu et al 2000, Katano et al 2002). 
To counteract this resistance mechanism, novel liposomal encapsulation 
technology was employed in platinum drugs and other potential antitumor drugs. 
Liposome acts to cany and protect the drugs through the cell membrane barrier 
towards the target site. 
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1.3.2.2 Drug Inactivation 
Cancer cells have different levels of thiols such as glutathione (GSH), 
metallothioneins (MTs). These thiol-molecules can detoxify platinum drugs 
intracellularly or extracellularly. Thiols reacted with cisplatin and prevented it from 
binding to DNA (Ishikawa et al 1993). Cellular levels of thiol-containing compounds 
increased by the treatment of cisplatin (Eastman et al 1987a). 
Thiols transport and catabolism are controlled by a plasma membrane protein 
gamma-glutamyl transpeptidase (GGT), which is often expressed in malignant 
tumors such as melanomas. GGT deficiency cells exhibited extracellular 
accumulation of GSH, GSSG and glutathione-cysteine disulfide, which rendered the 
cells more sensitive to platinum drugs (Paolicchi et al 2002). 
GSH is present in the cytoplasm at concentrations of 0.5-10 mM (Lempers et al 
1988). It can be deprotonated to generate thiolate GS', both a powerful reductant and 
a ligand with strong affinity for platinum moiety. As a ligand, GS' binds to platinum 
(II) with irreversible covalent bonding and thus prevent further binding to DNA. As a 
reductant, GS" acts to reduce platinum (IV)，which will undergo reductive 
elimination reactions to form platinum (II) and GSSQ transforming the inert 
octahedral platinum (IV) to reactive square planar platinum (II) (Lemma et al 2000b). 
Increased intracellular GSH levels were observed in some cisplatin-resistant ovarian 
cancer cell line A2780. GSH inactivated the platinum drug before it could take action 
in the cells. ZD0473 is one of the platinum drug candidate that was designed to 
reduce drug inactivation by GSH through steric hindrance exerted by methyl 
substituted pyridine side chain (Holford et al 2000). 
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1.3.2.3 Enhanced DNA Repair 
Cancer cell confered resistance by enhancing DNA damage repair and reducing 
drug accumulation (Parker et al 1991). Enhanced DNA repair capacity was caused by 
increased platinum-DNA adducts removal, DNA synthesis, repair synthesis or 
spontaneous reactivation of the cisplatin-damage DNA by the host (Kelland et al 
1993a). 
Several genes have been identified, which once disabled seem to either impair 
or enhance recognition of cisplatin adducts. The best-known of these are the DNA 
mismatch repair genes, hMSH2, hMSH6 and hMLHl. Testicular and ovarian tissues, 
among the most sensitive to cisplatin, have been reported to overexpress hMSH2 
(Mello et al 1996). Defects in DNA mismatch repair resulted from mutations or 
methylation mediated silencing of hMLHl, hMSH2, hPMSl or hPMS2, produced 
low level resistance to cisplatin. These resistances seemed to be caused by a failure 
to recognize the DNA-platinum adducts and propagated a signal to the apoptotic 
machinery (Vaisman et al 1993). Loss of MMR function indirectly promoted 
replicative bypass across cisplatin adducts by the DNA polymerase beta, zeta and 
gamma (Crul et al 1997，Chaney et al 1999). With the impaired MMR system, 
mis-incorporation of non-complementary bases by these polymerases generated 
point- or frameshift- mutations (Lin et al 1999). Lack of the MMR components 
would allow completion of DNA replication and promote cell growth. Thus, the 
inactive MMR allowed better tolerance to DNA damage and induced resistance to 
apoptosis (Chaney et al 1999). 
Increased NER activity in cisplatin-resistant cell lines appeared to be most 
Page 19 
strongly associated with increasing ERCCl and XPA expression. In 
cisplatin-resistant cell lines, the rate of platinum-DNA adducts removal was 
increased. Cisplatin- and oxaliplatin-DNA adducts were removed by NER at the 
same rate (Gibbons et al 1990, Schmidt et al 1993). No significant differences were 
observed in the excision of cisplatin, oxaliplatin and JM216 adducts by the human 
NER complex. Thus, NER was not responsible for the carrier ligand specific 
resistance of platinum drugs (Chaney et al 1999). 
Post-replication repair or replicative bypass is the replication of damaged DNA 
without introducing gaps or discontinuities into the DNA, or repair of those gaps or 
discontinuities following replication. It was proved to be the major mechanism of 
DNA damage tolerance (Kaufmann et al 1989). Cisplatin-resistant cell lines showed 
increased replicative bypass of cisplatin adducts, but little or no increase in 
replicative bypass of oxaliplatin adducts. Therefore, replicative bypass was the major 
discriminate between platinum DNA adducts with different carrier ligands (Gibbons 
a/ 1990). 
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1.4 Why Combinational Therapy? 
Platinum-induced DNA damage can modulate a variety of biological pathways 
in cancer cells, and mutations or bypass in these pathways may lead to cytotoxic 
resistance. Therefore combination chemotherapy of platinum compounds with 
signaling blockers or specific pathway inhibitors could be a novel strategy for 
combating cancer. Novel platinum and clinically used platinum compounds plays an 
important role in cancer treatment especially in their combinations with radiation 
therapy. 
Chemotherapy can either cure or kill, thus when chemotherapy is applied, there 
must a balance between efficacy and toxicity. To make it clear, combinational 
chemotherapy can increase therapeutic efficacy against cancer by exerting a 
synergistic effect. In drug combination, antitumor effect can be carried out at a 
reduced dose, i.e. to decrease toxicity or remove unwanted side effects. Drug in 
combinations may have multiple antitumor targets, thus minimizing or delaying the 
development of drug resistance. Drug combinations can probably enhance the drug 
activity in specific targets, i.e. selective synergism against one kind of cancer. 
Combination cancer chemotherapy can either be constructive, destructive or 
simply additive. An additive effect is the sum of the effect exerted by individual 
drugs. Constructive drug combination or synergism is more than the additive effect, 
it is where drugs act cooperatively to give a beneficial effect. Alternatively, 
destructive drug combination or antagonism is less than the additive effect. 
Combinational drug chemotherapy is not a novel strategy, it has been used clinically 
for thirty years. Platinum drugs can potentially benefit from other chemotherapeutic 
drugs in combinations. 
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1.4.1 Antimetabolites 
5-fluorouracil (5-FU) and gemcitabine are pyrimidine analogues. The 
counterfeit pyrimidine was incorporated into the RNA during the process of DNA 
transcription. It terminated the polymerization since the pyrimidine analogue became 
inert after binding to the RNA strand. 
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Figure 1.4.1.1 5-fluorouracil Figure 1.4.1.2 Gemcitabine 
Gemcitabine, a false nucleoside, is indicated in combination with cisplatin for 
the first line treatment of patients with locally advanced or metastatic NSCLC or 
adenocarcinoma of the pancreas. Gemcitabine and cisplatin acted synergistically. It 
increased platinum-DNA adducts formation and induced concentration- and 
time-dependent changes in ribonucleotide and deoxyribonucleotide pools in ovarian 
cancer cell lines (Van Moorsel et al 2003). Further clinical evidence indicated that 
carboplatin, like cisplatin, acted synergistically with gemcitabine, but surprisingly 
neurotoxicity and alopecia are absence in the entire regimen (Waters et al 2002). The 
combination of gemcitabine and cisplatin had proven effective as first-line 
chemotherapy for patients with breast cancer (Boulikas et al 2004). 
5-FU is a fluorinated pyrimidine that was metabolized to its active form, 
fluorodeoxyuridine monophosphate. It inhibited DNA synthesis by inhibiting the 
normal production of thymidine. 5-FU and cisplatin combination chemotherapy 
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activates a Fas receptor signaling pathway, leading to direct activation of cysteine 
aspartate-specific proteinases-3 (caspase-3) and apoptosis in gastric carcinoma cells 
(Kim et al 2002). Oxaliplatin in combination with 5-fluorouracil, had been recently 
approved in Europe, Asia and Latin America for the treatment of metastatic 
colorectal cancer. 
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1.4.2 Topoisomerase Inhibitors 
Irinotecan are topoisomerase I inhibitors. It can bind to the topoisomerase 
I-DNA complex and prevent religation of single-strand breaks. The cytotoxicity of 
this combination was sequence-dependent, oxaliplatin followed by irinotecan being 
more cytotoxic than either the reverse sequence or simultaneous administration. Its 
effect was significant in S phase, resulting in cell cycle arrest {review Raymond et al 
2002). It is used for the treatment of non-small cell lung cancer (Bunn PA Jr. et al). 
Etoposide, epirubicin and doxorubicin are cytotoxic anthracycline antibiotics, 
which inhibit DNA topoisomerase II. This class of drugs damages DNA by 
intercalation of the anthracycline portion, thus leading to DNA cleavage and 
resulting in apoptosis. 
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Figure 1.4.2.1 Irinotecan 
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Figure 1.4.2.2 Doxorubicin Figure 1.4.2.3 Etoposide 
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1.4.3 Tubulin-Active Antimitotic Agents 
Taxane is a family of antitubulin compounds, its members includes paclitaxel 
and docetaxel. Taxane promoted the assembly of microtubules from tubulin dimers 
and stabilized these by preventing depolymerization. This stability resulted in the 
inhibition of normal dynamic reorganization of the microtubules network that is 
essential for vital interphase and mitotic cellular functions, resulting in G2/M arrest. 
Paclitaxel was being widely used in a variety of human cancers as a single agent, 
including breast, ovarian, gastric, NSCLC and CRC (Malingre et al 2000). However, 
paclitaxel chemotherapy faced a major problem of clinical resistance induced by 
either overexpression of P-glycoprotein or mutations in tubulin (Boulikas et al 2004). 
Hence, combinational chemotherapy provides an alternative promising choice. 
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Figure 1.4.3.1 Paclitaxel 
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Figure 1.4.3.2 Docetaxel 
The use of vinorelbine, gemcitabine, paclitaxel and docetaxel in combination 
with cisplatin or carboplatin against non small cell lung cancer (NSCLC) had 
increased the overall survival as much as 10% each year. Carboplatin/paclitaxel 
-based combination chemotherapy had become a very popular combination 
chemotherapy in the USA against advanced NSCLC (Boulikas et al 2004 review). 
Paclitaxel in combination with a platinum agent was now accepted as the standard 
first line treatment for ovarian cancer (Sandercock et al 2002). Paclitaxel in 
combination with carboplatin and etoposide was a widely used regimen against small 
cell lung cancer (SCLC). Paclitaxel pretreatment showed synergy with nedaplatin 
against Lewis lung carcinoma. The effect was significantly higher than either 
combination with cisplatin or carboplatin (Yamada et al 2001). 
Docetaxel binds with tubulin with 2 folds higher affinity than paclitaxel. It had a 
broader activity than paclitaxel against human tumors and caused cell cycle arrest at 
the S phase rather than G2/M phases of the cell cycle (Georgoulias et al 2004). 
Docetaxel, when combined with either epirubicin or doxorubicin, led to cytotoxic 
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synergistic effects in hormone-refractoiy prostate cancer in vitro. However, clinical 
results showed that combination of cisplatin, carboplatin or etoposide with docetaxel 
against pancreatic cancer had lead to antagonism (Budman et al 2002). 
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1.4.4 Demethylcantharidin as a potential candidate for drug combinations 
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Figure 1.4.4.3 Endothall 
Demethylcantharidin (DMC) or nor-cantharidin is the demethylated anologue of 
a naturally occurring chemical, cantharidin, extracted from traditional Chinese 
medicine blister bee, Mylabris. Cantharidin was used in ancient Chinese as a remedy 
for the elimination of swelling (Li et al 1992，review McCluskey et al 2001). As a 
well-known protein phosphatase (PP) inhibitor ofPPl ( I C 5 0 = 1.78 i^M) and PP2A 
(IC50 = 0.26 nM) (McCluskey et al 2002), cantharidin was able to inhibit the 
dephosphorylation activity of PP which played a vital role in intercellular 
communication against the action of protein kinase (Duthe et al 2001). Cantharidin 
was also demonstrated to have anti-tumor activity against liver cancer (Wang et al 
1989). Its antitumor activity was attributed to the accelerated cell cycle progression, 
the induction of cell cycle arrest at G2/M (Wang et al 2000) and increased vascular 
endothelial permeability induced by enhancing the phosphorylation state of 
endothelial regulatory proteins (Knapp et al 1999). DNA damage induced by 
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oxidizing cantharidin was mainly associated to BER rather than NER, resulting in 
-dependent apoptosis (Efferth et al 2005). Downregulation of DNA repair gene 
was found in an analysis of gene expression profile of cantharidin-treated human 
colon cancer cell by cDNA microarray (Zhang et al 2004). In vitro coherent evidence 
revealed the inhibition of non-homologous end joining repair mechanism was mainly 
achieved by PPl inhibitory action (Herman et al 2002, Lankoff et al 2006). However, 
the use of cantharidin was restricted by the severe side effect induced in the mucous 
membrane of the urinary and the gastrointestinal tract (Tagwireyi et al 2000). 
DMC, an analogue of cantharidin with lower toxicity, issynthesized from furan 
and maleic anhydride via the Diels-Alder reaction (Ho et al 2001). DMC was 
demonstrated to inhibit growth of hepatoma in vitro (Yi et al 1991, Wu et al 2001) 
and in vivo (Yang et al 1997). DMC, like cantharidin, was a PP inhibitor of PPl ( I C 5 0 
=1.98 nM) and PP2A ( I C 5 0 = 0.37 i^M) (McCluskey et al 2002) but with a lower PP 
inhibition activity, lower vasoconstrictor potential and reduced cytotoxicity. An 
advantage of DMC is that it results in lower metabolic disturbances than cantharidin 
by preserving the ATP energy status and controlling the oxidized GSH at a lower 
level (Massicot et al 2005). A low dose of DMC accelerated the Gi/S phase transition, 
while higher doses or prolonged incubations inhibited cell cycle at G2/M phase (Liu 
et al 1995). Inhibition of proliferation-related genes proteins PCNA and Ki-67 has 
beendemonstrated in DMC treated human gallbladder carcinoma cells (Fan et al 
2004). DMC induced cell apoptosis in oral and colon cancer cells. It caused 
accumulation of cytosolic cytochrome c and activation of caspase-9, leading to 
down-regulation of antiapoptic protein Bcl-2 and BC1-XL. By activation of caspase-3 
through the mitochondrial pathway, apoptosis was initiated in melanoma in vitro 
(Peng et al 2002，An et al 2004). By maintaining the dephosphorylation state of 
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anti-apoptotic protein Bcl-2 by PP2A, cell survival signaling was sustained which 
may somehow induce apoptosis resistance. Therefore, inhibition of PP2A by either 
DMC or cantharidin can potentially reverse apoptotic resistance machinery (Simizu 
et al 2004). 
Cell adhesion proteins take part in a variety of tumor signaling pathways. By 
down-regulating several cadherin-catenin adhesion molecules, metastatic cancer cell 
could not adhere to subendothelial basement membranes. Thus cancer cell was 
prevented from entering other organs. DMC suppressed the expression of cell 
adhesion molecules including desmoglein, N-cadherin, a- and p-catenin. It helped to 
prevent metastasis. Down-regulation of protease metalloproteinase-2 (MMP2) and -9 
(MMP9) was also demonstrated in DMC treated cells. MMP2 and MMP9 possess 
gelatinase activity that can cleave plasminogen to form angiostatin. Angiostatin 
mediates angiogenesis, tumor invasion and metastasis, its inhibition ensuring the role 
of DMC in combating metastasis (Chen et al 2005). 
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1.5 Study Objectives 
An earlier study by To et al (To et al 2005) establishes that DMC-Platinum 
compounds show good anti-tumor properties. Dr. Kin-Wah To, graduated students 
from Dr. Yee-Ping Ho, we want to establish a clear preclinical drug combination 
profile of DMC with platinum-based drugs, utilizing Combination Index (CI) and 
Dose Reduction Index (DRI) as the parameter for evaluating the combination effect 
exerted by each combination. Several platinum-based compounds are used in this 
study including the two clinically in-used drugs Cisplatin and Oxaliplatin, and three 
DMC-containing platinum compounds [Pt(DMC)(NH3)2]，[Pt(DMC)(NH2CH3)2] and 
[Pt(DMC)(尺/?-DACH)] that are designed by this group previously (Ho et al 2001). 
All of these newly synthesized compounds are composed of DMC ligand and a 
platinum moiety, endothal (the diacid form of DMC, 
7-Oxabicyclo(2’2，l)heptane-2，3-dicarboxylic acid), which dissociates upon 
hydrolysis. DMC, once dissociated from the platinum moiety, can exert its own 
cellular activity individually in addition to that induced by the platinum moiety. The 
platinum moiety of [Pt(DMC)(/^, ACH)] is similar to that of oxaliplatin, thus 
presumably these compound pairs induced similar cytotoxic effect on DNA in spite 
of the relative binding rate. The same assumption can be applied in the compound 
pairs [Pt(DMC)(NH3)2] and cisplatin. Thus dual antitumor mechanisms originated 
from the two individual components, DMC and platinum, are expected. 
Drug combinations protocol established by To et al (2005) was employed to 
examine HCTl 16 and SK-Hepl in this study. Three kinds of drug combinations were 
analyzed. They are concurrent treatment, DMC pretreatment and platinum 
pretreatment. In order to optimize the efficiency of drug combinations, novel drug 
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combinations were examined. New drug combinations were also carried out by 
employing either platinum or DMC as a drug pre-sensitizer, followed by concurrent 
treatment. By comparing the time-dependent treatment profile of different drug 
combinations treatment, potential clinical combination protocols with highest 
efficacy and lowest toxicity are determined. 
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Chapter 2 
Materials and Methods 
2.1 Cell Lines 
Colorectal cancer cell lines and hepatoma cell lines are obtained from American 
Type Culture Collection. It is a precious gift from the Dr. Yee-Ping Ho, Associate 
Professor at School of Pharmacy in The Chinese University of Hong Kong. Two 
colorectal cell lines, HCTl 16 and HT29 and two liver cancer cell lines, SK Hepl and 
Hep G2 are chosen for in vitro drug screening. 
2.2 Cancer Cell Preparation 
2.2.1 Chemicals and Reagents 
Reagents used in the cell culture are of biological grade and are free of impure 
microorganisms or unknown cell, including ready-made solution mixtures: 0.25% 
trypsin in HBSS with 0.2g/L EDTA, lO.mM Non-Essential Amino Acid (NEAA), 
100 mM Sodium Pyruvate Solution, Pen-Strep solution with 10000 units/ml of 
Penicillin and 10000 昭/ml in 0.85% NaCl Minimum Essential Medium 
(MEM/EBSS) with L-Glutamine, RPMI 1640 Medium with L-Glutamine and US 
Characterized Fetal Bovine Serum (FBS) were purchased from Hyclone. Trypan blue 
dye was purchased from Fluka. 
95% ethanol was normally diluted to 70% as disinfectants. All chemicals used 
are of analytical grade including cisplatin and oxaliplatin (from Haereus) and 
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Phosphate Buffered Saline Tablets (PBS) (from International Laboratory USA). 
Thiazolyl blue tetrazolium bromide was purchased from Biochemika Compounds 
synthesized by our group were characterized by Nuclear Magnetic Resonance 
(NMR), High Performance Liquid Chromatography (HPLC) and Elemental Analysis 
before cell line testing. The purity of the compound is ensured to avoid 
contamination by other unknown chemicals. 
All materials and apparatus used in the cell culture experiment were sterilized 
either by 70% ethanol disinfectant or in the autoclave. Self-prepared liquid solutions 
was disinfected by filtering using sterilized HPLC filter with pores of 0.2 |.im 
diameter which can filter out most of the microorganisms and bacteria. For PBS 
liquid, the PBS tablets were diluted to suitable volume using 18.2 ohm deionized 
water. It was then autoclaved to kill bacteria and microorganism at high temperature 
and high pressure. 
2.2.2 Cell Culture Practice 
Cells are part of human which need frequent refreshing nourishment and waste 
removal. Too crowd a cell clone may prevent the cell from further proliferation, thus 
subculture is needed at a certain time interval. Proper handling of the cell lines can 
help to reduce potential contaminations and enhance reproducibility in experiments. 
To prevent bacterial invasion or contamination, as well as protecting oneself from 




For colorectal cancer cell lines, RPMI with 10% FBS and 5% Pen-Strep 
solution was used. MEM/EBSS medium with 10% FBS, 5% Pen-Strep solution, 5% 
NEAA solutions and 5% sodium pyruvate solution was used for the culture of liver 
cancer cell lines. 
For adherent cells, cells were normally attached to the culture dish or T-flask 
surface. During subculture, medium was removed and discarded in 1: 99 bleach 
disinfectant solutions. Then the cell layer was carefully washed with sterilized PBS 
to remove excess remaining medium, dead cells and floating cell debris. Ready-made 
trypsin solution was added to the culture dish. To facilitate cell detachment efficiently, 
about 2 to 3 ml trypsin solution should be added at minimum and constant swirling 
was needed to ensure the even spread of the enzyme over the whole cell layer surface. 
After 3-5 minutes, cells were detached from the bottom of the dish and were then 
collected into a centrifuge tube following by centrifugation of 1500 rpm for 5 
minutes at 20°C. Cells were packed into a pellet at the bottom of the tube after 
centrifugation. The cell pellet was separated from the medium by removing the upper 
medium layer which was then rocked to prevent cells from sticking together. By 
adding medium, the cells were diluted and suspended in medium, followed by 
pipetting up and down until the cells are dispersed into a single cell suspension. 
Tenth one of the cell suspension was transferred to a new culture dish. Cell density 
can be checked using microscope, to see if the cell count was suitable for further 
proliferation. Then, the culture dish was placed into the 37°C incubators with 5% 
CO2. Culture dish or culture container had to be replaced each time when the culture 
dish was fully grown. If the culture dish was not yet fully grown, culture medium had 
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to be replaced by fresh one for at least once a week. 
Colorectal cancer cells，HCT116 and HT29 replicate at a very high rate: itself 
being doubled for every 20 hours, and hence subculture should be performed at least 
twice a week. While for liver cancer cells, SK Hepl and Hep G2, with lower 




Cell Culture had to the preserved at -210°C in liquid nitrogen tank when it 
would not used in a short term or when the passage had to be kept for a long period 
time. Cultures to be cryopreserved should be healthy and free from contamination, 
and it growth should be maintained at late log phase growth for several days before 
freezing. 
Medium was removed from the culture dish and the cells were washed with 
PBS followed by trypsinization. After collecting the cells into a centrifuge tube, it 
was then centrifuged at 1500 rpm for 5 minutes at 20°C, cells were packed into a 
pellet. The unwanted medium layer was removed and was then rocked to disperse the 
cell into single cell suspension. Resuspending cells in the sterile culture medium 
containing 5% v/v dimethylsulfoxide (DMSO) and 10% fetal bovine serum (FBS)，it 
was then mixed thoroughly by pipetting up and down. From this time on, work must 
be proceeded rapidly to minimize the length of time the cells were exposed to DMSO 
in the liquid state because prolonged exposure to DMSO may cause irreversible 
damage to the cell passage and thus should be avoided. About 2 x 10^ to 5 x 10^ 
cells/lml cell suspension was prepared and 1.5 ml of the cell suspension was 
transferred to a 1.8 ml ampule specially designed for cryopreservation. The ampule 
was then placed into an isopropanol bath in a controlled-rate freezing apparatus 
(-l°C/minute) pre-cooled in a freezer at -70°C. After cooling at -70°C for 12 hours, 
the ampule was then transferred to the liquid nitrogen-filled storage tank of about 
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2.2.2.3 Thawing Cryopreservated Cells 
The thawed ampule freshly taken out from the Liquid Nitrogen tank should be 
defrosted in a 31°C water bath with constant agitation until the ice in the ampule was 
no longer visible. The surface of the ampule was then disinfected with 70% ethanol. 
Within a cabinet, the defrosted content and 1.5 ml culture medium were transferred 
to the 15 ml centrifuge tube and was warmed in a 37�C water bath with constant 
swirling. 3 ml and 6 ml medium were then added consecutively in 5 minutes time 
interval with constant warming at 37°C. The cell suspension was centrifuged at 1000 
rpm for ten minutes. The DMSO-containing medium was removed. The cells were 
resuspended in fresh medium and were then transferred into a new culture dish. The 
culture dish was incubated in the incubator. The cell viability had to be checked 24 
hours later to see if the cells can attach to the cell bottom. Any cell line testing should 
be done after the cells are stable for at least a week or more. Growth assay can be 
employed to check if the cells grow normally. Adnormal passage had to be discarded. 
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2.2.3 Development of Drug-Resistant Cell Lines 
Drugs were dissolved in deionized water at their maximum solubility. All 
weight measurements were taken from Shimadzu AY-120 analytical balance with 士 
0.1 mg standard deviation (SD). All volume measurements within 1000 were 
performed using Eppendorf Research pipettes of range 0.5 - 10 |il, 10 - 100 |il and 
100 - 1000 |il. The drug solution prepared was then sterilized using sterilized HPLC 
filter with pores of 0.2 [im diameter. 
Cancer cells were allowed to proliferate in the culture dish in the active log 
phase, drugs were added at their I C 5 0 to the culture dish. The cells were allowed to 
grow for one day or two. In the presence of antitumor drug, cell proliferation 
inhibition and cell detachment and even cell death would be resulted. The old 
drug-containing medium was replaced with fresh medium and was then allowed to 
grow for several days until the cell is active to proliferate. Antitumor drug was again 
added at their I C 5 0 . It was then allowed to incubate for one day or two. The drug 
addition process was repeated for two to three months and cells were then allowed to 
proliferate in drug-free medium for at least a week. Cell assay was used to determine 
if drug resistance was induced in the cell lines. 
Successful introduction of cisplatin resistance to SK Hepl and oxaliplatin 
resistance to HCTl 16 were achieved by Kay and Jeffrey，who are technicians and 
doctoral students respectively, both are supervised Dr. Yee-Ping Ho, Associate 
Professor at School of Pharmacy in The Chinese University of Hong Kong. 
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2.3 Growth Inhibition Assay 
2.3.1 Evaluation of Cytotoxicity in vitro 
The cytotoxicity of one drug can be evaluated by observing the growth 
inhibition exhibited by different concentration of drug. The dose responsible for 
inhibiting 50% of cell growth is defined as the I C 5 0 . Growth inhibition assay was 
employed to evaluate the cytotoxicity (Ruben et al 1987). 
Cells were trypsinized as the procedure mentioned before and were then 
centrifuged. The cells were rocked and then resuspended into 5 ml medium. Cell 
suspension was Pipetted up and down to disperse the cell into single cell suspension, 
which made it more accurate and convenient in cell count. The cell suspension was 
mixed with ready-made cell-staining trypan blue dye, 10 |il of the resultant mixture 
was transferred to the hemocytometer grids. The coverslip was carefully placed on 
the grids to avoid introduction of bubbles. The hemocytometer with the cell mixture 
was then placed under the microscope and was gently adjusted to focus. The number 
of cell in each Imm^ area with 0.1 mm^ volume was counted manually with the aid 
of a tally. The average cell count from the nine I mm area or 0.1 mm volume was 
used to calculate the concentration of the cell from the formula: 
cell concentration (cells / ml) = average cell count (cell/mm ) x volume counted (ml) 
By the cell count obtained, the cell suspensions was diluted to the cell 
concentration suitable for 72 hours cell assay, colorectal cancer cell suspension of 
4000 - 5000 cells / 0.1 ml and Liver cancer cell concentration of 5000 - 6000 cells / 
0.1 ml. 100 III of the diluted cell suspension was then added to 92 wells of the 96 
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well-plate, with the remaining 4 wells used as a background control by the addition 
of culture medium instead of cell suspension. The 96 well-plate was then incubated 
for 24 hours, allowing the cells to attach to the well surface before drug addition. 
Antitumor drug was first diluted in deionized water at their maximum solubility 
and was sterilized using sterilized filter of pores 0.2 |.im diameter. The drug in 
deionized water was further diluted to the 5 to 7 concentration using culture medium. 
100 of each concentration of the drug was added to each of the well in 4 replicates. 
4 replicates for background control and 4 replicates for cell growth control were 
employed to check the reading for the background noise and normal cell growth, 
which may derivate in each individual experiment. The 96 well-plate was further 
incubated for 72 hrs (3 days). 20 i^l of sterilized 5mg / ml 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide dye (MTT) solution 
was added to each well, followed by further incubation for 3 to 4 hours. Only viable 
cells having dehydrogenase enzymes could catalyze the dehydrogenation of 
co-enzyme NADH to NAD, generating hydrogen which would combine with the 
tetrazolium salt MTT to form visible purple formazan at the site of enzyme reaction. 
The formation of formazan was directly proportional to the number of living cell and 
therefore used as an indicator here to check how many cells were still alive 
(Mossman et al 1983). 
Each well was decanted and 100 |.il of DMSO was added to dissolve the purple 
formazan. The 96 well-plate was then placed into the BioRad Microplate Reader 
model 680 to determine the wavelength absorbance at 570 nm. 
Growth fraction was determined from the absorbance reading using the formula: 
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(Abs (drugs) - Abs (background)} 
Growth fraction = 
{Abs (cell control) - Abs (background)} 
Growth inhibition by chemicals at 50% is defined as the I C 5 0 and can be 
determined by plotting of growth fraction versus log [dose concentration] as shown 
in figure 2.3.1.1. 
All cytotoxicity data including the data point in the isobologram was evaluated 
from non-linear regression sigmoidal curve analysis (Fraser et al 1870 & 1872， 
Loewe et al 1926) rather than the linear regression median effect plot (Chou et al 
1984) due to the exaggerated errors induced by logarithmic data transformation in 
the latter method (Zhao et al 2004). 
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Figure 2.3.1.1 Sigmoidal Growth Inhibition Curve Page 42 
2.3.2 Drug Pretreatment 
Drug combination assay use the growth inhibition assay as a basis to determine 
the cell viability under a specific ratio of drug combination. Cells were seeded for 24 
hrs before drug addition. 
After 24 hrs cell seeding, cells were pretreated with either drugs for the first 24 
hrs. Then the drug-containing medium was removed and the cell layer was washed 
once with PBS. Another drug was added at a range of concentrations and left in 
contact for another 48 hrs. Control was set up using a single drug pretreatment for 24 
hrs, followed by washing and incubation in a drug-free medium for 48 hrs. 
Control Platinum 
Demethylcantharidin 
. . Platinum 




I 1 1 1 
0 24 48 72 • 
MTT Assay 
Table 2.3.2.1 Drug Exposure Time Profile for Drug Pretreatment 
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2.3.3 Drug Pre-sensitization with Concurrent Treatment 
Drug combination assay uses the growth inhibition assay as a basis to determine 
the cell viability under a specific ratio of drug combination. The experimental setup 
was carefully designed to make the procedure less complicated. Several 
modifications were made to facilitate more convenient drug addition for the 
evaluation of the time-dependent effect, i.e. the concurrent treatment with and 
without drug pre-sensitization. The details of experimental procedure and time 
profile are summarized in Table 2.3.3.1. 
The setup for a concurrent drug addition was similar to that of a normal growth 
inhibition assay described in Section 2.3.1. Drugs were added simultaneously at 24 
hours after cell seeding while drug pre-sensitization was simulated by addition of 
drugs 24 hrs prior to the concurrent treatment. 
The cell seeding procedure in a concurrent drug treatment was identical to that 
of a growth inhibition assay. 100 of the cell suspension of 5000 cells / 0.1 ml was 
added to 92 wells of the 96 well-plate with the remaining 4 wells used as a 
background control by the addition of culture medium instead of cell suspension. In a 
drug pretreatment combination, 50 |il of the cell suspension of 10000 cells / 0.1 ml 
was added to the well. Basically, the number of cells seeded in each well in 
sequential drug addition was the same as that used in a concurrent drug addition. 
In a concurrent drug combination experiment, 50 i^l of platinum drug and 50 |il 
of DMC were added simultaneously at 24 hours after cell seeding. Each drug 
combination utilizes 4 wells to obtain 4 replicates in each experimental setup, 
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followed by further incubation for 72 hours at 3TC. 
In drug pre-sensitization treatment, 50 |il of the drug pre-sensitizer was added to 
make up the total volume of 100 |.il at 24 hours after cell seeding. After incubation for 
another 24 hours, 50 |.il of platinum drug and 50 i^l o f D M C were added 
simultaneously to make up the total volume of 200 \i\. This drug mixture was further 
incubated for 48 hours (2 days). The details of the experimental setup were 
summarized below in the experimental setup time profile，Figure 2.3.3.1. By making 
these modifications, the concentration of pretreated drugs can be made consistent 
throughout the experiment without a need to remove the medium, which may 
potentially damage the cell layer. 
Control Platinum 
Demethylcantharidin 
� „ Platinum Platinum 
Platinum Pre-sensitization — r 
Demethylcantharidin 
Demethylcantharidin Pre- Platinum 
sensitization Demethylcantharidin Demethylcantharidin 
Concurrent Treatment for Platinum 
48 hrs Demethylcantharidin 
Concurrent Treatment for Platinum 
72 hrs Demethylcantharidin 
I 1 1 1 
0 24 48 72 
半 
MTT Assay 
Table 2.3.3.1 Drug Exposure Time Profile for Drug Pre-sensitization 
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2.4 Calculations for Drug Combinations 
The I C 5 0 for platinum drugs in the presence of a constant concentration of DMC 
was calculated to build up a data point, i.e. ( I C 5 0 of platinum drugs, DMC 
concentration) as one of the data point. By evaluating the I C 5 0 for platinum drugs at 
different concentration of DMC, isobologram of DMC I C 5 0 versus platinum drug 
I C 5 0 could be plotted. The isobologram could also be obtained at alternatively by 
evaluating the DMC I C 5 0 at different concentration of platinum drugs. Overlapping 
the two sets of point could help to determine if the trend shown was valid and 
reliable, Figure 2.4.1. 
• DMC IC50 at Fixed Platinum Concentration 
^ ~ • Platinum IC^^  at Fixed DMC Concentration 
.g ^ ^ Line of Additive Effect 
CO -
i- \ 
o • \ 
• \ 
O * 
• • • • • X 
1 I ~ ~ I I ~ I ~ ~ I ~ ~ I I I ~ ~ I I I • ~ ~ I I ~ ~ I ‘ ~ T - ^ ~ I ‘ 
Pla t i num Drug IC^^ in Drug Comb i n a t i o n 
Figure 2.4.1 Graphical Expression of Experimental Design in Isobologram 
Isobologram shown above is constructed from the I C 5 0 of DMC at fixed 
platinum drug concentration or I C 5 0 of platinum drug at fixed DMC concentration. It 
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is a graphical expression which can be transformed to mathematical formula: 
p i 二 D(pt) D(DMC) 
d "‘“ for concurrent treatment for 72 hrs 
上C 50 (72 hrs Pt) I C 50 (？之 hrs D M C ) 
厂 1 = D(pt) D (DMC) 
d — 十 for concurrent treatment for 48 hrs 
I C 50 (48 hrs Pt) I G 5 0 ^rs D M C ) 
CI = D(Pt) D ( D M C ) for platinum pre-sensitization 
IC ^ … � „ � i r followed by concurrent treatment 
n 50 (72 hrs Pt) 丄L 50 (48 hrs D M C ) 】 
CI = D(pt) + D(dmc) for DMC pre-sensitization 
IC 50 (48 hrs Pt) IC 50 饥 hrs DMC) by concurrent treatment 
= D ( p t ) D ( d m c ) 
d _ "‘ for platinum pretreatment 
I C 50 (24 hrs Pt) I G 50 (48 hrs D M C ) 
_ D ( p t ) D ( D M C ) 
LI ^ ~ ~ + for DMC pretreatment 
I C 50 (48 hrs Pt) I G 50 (24 hrs D M C ) 
For mutually exclusive drugs (having similar modes of action) where CI stands for 
the combination index, D � refers to either the fixed drug x concentration or the I C 5 0 
of drug X in fixed concentration of another drugs and I C 5 0 � is the 50% growth 
inhibition dose respective to drug x. If the growth inhibitory effect of the drug 
combination is simply additive of each individual drug efficacy, the data point will 
fall on the line of additive effect (CI 二 1) which is built up by connecting the two 
coordinates of the individual drug I C 5 0 , i.e. (0，DMC I C 5 0 ) and (Pt I C 5 0 , 0). 
Synergism is achieved when the total drug action exerted by the drug combination is 
greater than the additive effect，i.e. the same growth inhibitory effect can be achieved 
at lower drug concentrations (CI < 1). Antagonism is the opposite of synergism, the 
total drug action of a drug combination is less than the sum of the individual drug 
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action (CI > 1). 
c - t ^ • Antagonism 
i • • • • Additive Effect 
CO K • 
.E • • • Synergism 
E • 
0 - \ • • \ 
CD • \ • 
I： \ 
� • \ • 
1 • • \ 
。- ••• X • • • • • x • • • ^  
1 1~~I~I~I~I~~I~I~I~I~•~I~I~I~‘~I~‘~T—^I~‘ 
Platinum Drug IC5� in Drug Combination 
Figure 2.4.2 Graphical Expression of Drug Combination Effect 
Dose reductive index (DRI), is another parameter employed to compare the 
individual dose reduction of platinum drugs in a drug combination. DRI can be 
calculated from the formula below: 
D(PO 
where D(pt) refers to either the fixed platinum drug concentration or the I C 5 0 of 
platinum drug in fixed concentration of another drugs and IC50(pt) is the 50% growth 
inhibition dose respective to platinum drug. Additive is indicated when DRI = 1， 
DRI > 1 for synergism and DRI < 1 for antagonism. 
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2.5 Statistical Analysis 
Each experiment was set up with 4 replicates with background control (medium) 
and cell control (drug-free cell) for comparison. Individual experiment was repeated 
three times to give a valid data point determination within 95% confidence level. 
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Chapter 3 
Results and Discussions 
3.1 In vitro Cytotoxicity and Evaluation of Drug Resistance 
Drugs dose required to inhibit 50% cell growth is called I C 5 0 . The 72 hrs and 48 
H R S I C 5 0 F O R C I S P L A T I N , [ P T ( D M C ) ( N H 3 ) 2 ] ， [ P T ( D M C ) ( N H 2 C H 3 ) 2 ] ， 
[Pt(DMC)(尺/?-DACH)] and oxaliplatin were evaluated. The results are shown in 
Tables 3.1.1 and 3.1.2 respectively. 
Cytotoxicity Results (Refer to Table 3.1.1，Page 54) 
Oxaliplatin and [Pt(DMC)(/?, R-DACH)] are shown to be most potent in 
sensitive H C T l 16 ( I C 5 0 = 0.52 士 0.08 [iM，0.65 士 0.10 [iM respectively, refer to table 
3.1.1). Oxaliplatin is highly potent towards colorectal cancer cell line. This suggests 
the reason why oxaliplatin is used in clinical treatment of metastatic colorectal 
cancer (Graham et al 2001). Oxaliplatin shows superior activity towards H C T l 16 
and moderate activity towards other sensitive cell lines. In the same way, 
[Pt(DMC)(/^, R-DACH)] suggests a comparable mode of cytotoxicity for the two 
compounds. This similarity in cytotoxicity can be accounted for by the same 
platinum moiety of the two compounds, the amino group. Having the 
same platinum moiety, Pt(NH3) 2 ， [ P t ( D M C ) ( N H 3 ) 2 ] and cisplatin demonstrate 
similar degree of antitumor activity. Both compounds are more potent towards 
sensitive SK-Hepl liver cancer cell (IC50 = 3.14 士 0.43 [iM, 3.72 ± 0.62 ^ iM 
respectively) and HT29 ( I C 5 0 = 9.62 士 0.65 [iM，10.24 士 4.01 |.iM respectively). 
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However, [Pt(DMC)(NH3)2] is not sensitive to parental and resistant HCTl 16 as 
cisplatin does. 
A m o n g the three DMC-containing platinum compounds, [ P t ( D M C ) ( N H 3 ) 2 ] , 
[ P t ( D M C ) ( C H 3 N H 2 ) 2 ] and [Pt(DMC)(尺 i?-DACH)]，compound with R,R-DACU has 
the highest efficiency while compound with diamine group is less potent whereas 
platinum moiety with bis(methylamino) group has the least cytotoxicity. This trend is 
also recognized by Chaney (Chaney et al 1999) who suggests the significance of the 
carrier ligand in platinum-DNA adducts formation because different platinum-DNA 
adducts are processed by different D N A repair pathway (Petersen et al 1996)，i.e. 
resulting in different cytotoxicity. 
SK-Hepl cisplatin-resistant (SK-HepICisR) cell line exhibits 14.8 folds 
resistance to cisplatin, 6.22 folds to [ P t ( D M C ) ( N H 3 ) 2 ] and 2.9 folds to 
’ [Pt(DMC)(NH2CH3)2]. Thus, cisplatin-resistant is shown to be cross resistance with 
cisplatin, [ P t ( D M C ) ( N H 3 ) 2 ] and [Pt(DMC)( NH2CH3)2]. Both cisplatin and 
[ P t ( D M C ) ( N H 3 ) 2 ] forms the same platinum-DNA adducts, but reduced fold of 
resistance is observed in [ P t ( D M C ) ( N H 3 ) 2 ] . The only difference between the two 
compounds comes from the leaving group. Thus, does endothalate enhance the 
antitumor activity of platinum in resistant cell? To address this question, another drug 
pairs are compared. SK-Hep ICisR exhibits 2.0 folds resistance to 
[Pt(DMC)(足 i?-DACH)] and no resistance to oxaliplatin. Oxaliplatin is proved to 
be able to circumvent cisplatin-resistant (Vaisman et al 1998, Chaney et al 1999, 
Reardon et al 1999, Monti et al 2005). However, [Pt(DMC)(7?,/^-DACH)] does not 
significantly circumvent cisplatin-resistant when compare with oxaliplatin. Instead, a 
reduced cytotoxicity is resulted. The only difference between the two chemical 
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compounds is the leaving ligand, therefore, the effect of oxalate on cytotoxicity 
suggests another meaning for the leaving ligand. Apart from chelating the platinum 
and neutralizing the charge, leaving ligand is likely to pose its own biological effect 
in resistant cell (Izumi et al 2003). The enhancement effect of the leaving ligand can 
be arranged according to the following trend: oxalate > dianion of D M C diacid 
(endothalate) > chloride. 
Oxaliplatin-resistant HCTl 16 (HCT1160xaR) shows 8.0 folds resistance to 
oxaliplatin and 11.8 folds to [?t(DMC)(R,R-DACH)]. These data suggests oxaliplatin 
is cross-resistant to [Pt(DMC)(/?, ACH)]. Surprisingly, the potency of cisplatin is 
similar in both sensitive and resistant H C T l 16 (1.15 folds resistance). This simply 
implies a lack of cross-resistance to cisplatin. The same degree of fold in resistance is 
found in the cells treated by [ P t ( D M C ) ( N H 3 ) 2 ] (0.95 folds resistance). Despite the 
lack of cross-resistance, cisplatin would not be applied clinically for the treatment of 
colorectal cancer. It is because H C T l 16 is genetically deficient in M M R , cells that 
are lack of M M R exhibit lower sensitivity towards cisplatin treatment (Vaisman et al 
1998). 
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Ratio of 48 hrs I C 5 0 to 72 hrs I C 5 0 (Refer to table 3.1.4，Page 57) 
In general, the 48 hrs I C 5 0 is one- to twelve- times of the I C 5 0 determined at 72 
hrs. The lower the ratio, the faster the drug actions are optimized, the more efficient 
would be the antitumor drug action. The ratio is higher in compounds without D M C 
reaching a maximum of 9.76 folds for cisplatin in HCT1160xaR and 11.70 folds for 
oxaliplatin in SK-HeplCisR. The ratio for D M C and DMC-containing compounds 
are relatively lowered, 1.5- to 2.5-fold for D M C , 1.8- to 7.9-fold for 
[Pt(DMC ) (NH3)2]，1.3-to 2.7-fold for [Pt(DMC)(NH2CH3)2] and 1.69- to 6.71-fold 
for [Pt(DMC)(尺 i?-DACH)]. These results suggest that D M C acts to speed up the 
antitumor activity, i.e. significant growth inhibition is exhibited within 48 hrs of drug 
treatment. 
The ratio for oxaliplatin is 2- to 3-folds higher than that of 
[Pt(DMC)(兄/?-DACH)] in both resistant cell lines. Endothal dissociated can 
probably sensitize the cells towards platinum treatment. To analyze the difference in 
this ratio, several factors have to be considered: the hydrolysis rate of platinum 
compound (rate of active species production), the nature of the platinum moiety 
(degree of D N A distortion) and the biological action of the leaving ligand, all these 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3.1.3 Cytotoxicity Data for 24 hrs Drug Exposure 
24 hrs IC501 MM HCT116 SK-Hep1 
Demethylcantharidin 32.3 土 6.72 8.23 士 2.24 
Cisplatin 20.6 土 6.37 9.57 土 2.13 
[Pt(DMG)(NH3)2] 14.3 土 1.89 7.83 土 2.04 
[Pt(DMC)(NH2CH3)2] 30.4 ± 8.48 19.43 ± 4.34 
[Pt(DMC)(R,f?-DACH)] 1.19 士 0.25 3.08 土 1.05 
Oxaliplatin 1.19 士 0.16 3.77 土 1.27 
Cells are exposed to drug for 24 hrs followed by 48 hrs drug-free incubations 
Each Data is taken from 4 replicates in 3 individual experiment. Data is 



































































































































































































































































































































3.2 Role of Leaving Ligand in a Platinum Complex 
The structure of antitumor platinum drugs usually consists of three parts; the 
carrier ligand, the platinum atom and the leaving ligand. While the coordination of 
amino-containing ligand to the platinum forms the active platinum species, different 
carrier ligand can exert different effects on the binding to D N A according to its 
bulkiness, its stereochemistry and the rate of its production (Schmidt et al 1993， 
Vaisman et al 1999，Chaney et al 1999). The leaving ligand acts to neutralize the 
charge on the platinum atom and also help to control the rate of active species 
production, i.e. rate of hydrolysis. In this section, the chemistry of the platinum drugs 
is employed to analyze the potential biological effect of these drugs. 
In platinum compounds with cis geometry, the trans effect acts to weaken the 
bond strength of the opposite ligand. The amino ligand is a better electron donor than 
that of dicarboxylic ligand or chloride ion, the bond opposite to the amino group is 
weakened. Thus, the dicarboxylate or chloride ion dissociates instead of the amino 
group. The general equations for hydrolysis of the five compounds are shown in 
Figure 3.2.1 to 3.2.5. Cisplatin and [ P t ( D M C ) ( N H 3 ) 2 ] produce the same active 
species [Pt(OH2)2(NH3)2]2+ while oxaliplatin and [Pt(DMC)(i?,/?-DACH)] generate 
the same active species [Pt(OH2)2C^，i^DACH)]2+. Each activated platinum centre 
binds to D N A with the same geometry and it is expected to produce equivalent 
cellular response, which is reflected in the similarity of the cytotoxicity data of the 
two drug pairs. 
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C K ,NH3 卜20\广3]2+ — 
)Pt\ . \ 、、\ 、 Pt + 2CI 
c r ^NH, / \ 
3 HjO NH3 
Figure 3.2.1 Equation for Hydrolysis of Cisplatin 
O O 
/NH3 OH, 0H2 卜0\ 广3~| 2+ ^^y^^KQ-
p Pt\ 、 、 V 、 P^t + 〇 
^ ^ ^ ^ S j ^ O NH3 H2O NH3 
o o 
Figure 3.2.2 Equation for Hydrolysis of [Pt(DMC)(NH3)2] 
O O 
,NH2Me OH^ O K FHP^ ^ NH^Mel ‘ 
O Pt 、 、 、 、 ^ 、 Pt + 0 
VlHzMe H^o YlHzMe 
O O 
Figure 3.2.3 Equation for Hydrolysis of [Pt(DMC)(NH2CH3)2] 
O o 
^ / ^ ^ v y ^ O OH2 O K H ^ O 、 ^ / ^ s y ^ O -
p Pt , \ 、 . \ 、 〕P( + O 
o o 
Figure 3.2.4 Equation for Hydrolysis of [Pt(DMC)(i?,i?-DACH)] 
「 12+ 
• Y 。 O H 2 O K H^O 严 。 V - ^ 0 " " 
^ ^ ^ >t + 
Figure 3.2.5 Equation for Hydrolysis of Oxaliplatin 
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These general equations do not reveal the whole picture of the drug action of 
platinum drugs in vivo. Platinum drug has to be administrated intravenously in 
hypotonic saline solution. During the administration, platinum drug may undergo 
premature hydrolysis or ligand exchange, which is more likely to react with 
non-target biomolecules (Rixe et al 1996). Platinum drugs once injected in the 
bloodstream where chloride concentration is high ~0.1 M , labile ligand will be 
displaced by the chloride ion easily. Cisplatin is stabilized in this chloride 
concentration because the displacements of chloride ion are not favored. To analyze 
whether other ligands are labile, the acid dissociation constants, Kg and pKg is 
employed. The Kg provides a simple rule to predict the stability of the conjugate base 
(leaving ligand) and the acid strength of the acid. Upon hydrolysis or chloride 
substitution, DMC-containing compound produces endothalate, cisplatin generates 
chloride and oxaliplatin produces oxalate. The Figures and values of the acid 
dissociation constants, Ka and pKa, for the three ligands are shown below: 
h][A~ ] + -
K3 = 二 for acid H A - H + A for pK^ = -log Kg 
H+]2[A-] + 2-
K3 = for diacid HjA f 2 H + A for pKg = -log Kg = pKai+ pK^^ 
H2A 
where Kg^ is the acid dissociation constant for the first proton 
is the acid dissociation constant for the second proton 
Figure 3.2.6 Formula for Acid Dissociation Constant, K^ 
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。 Y 。 H 。 Y 。 - ， H : 。 。 -
Z 、 p K a ; = 1 . 2 7 at 25。C pK^;- 4.27 at 25°C 
HO \ 0 HO ^ O -O \ o 
C；：^ -
HO \ 0 q Z � � 
H 
Figure 3.2.7 Acid Dissociation of Oxalic Acid, overall pKa = 5.54 (Lane 1994) 
0 0 0 
OH HO 0~ 




HCI C f pKa 二 -8 
Figure 3.2.9 Acid Dissociation of Hydrochloric Acid, overall pKa = -8 (Source 
from http://daecrl.harvard.edu/pdf/evans_pKa table.pdf) 
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The lower the pKa, the stronger the acid, the more readily the conjugate base 
(the deprotonated acid) is stabilized. From the overall pKa shown above, it is shown 
that the acid strength decreases following the trend: hydrochloric acid〉oxalic acid > 
endothal. The stability of the conjugate base can be arranged in increase order 
following: chloride > oxalate > endothalate. Therefore, stability of the leaving group 
may provide a protective binding for the platinum moiety. 
From the results discussed in section 3.1，cytotoxicity enhancement effect is 
observed: oxalate > endothalate > chloride. This trend for dicarboxylate is equivalent 
to the trend of stability. These results suggest that the cytotoxicity of the platinum is 
highly related to the stability of the leaving group. It provides an alternative 
explanation for the antitumor effect of oxaliplatin, i.e oxalate stabilizes the platinum 
moiety and prevents premature hydrolysis. In addition to platinum stabilization, 
oxalate may also chelate other cations such as calcium and magnesium. Thus, oxalate 
indirectly inhibits the normal functions of calcium- and magnesium-containing 
biomolecules (Lane 1994，Recht et al 2004). 
Since calcium ion is known to be important in the binding site of many cell 
adhesions molecule, its chelation can potentially destroy the structure of extracellular 
matrix (ECM). Normal cells undergo apoptosis when they lose extracellular matrix 
(ECM) adhesion (Frisch et al 1994, review by Ruoslahti et al 1994). Oxalate is a 
calcium ion chelator, its biological effect in cell could be mimic by another calcium 
ion chelator, bis-(o-aminophenoxy)-N,N,N',N'-tetraacetic acid (BAPTA) (Grolleau 
et al 2001). As suggested by this author, oxalate in oxaliplatin may exert its 
antitumor activity by decreasing the intracellular calcium concentration. 
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Hypothesis verification 
To verify if the leaving ligands enhance the platinum drug cytotoxicity, another 
set of platinum drugs found in the literature (Monti et al 2005) are compared: 
Platinum compounds with oxalate, 1,1 -cyclobutanedicarboxylate and malonate are 
chosen for comparison. The acid dissociation constant is shown below in Figure 
3.2.9 to 3.2.10 and all the pKa value is summarized in Table 3.2.1. 
Table 3.2.1 pKa of the Organic Acid 
Ac i d pKai pKa2 pKa Re f e r ence 
Oxalic Acid 1.27 4.27 5.54 Lane 1994 
” http://www.herts.ac.Uk/aeru/f 
Endothal 3.4 6.7 10.1 00tDrint/ReD0rts/248.htm 
Malonic Acid 2.83 5.69 8.52 Byun et el 2000 
1,1-cyclobutanedicarboxylic acid - - > 8.52 -
Table 3.2.2 Literature I C 5 0 (\JM) Data in sensitive A2780 (Monti et al 2005) 
^ ^ ^ ^ ^ ^ ^ ^ ^ P l a t i n u m Mo ie ty Pt(NH3)2 P t (R ’R-DACH) 
L e a v i n g L i g a n d ^ ^ ^ ^ ^ ^ 
chlor ide ^ 1.03 
Oxa l a te - 0.48 
Ma lona te ^ 2.22 
1,1-cyclobutanedicarboxyl ic acid 7.66 1.52 
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O 0 o 
^ O H ^ ^ ^ ^ O H 乂H+ ^ o " 
\ pK^； = 2.83 at 25°C \ _ pK., = 5.69 at 25oC \ _ 
0 0 0 
Figure 3.2.10 Equation for Acid Dissociation of Malonic Acid, overall pKa = 8.52 
(Byun et el 2000) 
J <i。 0 0 0 
Figure 3.2.11 Equation for Acid Dissociation of 1,1 -cyclobutanedicarboxylic Acid, 
pKa not found 
1,1 -cyclobutanedicarboxylic acid is cyclobutyl derivative of malonic acid. This 
cyclobutyl group at the beta position tends to strengthen the 0-H bond at the -COOH 
group, i.e. reduce the acid strength and result in higher pKa (Brown et al 1955). Thus, 
the sum of pKai and pKa2 of 1,1 -cyclobutanedicarboxylic acid must be higher than 
that of malonic acid. The stability of the dicarboxylate decreases in the following 
trend: oxalate > malonate > 1,1 -cyclobutanedicarboxylate. 
The cytotoxicity data obtained from the literature is discussed below. For 
compound with 7?,/?-DACH-platinum moiety, the cytotoxity of platinum drug in 
A2780 sensitive breast cancer cell line decrease in the following trend: oxalate > 
1,1 -cyclobutanedicarboxylate > malonate (Monti et al 2005, summarized in Table 
3.2.2). In the same paper, the antitumor activity of another set of platinum compound 
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with Pt(NH3)2 moiety decrease according to the following trend: malonate > 
1,1 -cyclobutanedicarboxylate. The results imply that malonate and 
1，1 -cyclobutanedicarboxylate is similar to each other in cytotoxicity enhancement. 
The overall enhancement effect of the dicarboxylate can be summarized as shown: 
oxalate > 1,1 -cyclobutanedicarboxylate 〜malonate. This trend is similar to the trend 
observed in the stability. Hence, pKa, can potentially become a simple parameter in 
predicting the cytotoxicity enhancement effect exerted by dicarboxylate ligand. 
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3.3 Priority in Selecting the Most Effective Drug Combination 
The efficiency of the different drug combinations are evaluated from 
Combination Index (CI) obtained. 
广 1 _ D ( P T ) , D ( D M C ) ^ M 
L i - for concurrent treatment for 72 hrs 
^ ^ 50 (72 hrs Pt) I G 50 (？之 hrs DMC) 
广 1 - D ( P T ) D ( D M C ) ^ … 
~ + for concurrent treatment for 48 hrs 
I C 50 (48 hrs Pt) I C 50 (43 hrs DMC) 
CI = D(pt) + D (DMC) for platinum pre-sensitization 
IC CA ， Tr followed by concurrent treatment 
50 (72 hrs Pt) 上L 50 (48 hrs DMC) 】 
C l = D ( P T ) + D ( D M C ) for D M C pre-sensitization 
IC cn/.ou n � IC followed by concurrent treatment 
50 (48 hrs Pt) 丄L 50 (72 hrs DMC) 】 
pi = D(pt) D (DMC) 
L 广 p for platinum pretreatment 
丄L 50 (24 hrs Pt) I C 50 (48 hrs DMC) 
r ] 一 D ( P T ) D ( D M C ) 
TT~~ for D M C pretreatment 
IL 50 (48 hrs Pt) IC 50 (24 hrs DMC) 
The lower the CI, the more effective is the drug combination. In addition to 
efficiency, toxicity is another important issue widely of concern. The potential 







Since platinum drugs exhibit more side effects over the history of chemotherapy 
development, the DRI of the platinum drug is considered instead of D M C . The 
higher the DRI, the larger is the extent of reduced toxicity. 
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3.4 Drug Combination Studies 
3.4.1 Drug Combination Pre-screening 
Three different of drug combinations, namely D M C pretreatment, platinum 
pretreatment and concucurrent treatment of 48 hrs duration are evaluated in this 
section using the method reported by To et al (2005). Data for the two cell lines, 
H C T l 16 colorectal cancer cell and SK-Hepl liver cancer cell, are summarized in 
Appendix I - III. The combination index (CI) and dose reductive index (DRI) 
determined for all three treatment protocols are summarized respectively in Table 
3.4.1.1 & 3A1.2. 
Figure 3.4.1.1 Isobologram for Pre-screening in H C T l 16 Cell Line 
N o t e s : | - \ A n t a g o n i s m 
* C . 
T h e isobolograms for Concurrent Treatment ^ j \ 
for 48 hrs ( • A ) , D M C pretreatment ( O O ) ^ ： Additive Effect 
and Platinum Pretreatment ( • • ) are | ： \ 
presented on the left column, the middle 」 
column and the right column respectively. 」 
Details and data points are color-coated to - S y n e r g i s m 
indicate the relative treatment. . • . • 、 
** Platinum Potency Ratio 
Synergism is demonstrated w h e n the data 
point falls below the line of addivity (Diagonal • • D M C Dose Fixed 
Line) as indicated in the small graph on the D A O Platinum D o s e Fixed 
top of this page. Line of Additivity 
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o 
二 1 H C T 1 1 6 S 
s - - — -
一： 
0 f C o n c u r r e n t P D M C f Platinum 
2 K T r e a t m e n t | \ P r e t r e a t m e n t ^ t ^ 
1 - . . X ••••..CisBlatin 
§ I i^iSfc 1111111 ！Ns^ o —11 _ 丨 I 丨 I _ _ 11 i 111 
。： rPt(DMC)(NH,)o 
？ ： •-•• 
) 
. . . . . .—..K^::-
p I I I I I I 产丨•？Sfci I I I I I 、、1 I I I I I I I I I l^ ai 
J ° i [Pt(DMCHCH,NH,)o 
、 S -
a - ： b ： ° 
g . o 〕 
S § 4- — i-'?.."•••• 
rK K。 
1 • 
2 p I X i . , . . . I • • . 1 _ I I I I I I I I — 、 I 1 ' 1 I I I I I 
^ ° ： ； rPt(DMC)(R.R-DACH) 
S - -
P • . _ . X l I I I I 1 I I 1 1 ^ I I I • 1 I I I I 
• (o Qxalipiatin 
:::• 
p AX^Iij X , I I I I INP Ill 
° 0 . 0 0 0.50 1.00 1.60 0.00 0.50 1.00 1.50 0.50 1.00 1.50 2.00 
Platinum Potency Ratio (D / IC50) 
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Figure 3.4.1.2 Isobologram for Pre-screening in SK-Hepl Cell Line 
o 
p - I - I 
… SK-Hepl 
s ‘ > : 
• D 
g f Concurrent DMC l Platinum 
" ^ Treatment ^Pre t rea tment ^Pre t rea tment 
o \ : “ \ Cisplatin 
：: — . : J �—： ] - ^ 
[Pt(DMC)(NH,)o 
？ ： 5-6- ：• 
o ； ：：二 I 
曾 F \ = . . . — -
S \ A \ _•丨_ I丨丨丨I丨I丨丨I I I 
J O : r p _ c ) ( c H , _ 。 
^ s - ： ： 
Q - • q 
1 i It k k 
2 p 11111111XIIA11111 、一 — 11 
Q o -：陰:目 




° � " X ^ X ^ ：… ; . 
O ' ' ' • ' ' • ' ' y * ‘ ^ • ' ' - ' 1 ' ' • ' • ' • ' ^ • ‘ 
° 0 . 00 0.50 1.00 1.50 0.00 0.50 1.00 1.50 0.00 0.50 1.00 1.50 2.00 
Platinum Potency Ratio (D / IC50) 
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Table 3.4.1.1 Combination Index in Pre-screening 
Pt Dose : DMC Dose (umol/L) u广 t AAC cw^ 
Pt IC„ Ratio: DMC IcL Ratio H C T 1 1 6 SK-Hep1 
(Combination Index) Concurrent o i ^ P l a t i n u m Concurrent D i ^ ~ Platinum 
Treatment Pretreatment Pretreatment Treatment Pretreatment Pretreatment 
11.7 ： 4.50 10.9 ： 12.5 2.06 ： 6.22 7.68 ： 4.50 4.50 ： 11.8 3.12 ： 4.50 
C i sp la t in 0.57 ： 0.15 0.53 ： 0.39 0.83 ； 0.07 0.31 ; 0.41 0.47 ： 0.55 0.33 ： 0.41 
0.72 」 0.92 0.90 0.71 1.02 0.73 
5.44 ： 14.5 13.9 ： 9.00 9.35 ： 6.00 12.5 ： 4.50 16.1 ： 2.25 0.00 ： 11.5 
[Pt(DMC)(NH3)2] 0.19 ： 0.49 0.48 ： 0.28 0.65 ： 0.20 0.51 ： 0.41 0.65 ： 0.27 0.00 ； 104 
0.76 0.86 0.91 • 0.92 1 04 
I 13.9 ： 6.73"1 0.00 ： 30.1 17.6 ： 6.00 8.32 ： 2.52 1.50 ： 5.53 0.90 ： 7.42 
[Pt(DMC)(NH2CH3)2】 0.48 ： 0.23 0.00 ： 0,93 0.58 ： 0.20 0.67 ： 0.23 0.12 ： 0.67 0.05 ： 0.67 
0.70 0.93 0.78 0.90 0.79 0.72 
2.42 ： 4.50 2.15 ： 4.50 0.74 ： 5.40 3.18 ： 5.84 6.32 : 2.25 0.67 ： 7.89 
[Pt (DMC)(R ,R-DACH)】 0,55 ： 0.15 0.49 ； 0.14 0.62 ； 0.18 0.24 : 0.53 0.48 ； 0.27 0.22 ： 0.71 
0.71 0.63 0.80 0.77 0.75 0.93 
“ 0.93 ： 5.99 0.97 ： 4.80 0.30 ： 20.3 2.00 ： 4.43 5.53 ： 0.45 0.60 ： 5.73 
Oxal ip lat in 0.52 ： 0.20 0.54 ： 0.15 0.25 ： o.69 0.26 ： 0.40 0.71 ： 0.05 0.I6 ： 0.52 
0.72 0.69 0.94 0.66 0.77 0.68 
NOTES: 
• ICso Ratio is determined by the formula: DI ICm, where D is the dose used in the drug combination 
D (Pt) D (OMC) 
" C I of the drug combinations is determined by the following equations: CI = — + — 
'^50(Pt) ICRKDMC) 
The drug combinations with the lowest CI are bracketed 
Table 3.4.1.2 Dose Reduction Index in Pre-screening 
H C T 116 SK -Hep1 
Concurrent DMC Platinum Concurrent DMC Platinum 
Treatment Pretreatment Pretreatment Treatment Pretreatment Pretreatment 
C i s p l a t i n 1.8 1.9 1.2 3.3 2.1 3.1 
[ P t ( D M C ) ( N H 3 ) 2 ] I 5 .3 I 2.1 1.5 I 2.0 | 1 5 
[ P t ( D M C ) ( N H 2 C H 3 ) 2 ] I 2 1 I - 1.7 1.5 8.3 | 21.6 | 
[ P t ( D M C ) ( R , R - D A C H ) ] 18 | 2.0 | 1 6 4.2 2.1 | 4.6 | 
Oxa l i p l a t i n 1.9 1.8 | 4.0 | 3.9 1.4 | 6.3 [ 
N O T E S： _ ICSOTP.) 
‘DRI is determined from the formula: “ D^ p^^ " 
"The drug combinations with the highest DRI is bracketed 
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3.4.1.1 Comparison of the effectiveness of the three Drug Combinations 
In HCTl 16 colorectal cancer cell line, only concurrent treatment demonstrated a 
significant synergistic effect, all data points reported in Graph 3.4.1.1 fall below the 
line of additivity. For either D M C or platinum pretreatment, antagonism was clearly 
shown at high D M C or low platinum potency ratio, whereas synergism was 
demonstrated at lower D M C or high platinum potency ratio. Synergism was 
confirmed for all the five compounds using the concurrent treatment method, and the 
combination index ranges from 0.68 - 0.72 (refer to Table 3.4.1.1). By comparing the 
combination index shown in Table 3.4.1.1，concurrent treatment was found to be the 
most effective treatment among the three drug combinations in the three compounds 
cisplatin, [ P t ( D M C ) ( N H 3 ) 2 ] and [Pt(DMC)(NH2CH3)2]. For [Pt(DMC)(i?,i?-DACH) 
and oxaliplatin, D M C pretreatment was found to be more effective than the other 
treatments. On the other hand, platinum pretreatment was the least effective 
treatment among all five compounds studied. 
In SK-Hepl liver cancer cell line, both the clinically in-used compounds, 
cisplatin and oxaliplatin, demonstrated synergistic effect in concurrent treatment. 
Additive effect was observed in the concurrent treatment using the three 
DMC-containing platinum compounds as depicted by the purple dots in Graph 
3.4.1.2, which lied close to the line of additivity. Pretreatment with D M C confirmed 
a significant antagonistic effect at high D M C or low platinum potency ratio, where 
synergism was demonstrated at low D M C or high platinum potency ratio. The trend 
for platinum pretreatment was the reverse of that observed for D M C pretreatment, i.e. 
synergism at high D M C or low platinum potency ratio, and antagonism at low D M C 
or high platinum potency ratio. 
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3.4.1.2 Rationale for Drug Combination Studies presented in Section 3.4.2 & 
3.4.3 
From the results shown in section 3.4.1.1，it was concluded that concurrent 
treatment was the best drug combination treatment. Concurrent treatment 
demonstrated a high consistency in performance, which was be illustrated by a 
comparison of the combination index, CI = 0.68-0.72 in HCTl 16 for all the five 
compounds under testing. The results suggested a safe usage for patients since 
additive and/or synergism was demonstrated, for all the five compounds tested. 
Concurrent treatment with platinum and D M C demonstrated the best drug 
combinations among the three combinations tested. Can improvement be made to 
increase the efficiency (lower the CI) of these drug combinations? To answer this 
question, another drug combination protocol based on concurrent treatment was 
carried out and the results were reported in the following sections. The focus in 
Section 3.4.1.1 & 3.4.1.2 was to increase the combination index of concurrent 
treatment and provide an alternative drug combination for cancer chemotherapy. 
Novel drug combinations employ either D M C or platinum as a drug 
pre-sensitizer. Cells were pre-sensitized for the first 24 hrs, and were then treated by 
concurrent treatment for the next 48 hrs. Combination index (CI) and dose reductive 
index (DRI) are employed to evaluate the effectiveness of the novel drug 
combinations called D M C pre-sensitization and platinum pre-sensitization. 
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3.4.2 Drug Pre-sensitization Studies in Colorectal Cancer Cell Lines 
Two colorectal cancer cell lines were used in the screening, they are HCT116 
and HT29. Acquired oxaliplatin resistance was introduced into HCT116 
(HCTl 160xaR). All these three cell lines are under investigations. The CI and DRI 
of four kinds of drug combination, concurrent treatment for 48 hrs, concurrent 
treatment for 72 hrs, D M C pre-sensitization with concurrent treatment 
(DMC/concurrent treatment) and platinum pre-sensitization with concurrent 
treatment (Platinum/concurrent treatment) are summarized in Table 3.4.2.1 & Table 
3.4.2.2. The isobolograms are presented in Figure 3.4.2.1 where individual data sets 
(isobolograms) are shown in Appendix I，II & III. 
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Figure 3.4.2.1 Isobologram for colorectal cancer cell line 
(Cisplatin, [Pt(DMC)_3)2] and [Pt(DMC)_2CH3)2]) 
Notes: 
.9 \ 
I : \ Antagonism 
The isobolograms of drug combinations in HCT116 are presented on the Left column, g ： 
HT1160xaR in the middle and the HT29 on the right. The isobolograms presented in •§ ： 
the upper row show drug combinations of D M C and cisplatin, middle column for ^ ： Additive Effect 
[Pt(DMC)(NH3)2】 and lower row for [Pt(DMC)(CH3NH2)2】. | ： \ 
In the isobologram shown below, four kinds of drug combinations are shown. They 
are Platinum Pre-sensitization (••), Concurrent Treatment for 72 hrs (••), : Synerg ism 
Concurrent Treatment for 48 hrs ( A A ) and D M C Pre-sensitization (•〇)• Details and • • 
data points are color-coated to indicate the relative treatment. Platinum Potency Ratio 
*** • • • 參 D M C Dose Fixed 
Synergism is demonstrated when the data point falls below the line of addivity DOAO Platinum Dose 
(Diagonal Line) as indicated in the small graph on the top of this page. Fixed Line of 
o 
J K H C T 1 1 B s I h C T I 1 6 0 x a R N H T 2 9 
° ‘ \ \ \ Cisplatin 
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Figure 3.4.2.1 i Isobologram for colorectal cancer cell line 一 Concurrent Treatment 
(Cisplatin, [Pt(DMC脚3)2] and [Pt(DMC)_2CH3)2]) 
Notes: .0 T^ 
I： \ Antagonism 
* \ 
The isobolograms of drug combinations in HCT116 are presented on the Left column, g - \ 
HT1160xaR in the middle and the HT29 on the right. The isobolograms presented in § “ \ 
the upper row show drug combinations of D M C and cisplatin, middle column for o : Additive Effect 
[Pt(DMC)(NH3)2】 and lower row for [Pt(DMC)(CH3NH2)2]. Q: \ 
In each isobologram, two kinds of drug combinations are shown. They are Concurrent : « • 
Treatment for 72 hrs ( • • ) and Concurrent Treatment for 48 hrs ( • A). Details and • 乂门�“^⑴ \ 
data points are color-coated to indicate the relative treatment. Platinum potency Ratio 
*** • • D M C Dose Fixed 
Synergism is demonstrated when the data point falls below the line of addivity piatinum Dose Fixed 
(Diagonal Line) as indicated in the small graph on the top of this page. Une of Additivity 
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Figure 3.4.2.1 ii Isobologram for colorectal cancer cell line -
Platinum Pre-sensitization 
(Cisplatin, [ P t ( D M C ) _ 3 ) 2 ] and [Pt(DMC)(NH2CH3)2]) 
Notes: o 
I： \ Antagonism 
* S". \ 
The isobolograms of drug combinations in HCT116 are presented on the Left S : \ 
column, HT1160xaR in the middle and the HT29 on the right. The isobolograms 爱: \ 
presented in the upper row show drug combinations of D M C and cisplatin, middle y : Additive Effect 
column for [Pt(DMC)(NH3)2】 and lower row for [Pt(DMC)(CH3NH2)2]. Q ： \ 
In the isobologram shown below, drug combination Platinum Pre-sensitization ( • • q _ Nv 
•) are presented. Details and data points are color-coated to indicate the relative ； ^ " \ 
treatment. Platinum Potency Ratio 
*** • D M C Dose Fixed 
Synergism is demonstrated when the data point falls below the line of addivity 口 piatjnum Dose Fixed 
(Diagonal Line) as indicated in the small graph on the top of this page. — ^^ Additivity 
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Figure 3.4.2.1 iii Isobologram for colorectal cancer cell line - D M C Pre-sensitization 
(Cisplatin, [Pt(DMC)(NH3)2] and [Pt(DMC)(NH2CH3)2]) 
Notes: SKT 7~[ • 
2: \ Antagonism 
* f: \ 
The isobolograms of drug combinations in HCT116 are presented on the Left f ： \ 
column, HT1160xaR in the middle and the HT29 on the right. The isobolograms ^ ： Additive Effect 
presented in the upper row show drug combinations of D M C and cisplatin, middle ^ : \ 
column for [Pt(DMC)(NH3)2l and lower row for [Pt(DMC)(CH3NH2)2]. \ 
** In the isobolograms shown below, drug combination D M C Pre-sensitization (•〇） :Synergism Nv 
are presented. Details and data points are color-coated to indicate the relative ] .,,,.,. ,., ^ 
treatment. Platinum Potency Ratio 
*** 參 D M C Dose Fixed 
Synergism is demonstrated when the data point falls below the line of addivity „ Platinum Dose Fixed 
(Diagonal Line) as indicated in the small graph on the top of this page. — ^^ ^^。〒 Additivity 
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Figure 3.4.2.2 Isobologram for colorectal cancer cell line 
([Pt(DMC)(7?,/?-DACH), Oxaliplatin) 
Notes: B J \ r ~ ； 
2: \ Antagonism 
* I" \ 
The isobolograms of drug combinations in HCT116 are presented on the Left b . \ 
coloumn, HT1160xaR in the middle and the HT29 on the right. The isobolograms S. ： \ 
presented in the upper row show drug combinations of D M C and [Pt(DMC)(R • : Additive feet 
DACH), lower row for oxaliplatin. ° • 
* * \ 
In the isobologram shown below, four kinds of drug combinations are shown. They . \ 
are Platinum Pre-sensitization (••), Concurrent Treatment for 72 hrs (••), ‘ Synergism \ 
Concurrent Treatment for 48 hrs (AA) and D M C Pre-sensitization (•〇).Details Platinum'Potency Ratio 
and data points are color-coated to indicate the relative treatment. 
*** • • • 參 D M C Dose Fixed 
Synergism is demonstrated when the data point falls below the line of addivity n O A O Platinum Dose Fixed 
(Diagonal Line) as indicated in the small graph on the top of this page. _ _ _ _ _ 。{ Additivity 
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Figure 3.4.2.2i Isobologram for colorectal cancer cell line - Concurrent Treatment 
([Pt(DMC)(7?,/?-DACH), Oxaliplatin) 
Notes: 5 K ~ ； 
5 • \ Antagonism 
* \ 
The isobolograms of drug combinations in HCT116 are presented on the Left § _ \ 
coloumn, HT1160xaR in the middle and the HT29 on the right. The isobolograms ‘ \ 
presented in the upper row show drug combinations of D M C and [Pt(DMC)(R,/?- ^ : Additive Effect 
DACH), lower row for oxaliplatin. °: \ 
In each isobologram, two Kinds of drug combinations are shown. They are 
Concurrent Treatment for 72 hrs ( • • ) and Concurrent Treatment for 48 hrs ( • A). ‘ 丨sm \ 
Details and data points are color-coated to indicate the relative treatment. Platinum potency Ratio 
*** „ • • D M C Dose Fixed 
Synergism is demonstrated when the data point falls below the line of addivity piatjnum Dose Fixed 
(Diagonal Line) as indicated in the small graph on the top of this page. U^e of Additivity 
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Figure 3.4.2.2ii Isobologram for colorectal cancer cell line -
Platinum Pre-sensitization 
{[？t(PMC)(R,R-DACH), Oxaliplatin) 
Notes: I K ~ ； ^ 
2 “ \ Antagonism * “ \ 
The isobolograms of drug combinations in HCT116 are presented on the Left S ： \ 
coloumn, HT1160xaR in the middle and the HT29 on the right. The isobolograms S. • \ 
presented in the upper row show drug combinations of D M C and [Pt(DMC)(R,f?- | ： Additive ^ e c t 
DACH), lower row for oxaliplatin. 。• 
In the isobologram shown below, drug combination Platinum Pre-sensitization (••) ； 
are presented. Details and data points are color-coated to indicate the relative : Synergism \ 
treatment. 丨、 
Platinum Potency Ratio 
*** • D M C Dose Fixed 
Synergism is demonstrated when the data point falls below the line of addivity 口 piatjnum Dose Fixed 
(Diagonal Line) as indicated in the small graph on the top of this page. 一 ^^ Additivity 
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Figure 3.4.2.2iii Isobologram for colorectal cancer cell line - D M C Pre-sensitization 
([Pt(DMC)(/?,/?-DACH), Oxaliplatin) 
Notes: S T \ r ~ ； 
2: \ Antagonism 
* 『 \ 
The isobolograms of drug combinations in HCT116 are presented on the Left s \ 
coloumn, HT1160xaR in the middle and the HT29 on the right. The isobolograms S.: \ 
presented in the upper row show drug combinations of D M C and [Pt(DMC)(R ,R- 琴: Additive ^ect 
DACH), lower row for oxaliplatin. 。 
In the isobolograms shown below, drug combination D M C Pre-sensitization (•〇） ‘« Nv 
are presented. Details and data points are color-coated to indicate the relative “ 丨 s m \ 
treatment. Platinum Potency Ratio 
*** 眷 D M C Dose Fixed 
Synergism is demonstrated when the data point falls below the line of addivity 〇 piatjnum Dose Fixed 
(Diagonal Line) as indicated in the small graph on the top of this page. — ^^ Additivity 
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Table 3.4.2.2 Dose Reduction Index of Platinum Drugs in Colorectal Cancer Cell Lines 
Examp le H C T 1 1 6 H C T 1 1 6 0 x a R HT29 
D M C 
Drug Exposure Time 48 hrs 72 hrs 48 叫 72 hrsl 148 hrs 72 hrs " j 4 8 hrs 72 hrs 
T T ^ ~ P r e . s — ~ ~ 
C i sp l a t i n 
7 2 hrs „ .“ Platinum " Concurrent - 4 . 0 0 "4.OO 2.13 3.61 3.43 3.58 
Pre-sensitization Treatment 
48 hrs 5.32 2.06 2.65 3.44 
[Pt(DMC)(NH3)d 
72 hrs 8.59 2.67 2.48 1.67 16.0 2.15 
48 hrs 2.10 5.19 4.00 2.71 
[Pt(DMC)(NH2CH3)d 
72 hrs 30.9 3.32 3.57 3.57 3.39 4.26 
Notes: 
— DRI Is determined from the formula: ^ ― i 1 — — 1 1 — 
48 hrs 1.80 3.23 4.55 3.16 
[Pt(DMC)(R.R-DACH )； DR I = 
72 hrs D(py 1 47 3.05 2.79 1.78 1.75 2.55 
二 = s 二 r ' h e 1.94 3.65 ^ ^ 
Oxa l ip la t in 
72 hrs 13.0 1.63 6.01 2.30 8.86 4.43 
3.4.2.1 Comparison of Drug Pre-sensitization Treatment in Sensitive 
Colorectal Cancer Cell Lines 
In both sensitive colorectal cancer cell lines, i.e. HCT116 and HT29, synergism 
is demonstrated that all the points fall below the line of additivity (Refer to Figure 
3.4.2.1 & 3.4.2.2 respectively). In HCT116，a significant trend was revealed. The 
data showed that pre-sensitized with D M C is the most effective drug combination no 
matter what the platinum drug is, i.e. green dots being the most distant points away 
from the line of additivity. Though synergism was demonstrated, note that 
pre-sensitization with platinum drugs in HCT116 cell line produces the least effective 
drug combination. The values of CI are summarized in table 3.4.2.1 where drug 
combinations with the lowest CI are bracketed. 
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As shown in the isobolograms of HCT116 presented in figure 3.4.2.1 at page 75, 
individual isobologram in 76-78，the shape of the isobolograms of cisplatin and 
[Pt(DMC)(NH3)2] is similar to each other. Pre-sensitization with either cisplatin or 
[Pt(DMC)(NH3)2] results in data points which lie close to the line of additivity. Both 
drugs, when added concurrently with D M C , induces a prominent synergism at half of 
D M C IC50 and reduced synergism at lower concentration of D M C . These 
observations suggest a comparable mode of drug action for the two compounds 
although the leaving group is very different. In HCTl 16，cisplatin pre-sensitized with 
D M C produces synergistic effect at potency ratio of four to one (refer to Table 
3.4.2.1, page 66). Similarly, [Pt(DMC)(NH3)2] when pre-sensitized with D M C 
produces the same effect with the same potency ratio. These similarities suggest 
cisplatin and [Pt(DMC)(NH3)2] share a common antitumor mechanism. It is highly 
probable that [Pt(DMC)(NH3)2] is first chemically transformed to cisplatin in 
chloride-rich medium before it is transported into the cell, resulting in similar modes 
of drug action. 
The shape of the isobologram presented in Figure 3.4.2.1 for [Pt(DMC)(NH3)2] 
and [Pt(DMC)(CH3NH2)2] is completely different. This result suggests a different 
mode of drug action for the two compounds, which can be accounted for by the 
difference in the platinum moiety. 
The most effective drug combination in HCTl 16 is brought out by 
pre-sensitization with D M C . Refer to Table 3.4.2.1，pre-sensitization with 2.00 [ M 
D M C followed by 2.00 ^ iM D M C and 1.35 ^ iM [Pt(DMC)(尺i?-DACH)] concurrent 
treatment produces the lowest CI (0.43). The potency ratio is three to one. In the 
same drug combination treatment, oxaliplatin produces the same effect in potency 
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ratio one to one. Pre-sensitization with 6.00 nM D M C followed by 6.00 iiM D M C 
and 0.49 ^ M oxaliplatin provides the best efficiency (CI = 0.62). These findings 
suggest a different mode of drug action between the two compounds. The contrast 
between the two sets of isobolograms shown in Figure 3.4.2.2 supports this 
conclusion. These differences can be accounted for by the chemistry of the leaving 
group. Endothalate dissociated from [Pt(DMC)(尺i?-DACH)] and oxalate from 
oxaliplatin exhibits their antitumor effect differently, as suggested in section 3.2. 
In HT29, concurrent drug treatments are the most favorable, with cisplatin and 
[Pt(DMC)(NH3)2] being the two exceptional case. The isobolograms for the three 
compounds cisplatin, [Pt(DMC)(NH3)2] and [Pt(DMC)(CH3NH2)2] presented in 
Figure 3.4.2.1 are very different from each other in shape. It means HT29 responses 
to different drugs in a different way. That is different cell lines may possess different 
mechanism(s) in response to the same drug combination stimulation(s). 
Oxaliplatin when added concurrently with D M C produces synergism with 
highest efficiency at potency ratio of two to one. For the same drug combination, 
[Pt(DMC)(/?,7?-DACH)] produces the same effect at potency ratio of one to one. 
Though different in magnitude, the shape of the isobolograms for both compounds 
(refer to Figure 3.4.2.2) is similar. These finding suggests that HT29 is very sensitive 
to the platinum moiety, which is not the case in HCTl 16. Concurrent treatment is 
more favorable than D M C pre-sensitization in HT29. It demonstrates the main 
difference between the two cell lines 
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3.4.2.2 Comparison of Drug Pre-sensitization Treatment in Sensitive and 
Oxaliplatin Resistant HCT116 Colorectal Cancer Cell Lines 
Acquired oxaliplatin resistant (8 folds) is successfully introduced to HCTl 16. 
The drug Combinations in sensitive and resistant HCTl 16 (HCT1160xaR) are 
compared. In both sensitive and oxaliplatin-resistant HCTl 16，synergism is 
demonstrated. The details of drug combination data are shown in Table 3.4.2.1. The 
isobolograms presented in Figure 3.4.2.1 & 3.4.2.2 summarizes the data trend 
whereas individual data set are shown in Appendix I & II. 
In sensitive HCTl 16’ pretreatment with platinum drugs is generally 
accompanied with high concentration of D M C (half of D M C IC50) and low 
concentration of platinum (refer to table 3.4.2.1 at page 66). With the same 
combination treatment in oxaliplatin-resistant cell, lower concentration of D M C is 
required. This shows that sensitive HCTl 16 is generally more susceptible to 
platinum drugs and less sensitive to D M C than oxaliplatin resistant HCTl 16. In other 
words, oxaliplatin-resistant cell is more sensitive to D M C . Note also the highest DRI 
(2.65 to 7.33 times reduction) goes with the D M C pretreatment in HCT1160xaR 
(refer to table 3.4,2.2). This finding suggests D M C can be a potential drug candidate 
for treating resistant cancer. Hence, the role of D M C to sensitize resistant cell is 
clearly established here. 
The isobolograms of HCT1160xaR presented in Figure 3.4.1.1 (the middle 
column), the provides a comparison of the three platinum drugs, cisplatin, 
[Pt(DMC)(NH3)2] and [Pt(DMC)(CH3NH2)2]. The shape of the isobolograms of the 
two former compounds is similar to each other in shape. Mild synergism is 
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demonstrated in concurrent treatment and pretreatment with either cisplatin or 
[Pt(DMC)(NH3)2]. Either, when pretreated with D M C , produces a significant 
synergism. This finding further supports the conclusion that [Pt(DMC)(NH3)2] 
behaves similarly to cisplatin. The shape of isobolograms for [Pt(DMCXCH3NH2)2] 
shows much difference from the other two compounds, all the three time-dependent 
treatments provide the same combination efficiency surface, i.e. data points for the 
three drug combinations fall on a single curve. Thus, [Pt(DMC)(CH3NH2)2] produces 
synergism in all the three treatments with the same potency ratio of two to one (refer 
to Table 3.4.2.1) 
From the shape of the isobologram presented in 3.4.2.2, it can be shown that 
oxaliplatin-resistant HCTl 16 responses to oxaliplatin and [Pt(DMC)(足i?-DACH)] in 
a dissimilar mode. In case of oxaliplatin, platinum pretreatment is more favorable 
(shown by the red dots) while in the case of [Pt(DMC)(i?,i?-DACH)], D M C 
pretreatment is more favorable (shown by the green dots). 
Among all the platinum drugs tested, pretreatment with D M C is favored in both 
sensitive and oxaliplatin-resistant HCTl 16. This result suggests that pretreatment 
with D M C is a promising therapeutic regimen. In addition, platinum drugs gives 
lower CI in oxaliplatin-resistant cell than the respective treatment in sensitive one, i.e. 
enhanced efficiency is demonstrated in resistant cell. This enhancement is more 
significant for the two clinically-used compounds, cisplatin and oxaliplatin. 
Combination chemotherapy introduced here provides an alternate method for 
administrating cisplatin and oxaliplatin. 
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3.4.3 Drug Pre-sensitization Studies in Sensitive Liver Cancer Cell Lines 
Two Liver cancer cell lines were used in the testing of drug combinations, they 
are HEP G2 and SK Hepl. Cisplatin resistance was introduced into the SK-Hepl 
(SK-HeplCisR). The results for these three cell lines are discussed. The CI and DRI 
of three kinds of drug combination, concurrent treatment, D M C pre-sensitization 
with concurrent treatment (DMC/concurrent treatment) and platinum 
pre-sensitization with concurrent treatment (platinum/concurrent treatment) are 
summarized in Table 3.4.3.1 & 3.4.3.2. The isobolograms presented in Figure 3.4.3.1 
& 3.4.3.2 summarize the data trend whereas individual data sets are given in 
Appendix III，IV & V. 
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Figure 3.4.3.1 Isobolograms for liver cancer cell line 
(Cisplatin, [Pt(DMC)(NH3)2] and [Pt(DMC)(NH2CH3)2]) 
Notes: -B 7 " ： 
2: \ Antagonism 
* \ 
The isobolograms of drug combinations in HepG2 are presented on the Left column, oj ； \ 
SK-Hep1 in the middle and the SK-Hep1CisR on the right. The isobolograms S.'. \ 
presented in the upper row show drug combinations of D M C and cisplatin, middle ^ • Additive Effect 
row for [Pt(DMC)(NH3)2] and lower row for [Pt(DMC)(CH3NH2)2]. o • \ 
* * \ 
In the isobologram shown below, four kinds of drug combinations are shown. They . \ 
are Platinum Pre-sensitization (••)’ Concurrent Treatment for 72 hrs (••), : Synergism 
Concurrent Treatment for 48 hrs (AA) and D M C Pre-sensitization (•〇)• Details ‘ PI tin" m'poten'c Ratio 
and data points are color-coated to indicate the relative treatment. a mum o ency a lo 
*** •••參 D M C Dose Fixed 
？ynerg，is demonstrated when the data point falls below the line of addivity • •。〇 p,atinum Dose Fixed 
(Diagonal Line) as indicated in the small graph on the top of this page. af Additivity 
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Figure 3.4.3.1 i Isobolograms for liver cancer cell line - Concurrent Treatment 
(Cisplatin, [Pt(DMC)(NH3)2] and [Pt(DMC)(NH2CH3)2]) 
Notes: B T \ ； 
2: \ Antagonism 
* I ' \ 
The isobolograms of drug combinations in HepG2 are presented on the Left column,碧 \ 
SK-Hep1 in the middle and the SK-Hep1CisR on the right. The isobolograms S.: \ 
presented in the upper row show drug combinations of D M C and cisplatin, middle y •_ Additive ^ e c t 
row for [Pt(DMC)(NH3)2】 and lower row for [Pt(DMC)(CH3NH2)2]. ° \ 
* * 
In each isobologram, two kinds of drug combinations are shown. They are ^^  \ 
Concurrent Treatment for 72 hrs ( • • ) and Concurrent Treatment for 48 hrs ( • A). “ S y n e r g i s m \ 
Details and data points are color-coated to indicate the relative treatment. Platinum"Potency Ratio 
嫩 • • D M C Dose Fixed 
Synergism is demonstrated when the data point falls below the line of addivity piatinum Dose Fixed — 
(Diagonal Line) as indicated in the small graph on the top of this page. — ^ ^ ^ ^^ Additivity 
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Figure 3.4.3.lii Isobolograms for liver cancer cell line -
Platinum Pre-sensitization 
(Cisplatin, [Pt(DMC)(NH3)2] and [Pt(DMC)(NH2CH3)2]) 
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Figure 3.4.3.liii Isobolograms for liver cancer cell line - D M C Pre-sensitization 
(Cisplatin, [Pt(DMC)(NH3)2] and [Pt(DMC)(NH2CH3)2]) 
Notes: r ~ ； 
(2 • \ Antagonism 
* ？' \ 
The isobolograms of drug combinations in HepG2 are presented on the Left column, s \ 
SK-Hep1 in the middle and the SK-Hep1CisR on the right. The isobolograms (2 : \ 
presented in the upper row show drug combinations of D M C and cisplatin, middle y : Additive Effect 
row for [Pt(DMC)(NH3)2] and lower row for [Pt(DMC)(CH3NH2)2]. o : \ 
- \ 
In the isobolograms shown below, drug combination D M C Pre-sensitization (•〇） . \ 
are presented. Details and data points are color-coated to indicate the relative • S y n e r g i s m \ 
treatment. Platinum Potency Ratio 
*** 參 D M C Dose Fixed 
Synergism is demonstrated when the data point falls below the line of addivity q piatj^um Dose Fixed 
(Diagonal Line) as indicated in the small graph on the top of this page. 一 ^^ Additivity 
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Figure 3.4.3.2 Isobolograms for liver cancer cell line 
([Pt(DMC)(/?,/?-DACH)] and Oxaliplatin) 
Notes: r ~ 
2: \ Antagonism 
* ？ \ 
The isobolograms of drug combinations in HepG2 are presented on the Left column, s 
SK-Hep1 in the middle and the SK-Hep1CisR on the right. The isobolograms ‘ \ 
presented in the upper row show drug combinations of D M C and [Pt(DMC)(R,R- i • Additive ^ e c t 
DACH), lower row for oxaliplatin. 。•• 
* * \ 
In the isobologram shown below, four kinds of drug combinations are shown. They \ 
are Platinum Pre-sensitization (••), Concurrent Treatment for 72 hrs (••), “ Synerg ism \ 
Concurrent Treatment for 48 hrs (AA) and D M C Pre-sensitization (•〇).Details “ " ： _.•„•‘.•.‘； 
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and data points are color-coated to indicate the relative treatment. 
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Figure 3.4.3.2i Isobolograms for liver cancer cell line - Concurrent Treatment 
([Pt(DMC)(^,/e-DACH)] and Oxaliplatin) 
Notes: .9 T\ 
2: \ Antagonism 
* \ 
The isobolograms of drug combinations in HepG2 are presented on the Left column,龙 \ 
SK-Hep1 in the middle and the SK-Hep1CisR on the right. The isobolograms S. ： \ 
presented in the upper row show drug combinations of D M C and [Pt(DMC)(R,R- | •_ Additive ^ e c t 
DACH), lower row for oxaliplatin. 。‘ \ 
* * \ 
In each isobologram, two kinds of drug combinations are shown. They are “ \ 
Concurrent Treatment for 72 hrs ( • • ) and Concurrent Treatment for 48 hrs ( • A). • Synergism 
Details and data points are color-coated to indicate the relative treatment. 丨 广 
r Platinum Potency Ratio 
Synergism is demonstrated when the data point falls below the line of addivity 义々『尸H 
(Diagonal Line) as indicated in the small graph on the top of this page. ™ 
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Figure 3.4.3.2ii Isobolograms for liver cancer cell line -
Platinum Pre-sensitization 
‘ ([？t(DMC){R,R-DACH)] and Oxaliplatin) 
Notes: ~ ~ ： 
S ‘ \ Antagonism 
* ？’ \ 
The isobolograms of drug combinations in HepG2 are presented on the Left column, s \ 
SK-Hep1 in the middle and the SK-Hep1CisR on the right. The isobolograms ^ : \ 
presented in the upper row show drug combinations of D M C and [Pt(DMC)(R,R- i : Additive ^ e c t 
DACH), lower row for oxaliplatin. ° 
* * 
In the isobologram shown below, drug combination Platinum Pre-sensitization (••) ‘ « 
are presented. Details and data points are color-coated to indicate the relative • ^ yl^Ql^gism \ 
tr^ otmpnf ' ' • . -t^  
i r ea imen i . Platinum Potency Ratio 
• D M C Dose Fixed 
Synergism is demonstrated when the data point falls below the line of addivity 口 卩丨3她阳 Dose Fixed 
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Figure 3.4.3.2iii Isobolograms for liver cancer cell line - DMC Pre-sensitization 
([Pt(DMC)(7?,/?-DACH)] and Oxaliplatin) 
Notes: 2 K" ~ ~ ： 
(2: \ Antagonism 
* 昏 ： \ 
The isobolograms of drug combinations in HepG2 are presented on the Left column, s \ 
SK-Hep1 in the middle and the SK-Hep1 CisR on the right. The isobolograms ^ ’ \ 
presented in the upper row show drug combinations of D M C and [Pt(DMC)(R,R- i ‘ Additive ^ e c t 
DACH), lower row for oxaliplatin. 。‘ 
In the isobolograms shown below, drug combination D M C Pre-sensitization ( # 0 ) • ^^ . 
are presented. Details and data points are color-coated to indicate the relative ” synerg ism \ 
treatment. .二: 
Platinum Potency Ratio 
*** 參 D M C Dose Fixed 
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Table 3.4.3.2 Dose Reduction Index of Platinum Drugs in Liver Cancer Cell Lines 
Examp le HEP G2 SK-HEP1 3K-HEP1 C i s R 
DMC 
Drug Exposure Time 48 lus 72 hfs 48 hrs 72 hfs 148 hrs 72 hrs 148 hrs 72 hrs 
^ ~ 一 3 . 2 6 T ^ T T ^ T 
C i sp l a t i n ： 
72hrs D‘"Plati,nun;>. ••Concurrent •••ii i“i2.4 19.1 12.42 2.01 5.64 
Pre-sensitization Treatment 
48 hrs 1.97 7.72 2.63 
[Pt(DMC)(NH3)d 
72 hrs 2.25 9.00 1.95 2.79 
48 hrs 5.24 1.50 1.63 3.71 
[Pt(DMC)(NH2CH3)d 
72 hrs 5.51 10.2 3.68 3.75 5.57 3.09 
Notes: 
DRI Is determined from the formula: r — — — i 1 — — i 
48 hrs 11.8 4.2 87.9 3.93 
[Pt(DMC)(R,R-DACH )： = 
72 hrs D<pt> 5.22 2.64 2.21 3.04 4.56 4.36 
M S e T o ^ s r S r 丨he 3.90 5.55 
Oxa l ip la t in 
72 hrs 7.18 2.43 1.86 15.3 4.07 9.17 
3.4.3.1 Comparison of Drug Pre-sensitization Treatment in Sensitive Liver 
Cancer Cell Lines 
In both liver cancer cell lines, Hep G2 and SK-Hepl, synergism is demonstrated. 
Concurrent drug treatment with cisplatin produces the drug combinations with the 
highest efficiency in Hep G2 while Cisplatin pretreatment provides the best treatment 
in SK-Hepl (refer to Table 3.4.3.1). Similarly, [Pt(DMC)(NH2CH3)2] produces the 
same effect in the two cell lines. In the isobologram of Hep G2 presented in Figure 
3.4.3.1 (the left column), these two compounds demonstrate significant synergism in 
a similar pattern. In the drug combinations of these two drugs, D M C pretreatment 
produces the least efficient synergistic effect, while the efficiency of the platinum 
pretreatment is very close to the concurrent treatment. These observations suggest a 
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comparable mode of antitumor action of the two compounds. However, this 
conclusion is not observed in SK-Hepl, nor in SK-HeplCisR. As shown in the 
isobologram presented in Figure 3.4.3.2，Cisplatin, [Pt(DMC)(NH3)2] and 
[Pt(DMC)(NH2CH3)2] demonstrate a different mode of drug action in both SK-Hepl. 
In SK-Hepl, the drug combination having the highest efficiency is platinum 
pretreatment (shown by the red dots). These results indicate that liver cancer 
responses in a dissimilar way to the different platinum moiety. This conclusion can 
be supported by the similarities found in the [Pt(DMC)(i?,/?-DACH] and oxaliplatin 
drug combination treatment. 
The isobolograms presented in Figure 3.4.3.2 Page 73 (the left and the middle 
columns) show that (DMC)(i?，及-DACH] and oxaliplatin possess a different mode of 
antitumor action. In both sensitive cell lines Hep G2 and SK-Hepl, D M C 
pretreatment with either of these two compounds, produces synergism with the 
highest efficiency. Thus, it can be concluded that both liver cancer cell lines are 
sensitive to the platinum moiety. Oxaliplatin and (DMC){R,R-DACU] can be 
considered as a group and cisplatin, [Pt(DMC)(NH3)2] and [Pt(DMC)(NH2CH3)2] 
can be considered as another group. Each member in a group exerts similar overall 
cellular effects and produces similar drug combination efficiency. 
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3.4.3.2 Comparison of Drug Pre-sensitization Treatment in Sensitive and 
Cisplatin Resistant SK Hepl Liver Cancer Cell Line 
Acquired cisplatin resistant (14.8 folds) is successfully introduced to SK-Hepl. 
The drug combinations in sensitive and resistant SK Hepl are compared. The details 
of drug combination data are summarized in Table 3.4.3.1 and 3.4.3.2. The 
isobolograms presented in Figure 3.4.3.1 & 3.4.3.2 summarizes the data trend 
whereas individual data sets are given in Appendix 3.4.5 & 3.4.6. 
In both sensitive and cisplatin resistant SK Hepl, synergism is demonstrated. 
The isobolograms presented in Figure 3.4.3.1 on Page 73 shows that cisplatin, 
[Pt(DMC)(NH3)2] and [Pt(DMC)(NH2CH3)2] demonstrate different mode of 
antitumor activity . In sensitive SK-Hepl, though pretreatment with either one of 
these three platinum demonstrates the most efficient synergism (refer to table 3.4.3.1), 
the shape of the isobolograms of the three is completely different. In SK-Hep CisR, 
the same observations are found. The most efficient drug combination of these three 
compounds in SK-Hepl is brought about by platinum pretreatment while in 
SK-Hepl CisR, concurrent treatment is more favorable. 
Cytotoxicity of [Pt(DMC)(NH2CH3)2] is about two times of [Pt(DMC)(NH3)2]. 
Both compounds demonstrate a comparable mode of antitumor activity in four of the 
six cell line under testing as suggested in section 3.1. Therefore, 
[Pt(DMC)(NH2CH3)2] may possibly be chemically transformed to a cisplatin-like 
structure, [Pt(Cl)2(NH2CH3)2]，before it goes into the cell. However, the difference by 
a methyl group in the carrier ligand renders it less potent towards cancer cell, as 
suggested in other literature (Chaney et al 1999). 
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In SK-HeplCisR, the most efficient platinum pretreatment is bought about by 
higher concentration of D M C (2.00 to 15.4 ^ M refer to table 3.4.3.1). In sensitive 
SK-Hepl, for the same drug combination treatment, a relatively lower concentration 
of D M C is required (1.45 to 4.33 pM). This finding suggests that SK-Hepl CisR is 
less sensitive towards D M C than sensitive cell. Thus either platinum pretreatment or 
concurrent treatment can be a choice for the chemotherapy of liver cancer. 
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3.5 Possible Explanation to the Observed Drug Combination Effect 
How does D M C sensitize the cells towards platinum drug? D M C can affect the 
cells in such a way that it enhances platinum drug uptake, inactivating antiapoptotic 
protein and affecting cell-cell signaling. 
D M C is able to inhibit the dephosphorylation activity of protein phosphastase 
which works against protein kinases in intercellular signaling communication (Duthe 
et al 2001). Cantharidin is proved to increase the vascular endothelial permeability 
by enhancing the phosphorylation state of endothelial regulatory proteins (Knapp et 
al 1999). As an analogue of cantharidin and PP inhibitor, D M C may possibly play a 
part in monitoring the cell membrane permeability. By increasing the accumulation 
or decreased drug efflux, drug resistance mechanisms can be reversed. This 
conclusion can be supported indirectly by CI < 1，i.e. enhanced drug efficiency in 
both cisplatin resistant SK-Hepl and oxaliplatin resistant HCTl 16. For further 
validation of this point in the future, it is necessary to determinate if DMC-pretreated 
cell allows accumulation of higher concentration of platinum drugs. Direct in vitro 
evidence can be found by determining the cellular platinum content using 
AAS/graphite furnace. 
Rapid tumor growth and development with angiogenesis induces extracellular 
acidosis. Maintainance of pH homeostasis is crucial for solid tumor development, 
thus tumor cells express various pH regulators to avoid apoptosis. D M C can be 
hydrolysed to endothal, a diacid which may influence cellular pH during 
chemotherapy. It is found that cells exposed to hypoxia and low pH have a 
diminished capacity for D N A repair, when compared to cell under normal standard 
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growth conditions (Yuan et al 2000). It is highly probable that endothal dissociated 
from the platinum moiety act to suppress the D N A repair capacity by lowering the 
pH of the microenvironment, allowing platinum to bind on the D N A with reduced 
repairing and thus leading to apoptosis with a more efficient pathway. This point is 
supported by the finding of another paper (Izumi et al 2003) suggesting that 
cisplatin-DNA adduct formation is enhanced under acidic conditions and a lower 
chloride concentration. In cisplatin-resistant cell, where pH is even lower than that of 
normal cell, enhanced formation of DNA-cisplatin cross-links is associated with 
increased sensitivity to cisplatin. 
Cantharidin induce apoptosis by phosphorylation of p53, upregulation of 
downstream target genes, M D M 2 and p21 and also cleaved caspase-3 (Huh et al 
2004). Another study suggests that acidic media with pH 6.2 -6.6 cause an 
up-regulation of Bax protein expression, induce PARP cleavage and D N A 
fragmentation and caspases activation, finally leading to apoptosis in G1 phase (Park 
et al 1999). By lowering the pH, endothal may encourage apoptosis in D M C 
pretreated cancer cell. 
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3.6 General Protocols for Drug Combinations 
In all the cell lines evaluated, significant synergism was observed in a 
dose-dependent and time-dependent manner. Frankly speaking, with different cellular 
mechanism, cell lines response can sometimes be unpredictable. There is no simple 
rule in predicting or governing the cellular response to drug combinations. In general, 
drug combination effect can be affected by several reasons, 1) cell lines used, 2) time 
treatment profile, 3) carrier ligand of platinum. 
For colorectal cancer, either D M C pretreatment or concurrent treatment is more 
effective and less toxic. This suggested chemotherapy produces a prominent 
synergistic effect in both sensitive and resistant cell lines. Platinum dose can be 
reduced up to 15.0 folds for D M C pretreatment and up to 4.4 folds for concurrent 
treatment. 
For liver cancer, the case is slightly complicated since liver cell response 
according to the different platinum moiety. For platinum drug with diamine group or 
bis(methylamine) group as the carrier ligand, such as cisplatin, [ P t ( D M C ) ( N H 3 ) 2 ] 
and [Pt(DMC)(NH2CH3)2]，platinum pretreatment and concurrent treatment is the 
best choice for both sensitive and resistant cell line. For platinum drug containing 
R,R-DACH as the carrier ligand, such as oxaliplatin and [Pt(DMC)( i?，/^DACH)], 
D M C pretreatment or concurrent treatment is favored. This suggested treatment 
produces a significant synergistic effect in both sensitive and resistant cell lines. 
Platinum dose can be reduced up to 19.1 folds in platinum pretreatment and up to 




Cisplatin and oxaliplatin are nowadays the mainstream treatment for solid 
tumors in cancer chemotherapy, however, their clinical use is often limited by their 
severe side effects. In the case of cisplatin, nephrotoxicity and neurotoxicity is 
unavoidable. Thus novel DMC-containing platinum drugs are synthesized by this 
group previously to address on these problems. Three compounds namely, [Pt(DMC) 
(NH3)2]，[Pt(DMC) (NH2CH3)2] and [Pt(DMC)(尺i?-DACH)] are chosen for further 
development due to their higher potency and lower toxicity. 
DMC as a Sensitizer in Cancer Chemotherapy 
It is shown that D M C can sensitize both cisplatin resistant SK-Hepl and 
oxaliplatin resistant HCTl 16 towards platinum drug treatment. D M C probably 
sensitize the cell by several pathways: 1) enhancing the permeability of the cell 
membrane towards platinum uptake (Knapp et al 1999); 2) suppressing the D N A 
repair capacity (Yuan et al 2000); 3) speeding the platinum-DNA reaction by 
lowering the pH (Izumi et al 2003); and 4) inducing apoptosis by phosphorylation of 
p53 (Park et al 1999). In resistant cancer cells which are less sensitive to platinum 
moiety, D M C can be transformed to its diacid readily under an acidic 
microenvironment, which will in turn lowers the pH of the cancer cell. By altering 
the pH microenvironment of the cancer cell, the resistant cell allows faster 
platination of D N A , rendering the cell more sensitive towards chemotherapy 
regimen. 
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D M C can be used in combination with platinum drug in cancer chemotherapy. 
In drug combination chemotherapy, toxic platinum drug dosage is reduced and the 
possible side effect can be minimized. It is shown in this thesis that D M C drug 
combination is a safe regimen which can be potentially applied in a clinical setting 
due to its low toxicity and absence of adverse drug interaction, i.e. no antagonism is 
found. D M C can be easily synthesized through Diels-Alder reaction. Its production is 
relatively cheaper than costly platinum drug and thus combination of D M C with 
platinum can become an alternative economical regimen for cancer patients in the 
near future. 
To Design New Platinum Drugs with a Dual Drug Action Mechanism 
Throughout the studies, it has been shown that several chemical characteristics 
are able to enhance the potency. In designing a platinum drug, the most important 
thing should no doubt be platinum, the next essential component is the carrier ligand. 
The potency of platinum moiety decreases as shown in the following trend: [Pt 
(R,R-DACH)] > [Pt(NH3)2] > [Pt(NH2CH3)2]. Carrier ligand determines the 
DNA-binding mode and thus the cellular response to the compound (Chaney et al 
1999). Although efforts in search for another ligand to replace 尺/^DACH as the 
carrier ligand continue, however, there is not a successful candidate so far. Finally, to 
complete the complex as a neutral compound (charged compound is less likely to 
penetrate through the cell membrane), dianion or other chelating ligands can be 
considered. The better the stability of the leaving ligand, the better is the potency. 
Leaving ligand can help to refine the cytotoxicity of the platinum moiety, once 
dissociated from platinum. The leaving ligand probably chelate the platinum moiety 
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before it gets to the target, which can save the platinum moiety from unfruitful 
binding and avoid unwanted side effect. But if the leaving ligand binds too strongly 
towards the platinum like that exhibited by sulfide, the drug will be deactivated or 
become less potent like carboplatin. Thus leaving ligand should be carefully chosen 
to affect a suitable timing for platinum-DNA binding and exerts its own benefical 
biological effect in the chemotherapy. 
Role of Diacid as leaving ligand 
Of the five platinum drugs tested, only oxaliplatin can circumvent cisplatin 
resistant in SK-Hepl and no drugs can circumvent oxaliplatin resistant in HCTl 16. It 
is an important question to ask: why oxaliplatin alone can perform such a function? 
Oxaliplatin with oxalic acid and [Pt(DMC)(尺i?-DACH)] with D M C as the leaving 
ligands can make so much difference in the drug action. Though the mystery of 
oxaliplatin is still unresolved, it is clear that oxalic acid does help in the way D M C 
doesn't. Further study on oxalic acid points out that oxalic acid is a natural toxin 
possessing strong reducing ability. It is generated and destroyed by our body daily. 
Being a very good metal chelater, it may precipitate calcium and magnesium ions 
(Lane 1994’ Recht et al 2004). The clue of oxaliplatin possibly depends on the ability 
of oxalate to chelate metal ion. Oxalate can act as a carrier for platinum to the target 
D N A or as a trap for other important metal ions in essential proteins. 
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Appendix I a) Raw Data of Pre-screening for HCTl 16 
(Cisplatin, [Pt(DMC)(NH3)2] and Pt(DMC)(NH2CH3)2]) 
Raw Data for HCT116s ” dmc sd ci Pt dr i p^  so ci PtDRi 
(FIxsd) (Fixed) 
MM MM MM pM pM MM 
Cisplatin 
DMC Pretreatment 0.00 32.3 9.28 1.00 - 0.00 22.6 3.50 1.09 0.92 
0.22 44.0 4.26 1.38 94.4 0.54 20.9 5.59 1.03 0.99 
1.09 40.1 7.83 1.30 18.9 4.05 20.1 2.09 1.10 1.03 
2.19 38.2 3.37 1.29 9.44 8.10 15.4 3.21 1.00 1.34 
10.9 12.5 5.66 0.92 1.89 
21.9 3.71 0.76 1.17 0.94 
Concurrent Treatment 0.00 28.9 4.40 0.98 - 0.00 21.1 3.44 1.02 0.98 
0.80 27.8 5.13 0.98 25.8 0.45 15.5 2.32 0.77 1.33 
4.34 18.4 0.86 0.83 4.75 2.25 14.7 2.20 0.79 1.41 
8.69 11.6 0.67 0.81 2.38 4.50 11.7 2.67 0.72 1.76 
Platinum Pre-sensitization 0.00 29.8 16.8 1.01 - 0.00 8.06 0.68 1.08 0.93 
0.60 35.9 3.75 1.30 12.5 0.41 9.84 1.90 1.33 0.76 
3.00 25.0 17.3 1.25 2.50 2.06 6.22 0.36 0.90 1.20 
6.00 3.59 0.95 0.92 1.25 4.12 6.01 0.36 0.94 1.25 
20.62 5.03 1.32 1.37 1.49 
[Pt(DMC)(NH3)2] 
DMC Pretreatment 0.00 34.4 5.22 1.06 - 0.00 30.6 3.73 1.06 0.94 
0.60 42.1 15.2 1.32 48.2 0.60 23.4 7.33 0.83 1.24 
3.00 48.0 9.34 1.59 9.64 4.50 17.6 7.78 0.75 1.64 
6.00 49.6 6.49 1.74 4.82 9.00 13.9 4.05 0.76 2.08 
45.0 4.54 0.71 1.55 6.37 
Concurrent Treatment 0.00 28.9 6.31 0.98 - 0.00 29.4 2.56 1.02 0.99 
0.54 24.8 2.27 0.86 53.2 0.45 24.9 1.29 0.88 1.16 
2.72 20.0 3.17 0.77 10.6 2.25 21.3 5.98 0.81 1.36 
5.44 14.5 0.93 0.68 5.32 4.50 16.3 8.17 0.72 1.77 
27.2 2.56 0.27 1.03 1.06 
Platinum Pre-seiisilization 0.00 31.5 10.2 1.07 - 0.00 14.6 1.80 1.02 0.98 
0.90 42.0 7.44 1.49 15.9 0.60 12.9 0.85 0.92 1.11 
4.50 41.4 0.46 1.72 3.18 3.00 11.1 1.12 0.88 1.29 
9.00 26.8 12.8 1.54 1.59 6.00 9.35 0.70 0.86 1.53 
30.0 8.40 3.04 1.60 1.70 
[Pt(DMC)(CH3NH2)2】 
DMC Pretreatment 0.00 30.1 1.34 0.93 - 0.00 31.3 7.67 1.07 0.93 
0.45 44.6 4.51 1.40 65.5 0.90 40.2 10.5 1.41 0.73 
2.23 43.7 10.0 1.43 13.1 4,50 44.5 7.01 1.66 0.66 
4.46 39.1 20.0 1.37 6.55 9.00 42.9 1.80 1.75 0.68 
22.3 28.8 11.8 1.66 1.31 45.0 4.95 0.92 1.56 5.90 
Concurrent Treatment 0.00 30.9 7.05 1.05 - 0.00 28.3 7.55 0.97 1.03 
0.14 29.2 11.9 1.00 210 0.45 24.1 7.89 0.84 1.21 
0.69 25.9 10.5 0.90 42.1 2.25 23.7 12.7 0.89 1.23 
1.39 24.6 9.85 0.88 21.0 4.50 18.9 5.93 0.80 1.54 
6.93 14.0 4.63 0.71 4.21 22.5 2.74 0.61 0.86 10.6 
13.9 6.73 1.28 0.70 2.10 
Platinum Pre-sensitization 0.00 30.9 12.6 1.05 - 0.00 30.7 9.18 1.01 0.99 
0.90 36.5 7.74 1.27 33.8 0.60 26.3 3.48 0.89 1.15 
4.50 30.9 16.57 1.20 6.76 3.00 23.6 9.60 0.88 1.29 
9.00 42.6 3.84 1.74 3.38 6.00 17.6 2.72 0.78 1.73 
30.0 15.2 4.97 1.52 2.00 
Abbreviation: Combination Index (CI). Dose Reduction Index (DRI). Demethylcantharidin (DMC), Platinum (Pt), 
Standard Deviation (SD) 
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Appendix I b) Raw Data of Pre-screening for HCTl 16 
([Pt(DMC)(足i?-DACH)] and Oxaliplatin) 
p* DMC 
Raw Data for HCT116s dmc sd ci Pt dr i Pt sd ci Pt dr i 
(PIxad) (Fixed) 
MM JJM MM MM MM MM 
[Pt(DMC)(R,R-DACH)] 
DMC Pretreatment 0.00 32.6 8.86 1.01 - 0.00 4.17 1.52 0.96 1.04 
0.03 44.2 3.19 1.38 126 0.60 2.90 1.15 0.68 1.50 
0.17 45.7 8.49 1.46 25.2 4.50 2.15 0.53 0.63 2.03 
0.35 21.7 6.74 0.75 12.6 9.00 1.59 0.52 0.64 2.74 
1.73 10.1 3.07 0.71 2.52 
Concurrent Treatment 0.00 31.7 3.17 1.08 - 0.00 4.04 0.50 0.93 1.08 
0.08 30.3 4.19 1.05 51.9 0.45 4.00 1.26 0.93 1.09 
0.42 29.5 3.72 1.10 10.4 2.25 3.04 1.92 0.77 1.43 
0.84 15.9 4.29 0.73 5.19 4.50 2.42 0.12 0.71 1.80 
22.5 0.77 0.24 0.94 5.67 
Platinum Pre-sensitization 0.00 31.9 1.61 1.08 - 0.00 1.20 0.24 1.00 1.00 
0.13 27.8 7.13 1.06 8.82 0.54 1.70 0.75 1.44 0.70 
0.67 18.1 12.9 1.18 1.76 2.70 1.03 0.22 0.95 1.16 
5.40 0.74 0.13 0.80 1.62 
27.0 0.43 0.12 1.28 2.76 
Oxaliplatin 
DMC Pretreatment 0.00 32.8 11.9 1.02 - 0.00 1.78 0.27 0.99 1.01 
0.02 58.0 8.49 1.81 92.3 0.60 2.12 0.52 1.19 0.85 
0.10 57.9 5.50 1.85 18.5 4.50 1.27 0.22 0.85 1.41 
0.19 55.0 5.72 1.81 9.23 9.00 1.26 0.28 0.98 1.43 
0.97 4.80 3.76 0.69 1.85 45.0 1.07 0.19 1.99 1.68 
Concurrent Treatment 0.00 27.9 2.16 0.95 - 0.00 1.91 0.12 1.06 0.94 
0.03 24.9 6.11 0.86 60.0 0.60 1.87 0.58 1.06 0,96 
0.15 22.7 3.67 0.85 12.0 3.00 1.37 0.72 0.86 1.31 
0.30 18.6 2.98 0.80 6.00 5.99 0.93 0.29 0.72 1.94 
1.50 0.92 0.50 0.86 1.20 
Plaliruim Pre-sensitization 0.00 28.7 6.65 0.97 - 0.00 1.23 0.17 1.04 0.97 
0.30 20.3 6.33 0.94 3.95 0.60 1.26 0.11 1.08 0.94 
0 60 1 4 2 4.53 0.99 1.98 3.00 1.27 0.14 1.18 0.93 
6.00 0.90 0.28 0.97 1.31 
30.0 0.21 0.08 1.20 5.59 
Abbreviation: Combination Index (CI), Dose Reduction Index (DRI), DemethylCantharidin (DMC). Platinum (Pt). 
Standard Deviation (SD) 
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Appendix II a) Raw Data of Pre-screening for SK-Hep 1 
(Cisplatin, [Pt(DMC)(NH3)2] and Pt(DMC)(NH2CH3)2]) 
Raw Data for SK-Hep1 *** dmc sd ci pt dri pt so ci pt dri 
r (Fixed) (Fixed) 
mM MM MM KIM MM pM 
Cisplatin 
DMC Pretreatment 0.00 8.22 2.67 1.00 - 0.00 26.0 8.83 1.04 0.97 
0.11 13.8 3.02 1.68 222 0.45 29.4 14.3 1.23 0.85 
0.56 12.8 2.33 1.58 44.4 2.25 23.6 8.80 1.22 1.06 
I.13 11.6 1.72 1.46 22.2 4.50 11.8 3.24 1.02 2.12 
5.65 6.65 1.04 1.03 4.44 
II.3 4.81 0.86 1.04 2.22 
Concurrent Treatment 0.00 11.9 1.96 1.08 - 0.00 23.8 0.39 0.95 1.05 
0,16 11.6 0.45 1.06 153 0.45 24.3 3.98 1.01 1.03 
0.82 10.6 0.88 0.99 30.5 2.25 18.4 2.07 0.94 1.36 
1.64 7.91 1.39 0.78 15.3 4.50 7.68 0.97 0.71 3.26 
8.20 4.81 1.10 0.76 3.05 
16.4 3.23 0.81 0.95 1.53 
Platinum Pre-sensitization 0.00 11.9 1.65 1.07 - 0.00 26.0 8.83 1.00 1.00 
0.60 7.68 0.97 0.76 15.9 0.45 29.4 14.3 0.79 1.34 
3.00 4.73 0.88 0.74 3.19 2.25 23.6 8.80 0.76 1.80 
6.00 1.54 0.86 0.77 1.59 4.50 11.8 3.24 0.73 3.06 
[Pt(DMC)(NH3)2】 
DMC Pretreatment 0.00 9.01 1.78 1.09 - 0.00 24.4 2.45 0.99 1.01 
0.72 11.7 2.97 1.45 34.2 0.45 28.8 5.11 1.22 0.86 
3.62 11.9 1.60 1.59 6.83 2.25 16.1 2.26 0.92 1.54 
7.24 9.41 1.60 1.44 3.42 4.50 11.7 3.54 1.02 2.11 
Concurrent Treatment 0.00 11.1 1.52 1.01 - 0.00 24.5 3.10 0.99 1.01 
0.90 10.3 2.28 0.97 27.5 0.45 27.5 2.54 1.15 0.90 
4.50 9.79 0.98 1.07 5.49 2.25 17.9 1.43 0.93 1.38 
9.00 6.66 0.53 0.97 2.75 4.50 12.5 1.84 0.91 1.97 
Platinum Pre-sensitization 0.00 11.5 2.19 1.04 - 0.00 8.14 3.06 1.04 0.96 
0.90 16.1 5.89 1.57 8.70 0.90 8.99 2.02 1.23 0.87 
4.50 5.90 1.13 1.11 1.74 4.50 6.13 1.92 1.19 1.28 
9.00 5.13 0.01 1.61 0.87 9.00 3.71 0.37 1.29 2.11 
45.0 2.62 0.51 4.41 2.99 
[Pt(DMC)(CH3NH2)2】 
DMC Pretreatment 0.00 8.32 2.39 1.01 - 0.00 13.3 0.90 1.06 0.94 
0.30 9.02 1.52 1.12 41.6 0.31 12.3 2.04 1.02 1.02 
1.50 5.53 0.61 0.79 8.32 1.54 8.43 1.58 0.86 1.48 
3.00 5.01 0.57 0.85 4.16 3.07 5.35 0.08 0.80 2.33 
Concurrent Treatment 0.00 10.0 1.02 0.91 - 0.00 13.3 1.43 1.07 0.94 
0.40 11.7 1.49 1.09 30.8 0.50 15.3 6.30 1.27 0.81 
2.02 11.0 2.17 1.16 6.16 2.52 8.32 1.23 0.90 1.50 
4.05 8.38 1.00 1.08 3.08 5.05 6.65 0.71 0.99 1.88 
Platinum Pre-sensftizatiori O.OO 11.1 4.53 1.00 - 0.00 18.3 5.14 0.94 1.06 
0.90 7.42 0.01 0.72 21.6 0.90 15.5 3.45 0.88 1.26 
4.50 6.36 0.58 0.81 4.32 4.50 13.4 1.57 1.10 1.45 
9.00 6.52 2.62 1.05 2.16 9.00 0.28 0.00 0.83 69.7 
Abbreviation: Combination Index (CI), Dose Reduction Index (DRI), DemethyiCantharidin (DMC), Platinum (Pt), 
Standard Deviation (SD) 
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Appendix II b) Raw Data of Pre-screening for SK-Hep 1 
([Pt(DMC)(;?,i?-DACH)] and Oxaliplatin) 
Raw Data for SK-Hep1 ‘** dmc sd ci Pt dri Pt sd ci Pt dri 
^ (Fixed) (Fixed) 
pM pM pM pM pM pM 
[Pt(DMC)(/?,/?-DACH)] 
DMC Pretreatment 0.00 8.15 3.66 0.99 - 0.00 13.3 4.07 1.01 1.00 
0.30 8.28 0.36 1.03 44.0 0.45 14.0 3.12 1.12 0.94 
1.50 6.96 1.69 0.96 8.79 2.25 6.32 0.67 0.75 2.09 
3.00 6.66 2.17 1.04 4.40 4.50 4.21 0.09 0.87 3.13 
Concurrent Treatment 0.00 9.93 0.84 0.90 - 0.00 13.6 0.37 1.03 0.97 
0.32 10.3 0.74 0.95 41.5 0.45 12.6 2.26 1.00 1.04 
1.59 8.92 1.03 0.93 8.31 2.25 8.27 0.20 0.83 1.60 
3.18 5.84 0.97 0.77 4.15 4.50 6.05 0.58 0.87 2.18 
Platinum Pre-sensitization 0.00 12.8 4.19 1.16 - 0.00 3.08 1.05 1.00 1.00 
0.67 7.89 2.69 0.93 4.57 0.45 3.54 0.49 1.19 0.87 
1.35 5.96 0.92 0.98 2.28 2.25 2.56 0.10 1.03 1.20 
4.50 2.11 0,33 1.09 1.46 
Oxaliplatin "“ 
DMC Pretreatment 0.00 7.46 0.69 0.91 - 0.00 7.87 2.06 1.01 0.99 
0.07 10.6 1.66 1.30 106 0.45 5.53 2.58 0.77 1.41 
0.37 11.2 1.32 1.40 21.2 2.25 5.40 1.17 0.97 1.44 
0.73 6.94 1.64 0.94 10.6 4.50 2.56 0.44 0.88 3.04 
3.67 3.61 0.93 0.91 2.12 
Concurrent Treatment 0.00 10.1 1.65 0.92 - 0.00 7.34 2.47 0.94 1.06 
0.04 13.7 2.97 1.25 195 0.45 7.39 0.25 0.99 1.05 
0.20 9.01 1.03 0.84 39.0 2.25 6.27 1.64 1.01 1.24 
0.40 8.38 1.11 0.81 19.5 4.50 3.16 0.58 0.81 2.47 
2.00 4.43 0.39 0.66 3.90 
4.00 3.36 0.46 0.82 1.95 
Platinum Pre-sensitization 0.00 10.0 2.45 0.91 • 0.00 3.80 1.55 1.01 0.99 
0.30 8.34 0.53 0.83 12.6 0.45 5.20 1.07 1.42 0.72 
0.60 5.73 3.75 0.68 6.28 2.25 4.15 1.35 1.31 0.91 
3.00 4.46 0.29 1.20 1.26 4.50 1.15 0.20 0.71 3.27 
Abbreviation: Combination Index (CI), Dose Reduction Index (DRI), DemethylCantharidin (DMC). Platinum (R), 
Standard Deviation (SD) 
125 
Appendix III a. i) Isobolograms for H C T l 16 (Cisplatin, [Pt(DMC)(NH3)2] and 
[Pt(DMC)(CH3NH2)2])，x-axis is the concentration of platinum 
drugs in |JM, y-axis is the concentration of D M C in |JM. The 
enlarged dot indicates the most effective drug combinations with 
the data shown in bracket (platinum dose, D M C dose). 
Platinum Pretreatment Concurrent Treatment DMC Pretreatment 
• Antagonism 
Q : • • • • • Additive Effect 
y >v ••• • Synergism 
•• x ^ • 教•鲁 DMC Dose Fixed 
• • 〇 Platinum Dose Fixed 
.,.• , , . Line of Additivity 
Platinum Dose 
8 ^ 




(1.31,20.0) • (4.23,4.00) • (14.1, 1.80) 
八 ： ： 
f 8 a \ ： ： m m s m M 2 . . . . 
i画丨:\-—b^......………卜;:. 
• . . . . . . • • \ o • • \ 
•\ (0.45, 21.6) - (4.18,6.50) • (5.62,6.86) 
o h \ rPt(DMC)(CH.NHp), 
^ r\ ^ I 
： N ^ - - 丨 
o ~‘‘~I~I~I_M^- 1 I _ _ I _ I _ I _ _ I _ I _ • _ I _ I _ I _ I — J _ _ I I ~ ~ I ~ ~ I ~ ~ I I ~ I ~ I ~ ~ I ~ I ~ I ~ ~ I ~ ~ I - ^ J 
OQ.OO 10.00 20.00 10.00 20.00 10.00 20.00 30.00 
Platinum Dose (pM) 
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Appendix III a. ii) Raw Data for HCT116 (Cisplatin, [Pt(DMC)(NH3)2] and 
[Pt(DMC ) ( C H 3 N H 2 ) 2 ] ) 
Raw Data for HCT116s *** DMC SD CI pt DRI °抓 pt so ci pt DRI 
(FIx.d) (Fixed) 
MM mM mM pM pM pM 
Cisplatin 
DMC Pre-sensltization 0.00 16.5 3.76 0.95 - 0.00 22.7 2.61 1.10 0.91 
0.30 13.2 3.95 0.78 68.8 0.40 23.7 7.88 1.17 0.87 
1.50 10.4 4.08 0.68 13.8 2.00 9.78 3.10 0.59 2.11 
3.00 8.82 2.74 0.66 6.88 4.00 7.75 3.74 0.61 2.66 
15.0 1.62 0.54 0.82 1.38 
Concurrent Treatment 0.00 17.2 1.54 1.00 - 0.00 2.23 0.20 0.93 1.08 
0.30 8.82 2.11 0.64 7.99 0.40 2.08 0.23 0.89 1.15 
0.60 6.03 0.98 0.60 4.00 2.00 1.85 0.15 0.89 1.29 
0.90 5.57 1.62 0.70 2.66 4.00 1.36 0.15 0.80 1.76 
1.20 4.23 1.02 0.75 2.00 
Platinum Pre-sensitization 0.00 28.6 8.84 0.97 - 0.00 2.66 0.33 1.11 0.90 
0.06 35.4 14.4 1.22 40.0 0.30 3.74 0.44 1.57 0.64 
0.30 25.5 10.5 0.99 7.99 1.50 1.64 0.39 0.73 1.46 
0.56 11.8 2.97 0.63 4.28 3.00 1.64 0.09 0.79 1.46 
15.0 0.53 0.14 0.73 4.50 
30.0 0.08 0.03 1.05 31.1 
[Pt(DMC)(NH3)2】 
DMC Pre-sensitization 0.00 17.7 1.75 1.02 - 0.00 30.1 4.11 1.04 0.96 
0.20 15.2 2.82 0.89 145 0.18 25.0 1.21 0.87 1.16 
1.00 11.5 0.76 0.70 28.9 0.90 18.9 6.05 0.71 1.53 
2.00 9.85 0.73 0.64 14.5 1.80 14.1 3.68 0.59 2.06 
10.0 2.27 0.48 0.48 2.89 9.00 4.26 0.73 0.67 6.79 
18.0 1.02 0.31 1.08 28.47 
Concurrent Treatment 0.00 16.5 3.00 0.96 - 0.00 12.0 2.57 1.07 0.94 
0.10 14.9 1.05 0.87 113 0.40 13.1 2.88 1.19 0.86 
0.50 11.7 1.65 0.72 22.6 2.00 5.88 0.35 0.64 1.92 
1.00 9.02 2.67 0.61 11.3 4.00 4.23 0.85 0.61 2.67 
5.00 3 .67 0.31 0.66 2.26 
10.0 2.40 0.74 1.03 1.13 
Platinum Pre-sensitization 0.00 27.9 10.8 0.95 - 0.00 11.3 0.08 1.00 1.00 
0.26 24.3 7.52 0.85 43.0 0.20 10.2 1.64 0.91 1.11 
1.31 20.0 5.50 0.79 8.59 1.00 9.64 1.43 0.89 1.17 
2.62 15.9 5.57 0.77 4.30 2.00 9.46 3.03 0.91 1.19 
10.0 5.64 0.64 0.84 2.00 
20.0 1.01 0.26 0.77 11.17 
[Pt(DMC)(CH3NH2)2】 
DMC Pre-sensitization 0.00 18.8 3.01 1.09 - 0.00 30.1 12.58 1.03 0.97 
0.56 13.2 3.42 0.78 51.9 0.60 31.6 8.73 1.12 0.92 
2.81 9.94 2.45 0.67 10.4 3.00 13.4 3.92 0.63 2.17 
5.62 6.86 2.51 0.59 5.19 6.00 7.54 1.99 0.61 3.87 
28.1 1.58 0.50 1.06 1.04 
Concurrent Treatment 0.00 18.6 3.16 1.08 - 0.00 14.6 1.91 1.05 0.95 
1.39 11.7 4.37 0.78 9.97 0.40 16.0 2.28 1.18 0.87 
2.78 9.57 3.52 0.75 4.99 2.00 8.62 1.02 0.74 1.61 
4.18 6.50 1.98 0.68 3.32 4.00 7.45 1.05 0.77 1.86 
6.96 5,05 1.22 0.79 1.99 
13.9 1.31 0.43 1.08 1.00 
Platinum Pre-sensitization 0.00 29.1 2.00 0.99 - 0.00 13.7 2.46 0.98 1.02 
0.45 21.6 2.46 0.77 30.9 0.40 15.9 2.13 1.16 0.87 
2.25 19,4 3.68 0.82 6.17 2.00 13.0 5.09 1.01 1.06 
4.50 14.8 3.14 0.83 3.09 4.00 10.3 1.79 0.88 1.35 
20.0 2.21 1.04 0.84 6.29 
Abbreviation: Combination Index (CI), Dose Reduction Index (DRI), DemethylCantharidin (DMC). Platinum (Pt). 
Standard Deviation (SD) 
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Appendix III b. i) Isobolograms for HCTl 16 ([Pt(DMC)(i?’/^DACH)] and 
Oxaliplatin), x-axis is the concentration of platinum drugs in |JM, 
y-axis is the concentration of D M C in pM. The enlarged dot 
indicates the most effective drug combinations with the data shown 
in bracket (platinum dose, D M C dose). 
Platinum Pretreatment Concurrent Treatment PMC Pretreatment 
g • Antagonism 
8 ‘ • • • • • Additive Effect 
y ••• • Synergism 
圔•春 D M C Dose Fixed 
•**•• • • 〇 Platinum Dose Fixed 
- , • Line of Additivity 
Platinum Dose 
o 
° i (0.44,2.50) ： (0.21,6.26) ： (1.35,2.00) 
g R : rPt(DMC)(R/?-DACH) 
^ 5 ； 
！ • I \ - 一 . . . . . . 
0) • m\ , \ flL \ 
(/) I. I » ill t I I I I I I I I I i I « » I « » « . • , I • • . [’， .• , -• I I I « I t t • _ _ ' * . •，’ * * • * 蠢• • • I、、• 
O A 
Q I (0.04, 18.7) (0.32, 2.73) (0.49, 6.00) 
IE o -I Oxaliplatin 
O I fl t 
, E = t k - . . . 
3 • ^ I I •••• I • • I I • 
°0.00 1.00 2.00 3.00 1.00 2.00 3.00 1.00 2.00 3.00 4.00 
Platinum Dose (pM) 
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Appendix IV b. ii) Raw Data for HCTl 160xaR ([Pt(DMC)(i?,i^-DACH)] and 
Oxaliplatin) Raw Data for HCT116s dmc sd ci Pt dr i Pt so ci PtDW 
(Fixed) (Fixed) 
MM mM MM MM MM MM 
[Pt(DMC)(R,R-DACH)] 
DMC Pre-sens i t i zat ion 0 .00 16.5 3.76 0 .95 - 0.00 4.14 1.73 0.95 1.05 
0.30 8.00 2.43 0.53 14.5 0.40 4.55 2.41 1.07 0.96 
1.50 1.14 0.52 0.41 2.90 2.00 1.35 0.23 0.43 3.23 
3.00 0 .32 0 .15 0 .71 1.45 4.00 1.14 0.09 0.49 3.82 
Concurrent Treatment 0 .00 18.4 1.31 1.07 - 0.00 0.69 0.22 1.06 0.95 
0.01 14.4 2.06 0 .84 91.6 0.55 0.79 0.27 1.24 0.83 
0.01 13.6 0.79 0.81 45.8 
0.02 13.5 1.47 0.81 30.5 
0.03 11.2 1.64 0.69 22.9 
0.04 11.0 0.73 0.69 18.3 
0 .07 11.4 1.23 0.77 9.16 
0.21 6.26 1.30 0.69 3.05 
0.28 5.92 1.77 0.78 2.29 
0.35 4.11 0.99 0.78 1.83 
Platinum Pre-sens i t i zat ion 0 .00 31 .3 3.57 1.06 - 0.00 0.65 0.05 0.99 1.01 
0 .05 24.2 2.01 0.90 12.2 0.50 0.61 0.07 0.95 1.07 
0.11 22.9 3.19 0.94 6.11 2.50 0.44 0.03 0.76 1.47 
0.16 18.6 5.37 0.88 4.07 5.00 0.40 0.03 0.79 1.61 
0.21 15.6 2.64 0.86 3.05 25.0 0.08 0.03 0.97 8.04 
0.27 13.5 3.28 0.87 2.44 
Oxaliplatin 
DMC Pre-sens i t i za t ion 0 .00 17.8 4 .83 1.03 - 0.00 1.77 0.31 0.98 1.02 
0.07 17.7 7.41 1.06 24.0 0.60 1.63 0.41 0.94 1.10 
0.37 7.68 4.44 0.65 4.80 3.00 1.18 0.60 0.83 1.52 
0.75 4.33 3.45 0.67 2.40 6.00 0.49 0.04 0.62 3.65 
Concurrent Treatment 0 .00 17.9 3.49 1.03 • 0.00 0.55 0.05 1.05 0.95 
0.02 15.4 2.15 0.93 23.9 0.55 0.41 0.02 0.81 1.28 
0.07 14.4 3.51 0.96 7.98 2.73 0.32 0.04 0.77 1.63 
0.09 13.5 4.31 0 .95 5.98 5.46 0.27 0.01 0.84 1.90 
0.11 12.5 0.24 0.94 4.79 
Platinum Pre-sensitization 0.00 28.4 5.19 0.96 • 0.00 0.58 0.05 1.11 0.90 
0.04 18.7 6.22 0.71 13.0 0.30 0.62 0.08 1.19 0.84 
0.20 10.6 0.74 0.74 2.61 1.50 0.43 0 .05 0.87 1.22 
0.40 2.67 0.92 0.86 1.30 3.00 0.33 0.07 0.74 1.58 
15.0 0.15 0.03 0.80 3.44 
Abbreviation: Combination Index (CI). Dose Reduction Index (DRI), Demethylcantharidin (DMC), Platinum (Pt). 
Standard Deviation (SD) 
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Appendix IV a. i) Isobolograms for HCT1160xaR (Cisplatin, [ P T ( D M C ) ( N H 3 ) 2 ] and 
[Pt(DMC)(CH3NH2)2])，X-axis is the concentration of platinum 
drugs in PM, y-axis is the concentration of DMC in |JM. The 
enlarged dot indicates the most effective drug combinations with 
the data shown in bracket (platinum dose, D M C dose). 
Platinum Pretreatment Concurrent Treatment DMC Pretreatment 
gj 丄 • Antagonism 
Q : • • • • • Additive Effect 
y >v • • • Synergism 
• • ••參 D M C Dose Fixed 
• • 〇 Platinum Dose Fixed 
• • • Line of Additivity 
Platinum Dose 
f f 
^ (1.29,6.87) ： (0.77. 5.40) ： (3.68,5.40) 
j • • 
g Cisplatin 
^ fi • I t " 
,1........: : — 
' I I ' • I I I I I I I I • I rtl^ I I I I I I, l . , i ,,l.. I , . l .1 ..I., ： I ,1 I I I _••__•_••!• _•_ I I I I 1,1., 
I (4.33, 6.00) (6.43. 4.00) ： (14.2, 3.00) 
S o f\ r P t ( D M C ) ( _ , 
^ • • • • • ‘ • • ‘ • • f • • • _ 1 • f _ — _ f [ • • • ‘ • • • I I .1 • J. .1 I I I titi I 7J}> I , . 
K (5.62,8.60) (5.62,5.30) ： (8.09,5.10) 
o • \ rPt(DMC)(CH,NH,), 
！ ^ - . . - f ^ -
g 「 _ • I • I • I I • I • • •「 I I I I I IJ il 11 I 11 I 11 I'' ••|0|、 I 11 
°0.00 10.00 20.00 30.00 10.00 20.00 30.00 10.00 20.00 30.00 40.00 
Platinum Dose (|JM) 
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Appendix IV a. ii) Raw Data for HCTl 160xaR (Cisplatin, [Pt(DMC)(NH3)2] and 
[Pt(DMC)(CH3NH2)2]) 
Raw Data f o r HCT1160xaR ^ DMC SD CI Pt DRI Pt SD CI PTOM 
(Fixvd) (Fixed) 
pM pM mM MM |JM pM 
Cisplatin 
DMC Pre-sensitization 0.00 18.1 4.84 1.04 - 0.00 27.1 3.68 1.00 1.00 
1.00 11.0 1.40 0.67 27.0 1.08 14.7 1.76 0.61 1.83 
5.00 5.14 0.88 0.48 5.39 5.40 3.68 0.26 0.45 7.33 
10.0 2.06 0.11 0.49 2.70 10.8 1.25 0.51 0.67 21.6 
Concurrent Treatment 0.00 16.8 4.92 0.96 - 0.00 2.90 0.25 1.05 0.95 
0.37 8.82 2.12 0.64 7.37 0.54 2.45 0.34 0.92 1.13 
1.87 3.19 0.24 0.86 1.47 2.70 1.39 0.25 0.66 1.98 
3.75 0.27 0.05 1.37 0.74 5.40 0.77 0.27 0.59 3.61 
Platinum Pre-sensitization 0.00 28.2 8.34 0.99 - 0.00 2.61 0.46 0.94 1.06 
0.37 17.4 7.71 0.75 7.37 1.37 2.47 0.16 0.94 1.12 
1.87 4.12 1.79 0.82 1.47 6.87 1.29 0.17 0.71 2.13 
3.75 0.09 0.05 1.36 0.74 13.7 0.55 0.13 0.68 5.05 
[Pt(DMCKNH3)2] “ 
DMC Pre-sensitization 0.00 17.9 2.44 1.03 - 0.00 36.3 8.10 0.96 1.04 
0.50 16.2 0.39 0.94 75.4 0.30 31.5 1.67 0.85 1.20 
2.50 14.6 2.28 0.91 15.1 1.50 22.6 3.87 0.69 1.67 
5.00 11.5 2.27 0.79 7.54 3.00 14.2 3.73 0.55 2.65 
15.0 3.84 0.91 0.96 9.82 
Concurrent Treatment 0.00 16.6 7.36 0.95 - 0.00 12.6 2.18 1.17 0.85 
0.37 15.9 3.78 0,95 28.6 0.40 10.5 2.66 1.01 1.02 
1,87 12.8 3.99 0.91 5.72 2.00 8.43 2.55 0.90 1.27 
3.75 8.86 2.52 0.86 2.86 4.00 6.43 2.00 0.83 1.67 
Platinum Pre-sensitization 0.00 28.5 4.86 1.00 - 0.00 10.5 3.62 0.98 1.02 
0.25 24.0 11.47 0.87 42.9 0.60 8.38 2.70 0.80 1.28 
1.25 17.2 7.91 0.72 8.58 3.00 6.02 0.90 0.67 1.78 
2.50 12.2 3.49 0.66 4.29 6.00 4.33 1.38 0.61 2.48 
[Pt(DMC)(CH3NH2)2】 “ 
DMC Pre-sensitization 0.00 16.8 4.91 0.96 - 0.00 32.0 1.37 0.99 1.01 
2.70 8.79 1.39 0.59 12.0 1.02 24.7 3.62 0.82 1.31 
13.5 3.44 0.41 0.61 2.40 5.10 8.09 1.88 0.54 4.00 
27.0 0.81 0.22 0.88 1.20 10.20 1.67 0.76 0.64 19.4 
Concurrent Treatment 0.00 16.8 2.93 0.97 - 0.00 19.6 6,52 0,97 1.03 
I .12 12.6 3.27 0.78 17.9 0.42 16.9 1.80 0.86 1.19 
5.62 5.30 0.64 0.58 3.57 2.10 14.2 3.61 0.83 1.42 
I I . 2 3.19 1,69 0.74 1.79 4.20 7.52 2,48 0.61 2.67 
Platinum Pre-sensitization 0.00 29.7 6.69 1.04 - 0.00 19.4 1.72 0.97 1.04 
I.12 17.8 5.12 0.68 17.9 1.50 18.4 5.79 0.97 1.09 
5.62 8.60 2.82 0.58 3.57 7.50 6.98 0.22 0.61 2.88 
I I .2 1.42 0.16 0.61 1.79 15.0 1.92 0.45 0.62 10.4 
Abbreviation: Combination Index (CI), Dose Reduction Index (DRI), DemethylCantharidin (DMC), Platinum (Pt), 
Standard Deviation (SD) 
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Appendix IV b. i) Isobolograms for HCTl 160xaR ([Pt(DMC)(足7MDACH)] and 
Oxaliplatin), x-axis is the concentration of platinum drugs in |JM, 
y-axis is the concentration of D M C in pM. The enlarged dot 
indicates the most effective drug combinations with the data shown 
in bracket (platinum dose, D M C dose). 
Platinum Pretreatment Concurrent Treatment DMC Pretreatment 
8j 1 • Antagonism 
S : • • • • • Additive Effect 
y • • • Synergism 
• • 春 D M C Dose Fixed 
*、 • n O O Platinum Dose Fixed 
• . . Line of Additivity 
Platinum Dose 
纏 
� k (2.74. 7.50) ： (4.30, 3.00) ： (2.84,4.21) 
g 丨？ \ ： rPt(DMC)(RR-DACH) 
I ‘ ^  ^  N ； 
O t (0.70,4.51) (182. 2.10) • (3.11,5.89) 
O .\ 
S . \ Oxaliplatin 
O 9 -••V 
丨 - k 一 f e E 
§ ~ ‘ ~ I ~ ~ I ~ I — I I — I _ U - 1 _ I — I _ _ 1 — 1 _ 1 I_L_l_l_l_I—I_l- l—11—1_l_J_I—J_1—1—I 1*1 >gl—1— 
° 0 . 0 0 5 . 0 0 1 0 . 0 0 I 5 . 0 0 10 .00 ’ 5 .00 10.00 15.00 
Platinum Dose (|JM) 
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Appendix IV b. ii) Raw Data for HCTl 160xaR ([Pt(DMC)(i?,i^-DACH)] and 
Oxaliplatin) 
Raw Data for HCT1160xafR DMC SD CI PTDRI f Pt so ci PTDRI 
(Fixvd) (Fixed) 
pM pM MM pM MM MM 
[Pt(DMC)(R,/?-DACH)] 
DMC Pre-sensit izat ion 0.00 18.2 0.50 1.05 - 0.00 13.0 1.86 1.00 1.00 
1.40 7.59 1.00 0.54 9.23 0.42 8.69 1.29 0.70 1.49 
7.00 0.42 0.04 0.57 1.85 2.11 5.08 0.42 0.51 2.54 
4.21 2.84 0.43 0.46 4.55 
Concurrent Treatment 0.00 18.0 3.95 1.03 - 0.00 7.46 0.94 0.97 1.03 
0.10 17.5 5.60 1.02 76.5 0.60 6.10 1.14 0.83 1.25 
0.50 16.5 4.78 1.01 15.3 3.00 4.30 1.11 0.73 1.78 
1.00 12.3 6.40 0.83 7.65 6.00 3.32 1.03 0.78 2.30 
5.00 3.45 0.30 0.85 1.53 
Platinum Pre-sensit ization 0.00 26.9 2,93 0.94 - 0.00 7.94 0.85 1.04 0.96 
0.09 23.6 4.82 0.84 85.0 1.50 7.16 2.29 0.99 1.07 
0.45 18.7 4.62 0.72 17.0 7.50 2.74 0.31 0.62 2.79 
0.90 16.8 3.45 0.71 8.50 15.00 1.52 0.11 0.73 5.04 
4.50 3.34 0.81 0.71 1.70 
Oxaliplatin 
DMC Pre-sensit izat ion 0.00 17.7 6.04 1.01 - 0.00 12.7 3.18 1.00 1.00 
0.62 11.7 3.00 0.72 20.4 0.87 10.5 3.16 0.88 1.21 
3.11 5.89 2.09 0.58 4.08 4.37 5.85 0.79 0.71 2.17 
6.22 3.26 0.54 0.68 2.04 8.75 1.91 0.97 0.65 6.67 
Concurrent Treatment 0.00 18.6 3.42 1.07 - 0.00 3.94 0.94 0.94 1.06 
0.07 14.9 6.18 0.88 55.7 0.42 3.72 1.13 0.91 1.12 
0.37 10.7 0.63 0.71 11.15 2.10 1.82 0.59 0.55 2.30 
0.75 7.31 0.88 0.60 5.57 4.20 1.32 0.22 0.56 3.17 
Platinum Pre-sensit izat ion 0.00 28.3 12.6 1.00 - 0.00 4.18 2.31 1.00 1.00 
0.10 16.0 9.37 0.59 40.3 0.45 3.36 1.22 0.82 1.24 
0.52 8.63 0.48 0.43 8.06 2.26 2.13 0.27 0.59 1.96 
1.04 4.18 0.11 0.40 4.03 4.51 0.70 0.03 0.33 6.01 
Abbreviation: Combination Index (CI). Dose Reduction Index (DRI), Demethylcantharidin (DMC), Platinum (Pt), 
Standard Deviation (SD) 
133 
Appendix V a. i) Isobolograms for HT29 (Cisplatin, [Pt(DMC)(NH3)2] and 
[Pt(DMC)(CH3NH2)2])，x-axis is the concentration of platinum 
drugs in pM, y-axis is the concentration of D M C in pM. The 
enlarged dot indicates the most effective drug combinations with 
the data shown in bracket (platinum dose, D M C dose). 
Platinum Pretreatment Concurrent Treatment DMC Pretreatment 
g 1 • Antagonism 
Q • • • • • • Additive Effect 
y ••• • Synergism 
• * ^ • • 參 D M C Dose Fixed 
* • • * • • • 〇 Platinum Dose Fixed 
- , . Line of Additivity 
Platinum Dose 
S i- L L 
° 1 (2.98,3.00) . (2.86,2.50) . (3.00,5.24) 
\ <f 
g • \ ； K Cisplatin 
8 i::.:.•:..:..:...:..:..:..:...:..:.••...... 
另 L (0.60. 17.0) . (4.47, 2.00) (5.00,2.23) 
S f\ 
3 
g § "U i K rPt(DMC)(NH,), 
i ‘ ^ K— 
• I • I _ •〇•。、 
S「..:：……………………••:..: 
O (6.28,3.00) . (5.00,0.91) . (20.8,2.00) 
\ 
i \ • “ 
• \ . • 
V 
8 \ \ ^ rPt{DMC)(CH爲h 
^ E 一 ^ . . i s ^ 
o I I I I • iVi> I II I I I~• • ^-t • • \ I I I ' *•、，_ 
OQ.OO 20.00 40.00 60.00 20.00 40.00 20.00 40.00 60.00 
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Appendix V a. ii) Raw Data for HT29 (Cisplatin, [Pt(DMC)(NH3)2] and 
[Pt(DMC)(CH3NH2)2]) 
Raw Data for HT29 ‘** DMC SD CI Pt DRI pt SD CI Pt DRI 
<Flx*d> (Fix«d) 
mM pM pM MM pM pM 
Cisplatin 
DMC Pre-sensit ization 0.00 13.1 1.70 1.10 - 0.00 45.6 38.1 1.02 0.98 
0.30 8.64 2.06 0.73 150 2.00 40.0 13.3 1.06 1,12 
1.50 6.51 1.65 0.58 29.9 4.00 12.0 3.17 0.60 3.74 
3.00 5.24 2.34 0.50 15.0 
15.0 3.55 0.54 0.63 2.99 
30.0 2.10 0.34 0.84 1.50 
Concurrent Treatment 0.00 12.1 4.11 1.01 - 0.00 10.6 6.90 1.04 0.96 
0.24 9.84 1.27 0.85 42.7 0.50 6.50 0.54 0.68 1.57 
1.20 5.69 0.74 0.59 8.53 2.50 2.86 0.52 0.49 3.58 
2.40 4.29 0.51 0.59 4.27 5.00 1.51 0.36 0.57 6.76 
Platinum Pre-sensit ization 0.00 19.1 2.21 0.97 - 0.00 9.85 1.12 0.96 1.04 
0.12 20.5 2.54 1.05 85.3 0.30 5.88 1.27 0.59 1.74 
0.60 14.7 4.42 0.80 17.1 1.50 6.03 1.11 0.66 1.70 
1.20 8.34 2.84 0.54 8.53 3.00 2.98 0.33 0.44 3.43 
6.00 1.75 0.08 0.67 1.71 15.0 0.73 0.15 0.83 14.1 
[Pt(DMC)(NH3)2】 
DMC Pre-sensit ization 0.00 12.3 2.27 1.03 - 0.00 17.3 2.78 1.00 1.00 
1.00 7.16 0.12 0.66 17.2 0.90 7.86 1.14 0.53 2.19 
5.00 2.23 0.69 0.48 3.44 4.51 2.53 0.41 0.52 6.80 
10.0 0.69 0.22 0.64 1.72 9.01 0.64 0.31 0.79 27,0 
Concurrent Treatment 0.00 11.4 1.70 0.96 - 0.00 9.39 0.55 0.98 1.02 
0.50 8.17 1.13 0.74 19.2 0.40 7.65 0.66 0.83 1.26 
2.50 5.08 1.61 0.68 3.85 2.00 4.47 0.46 0.63 2.15 
5.00 2.29 0.82 0.71 1.92 4.00 3.74 0.75 0.72 2.58 
Platinum Pre-sensit ization 0.00 20.7 3.97 1.05 - 0.00 10.6 0.75 1.10 0.91 
0.60 16.9 2.87 0.92 16.0 0.60 10.1 1.76 1.08 0.95 
3.00 14.3 3.75 1.03 3.21 3.00 8.98 0.55 1.08 1.07 
6.00 10.1 3.22 1.13 1.60 6.00 7.06 1.37 1.04 1.36 
[Pt(DMC)(CH3NH2)2】 
DMC Pre-sensit ization 0.00 12.6 3.84 1.05 - 0.00 53.0 9.79 0.94 1.07 
0.67 11.9 0,64 1.01 83.6 0.20 34.8 4.63 0.63 1.62 
3.37 8.34 2.09 0.76 16.7 1.00 26.7 3.32 0.56 2.11 
6.75 5.96 1.54 0.62 8.36 2.00 20.8 12.5 0.54 2.71 
33.7 1.09 0.92 0.69 1.67 10.0 2.26 1.58 0.88 25.0 
Concurrent Treatment 0.00 11.3 4.80 0.95 - 0.00 21.5 2.28 1.01 0.99 
0.50 7.26 3.98 0.63 42.6 0.15 9.43 1.12 0.45 2.26 
2.50 2.42 0.94 0.32 8.53 0.75 5.92 1.02 0.34 3.60 
5.00 0.91 0.58 0.31 4.26 1.50 4.19 0.27 0.32 5.08 
7.50 1.16 0.94 0.68 18.3 
Platinum Pre-sensit ization 0.00 18.5 1.36 0.90 - 0.00 22.9 4.53 1.08 0.93 
0.45 12.0 3.19 0.60 47.4 0.30 15.6 1.05 0.75 1.36 
2.25 8.83 2.20 0.53 9.48 1.50 11.9 3.41 0.63 1.79 
4.50 5.15 0.24 0.46 4.74 3.00 6.28 0.74 0.44 3.39 
22.5 1.09 0.14 1.11 0.95 15.0 0.85 0.06 0.77 25.2 
Abbreviation: Combination Index (CI). Dose Reduction Index (DRI), Demethylcantharidin (DMC), Platinum (Pt), 
Standard Deviation (SD) 
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Appendix V b. i) Isobolograms for HT29 ([Pt(DMC)(7?,/?-DACH)] and Oxaliplatin), 
x-axis is the concentration of platinum drugs in \M, y-axis is the 
concentration of DMC in |JM. The enlarged dot indicates the most 
effective drug combinations with the data shown in bracket 
(platinum dose, D M C dose). 
Platinum Pretreatment Concurrent Treatment DMC Pretreatment 
S 1 • Antagonism 
8 • • • • • • Additive Effect 
y • • • Synergism 
X ^ ^ • • 春 D M C Dose Fixed 
**** • • 〇 Platinum Dose Fixed 
. • Line of Additivity 
Platinum Dose 
8 V. I I 
° K ( 0 . 6 8 , 1 . 5 0 ) . ( 0 . 4 6 , 2 . 0 0 ) . ( 1 . 25 ,2 .87 ) 
- \ - -
\ 
0 • \ t i rPt(DMC)(RR-DACH) 
o 4 
° i ( 0 . 1 5 . 8 . 4 0 ) . ( 0 . 3 0 , 2 . 3 6 ) . ( 2 . 56 ,2 . 00 ) 
s \ 
Q 
8 i 2EliE!2!!J2.... 
1 f : \ 
• 4。 - •。 \ \ 
Oq.OO 2 . 00 4 . 0 0 6 . 0 0 8 .00 2 .00 4 .00 6 .00 2 .00 4 .00 6.00 8.00 
Platinum Dose (|JM) 
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Appendix IV b. ii) Raw Data for HCTl 160xaR ([Pt(DMC)(i?,i^-DACH)] and 
Oxaliplatin) 
Pt DIMC 
Raw Data for HT29 DMC SD CI Pt DRI pt so ci Pt DRI 
(Fixsd) (Fixed) 
pM pM pM |JM MM MM 
[Pt(DMC)(R,R-DACH)] 
DMC Pre-sensit ization 0.00 12.3 3.30 1.03 - 0.00 3.88 1.94 0.98 1.02 
0.12 7.74 2.28 0.68 31.6 0.40 8.65 2.22 2.23 0.46 
0.62 5.09 1.37 0.58 6.31 2.00 1.59 0.52 0.57 2.49 
1.25 2.87 0.96 0.56 3.16 4.00 0.90 0.30 0.56 4.40 
Concurrent Treatment 0.00 11.5 3.90 0.96 - 0.00 1.15 0.62 0.97 1.03 
0.15 9.39 2.29 0.91 7.91 0.40 1.05 0.52 0.92 1.13 
0.75 0.36 0.07 0.66 1.58 2.00 0.46 0.13 0.56 2.55 
4.00 0.35 0.11 0.63 3.38 
Platinum Pre-sensit ization 0.00 21.5 0.24 1.09 - 0.00 1.11 0.44 0.93 1.07 
0.10 18.1 3.09 1.00 11.9 0.30 0.97 0.44 0.83 1.22 
0.50 5.19 1.61 0.68 2.37 1.50 0.68 0.31 0.65 1.75 
3.00 0.60 0.02 0.66 1.97 
Oxaliplatin 
DMC Pre-sensit ization 0.00 11.7 3.24 0.98 - 0.00 7.79 3.78 1.03 0.97 
0.06 9.80 2.79 0.83 126 0.40 7.96 2.52 1.09 0.95 
0.30 9.08 1.64 0.80 25.2 2.00 2.56 0.21 0.51 2.96 
0.60 7.84 3.69 0.73 12.6 4.00 1.61 0.51 0.55 4.70 
3.00 1.96 0.49 0.56 2.52 
Concurrent Treatment 0.00 11.2 3.19 0.94 - 0.00 1.33 0.75 1.00 1.00 
0.06 8.47 2.52 0.75 22.1 0.40 0.74 0.27 0.59 1.80 
0.30 2,36 0.42 0.42 4.43 2.00 0.44 0.06 0.50 3.04 
0.60 1.50 0.02 0.58 2.21 4.00 0.20 0.06 0.48 6.77 
20.0 0.01 0.00 1.68 120 
Platinum Pre-sensit ization 0.00 20.4 6.46 1.03 - 1.35 0.00 0.59 1.02 0.98 
0.03 13.5 4.01 0.70 44.3 1.18 0.40 0.48 0.91 1.13 
0.15 8.40 1.27 0.54 8.86 1.04 2.00 0.07 0.88 1.28 
0.30 6.49 0.91 0.55 4.43 0.51 4.00 0.09 0.59 2.61 
1.50 1.07 0.12 1.18 0.89 0.03 20.0 0.01 1.04 38.4 
3.00 0.45 0.23 2.28 0.44 
Abbreviation: Combination Index (CI). Dose Reduction Index (DRI), Demethylcantharidin (DMC). Platinum (Pt), 
Standard Deviation (SD) 
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Appendix VI a. i) Isobolograms for Hep G2 (Cisplatin and [Pt(DMC)(NH3)2])，x-axis 
is the concentration of platinum drugs in |JM, y-axis is the 
concentration of DMC in |JM. The enlarged dot indicates the most 
effective drug combinations with the data shown in bracket 
(platinum dose, D M C dose). 
Platinum Pretreatment Concurrent Treatment DMC Pretreatment 
^ 1 • Antagonism 
g . • • • • • Additive Effect 
y 5K ••• • Synergism 
。 \ 
_ • 春 D M C Dose Fixed 
^ ^ • • 〇 Platinum Dose Fixed 
rtt卞亨tk. • . Line of Additivity 
Platinum Dose 
ci (0.50, 15.4) (0.45, 5.91) ； (8.32, 3.60) 
q i Cisplatin 
： I ； j : 
I \ ： 
0) § ？ • •乂 
O ° (4.80, 12.5) ： (2.60’ 5.00) ： (6.25, 8.32) 
O 8 ： ； [Pt(DMC)(CH,NH,U 
S d \ 
Q 对 - \ 
_ —fs：— IZ^：— 
3 I ''''' I I • I • • • • _ •卜、1 •纪. 
°0.00 10.00 20.00 30.00 10.00 20.00 30.00 . 10.00 20.00 30.00 40.00 
Platinum Dose (|JM) 
138 
Appendix VI a. ii) Raw Data for Hep G2 (Cisplatin and [Pt(DMC)(NH3)2]) 
Raw Data for Hep G2 ‘** DMC SD CI Pt DRI pt SD CI pt DRI 
r (Fixed) (Fixed) 
MM pM pM pM pM pM 
Cisplatin 
DMC Pre-sensitization 0.00 20.4 1.93 0.95 - 0.00 14.9 1.50 1.01 0.99 
0.75 19.3 4.41 0.95 19.7 0.36 15.4 2.39 1.06 0.96 
3.75 13.4 3.18 0.88 3.95 1.80 11.1 1.99 0.83 1.34 
7.50 7.14 1.20 0.84 1.97 3.60 8.32 1.19 0.73 1.78 
18.0 1.96 0.75 0.97 7.56 
Concurrent Treatment 0.00 21.6 4.12 1.01 - 0.00 5.54 2.19 1.00 1.00 
0.45 5.91 1.20 0.36 12.4 0.20 3.47 0.89 0.63 1.60 
2.25 0.28 0.10 0.42 2.47 1.02 2.24 0.62 0.45 2.48 
4.50 0.12 0.07 0.81 1.24 2.03 1.18 0.19 0.31 4.73 
10.2 0.23 0.11 0.51 24.6 
Platinum Pre-sensitization 0.00 50.0 28.7 0.96 - 0.00 5.43 0.77 0.98 1.02 
0.50 15.4 4.95 0.38 11.1 0.25 4.80 3.04 0.87 1.16 
2.50 5.04 0.62 0.55 2.23 1.25 4.05 0.09 0.75 1.37 
5.00 0.98 0.03 0.92 1.11 2.50 3.10 2.98 0.60 1.80 
12.5 0.85 0.39 0.39 6.57 
25.0 0.45 0.29 0.56 12.5 
[Pt(DMC)(CH3NH2)2】 
DMC Pre-sensltization 0.00 23.8 1.31 1.11 - 0.00 35.2 13.1 1.08 0.93 
1.25 18.5 4.76 0.90 26.2 1.00 26.2 11.7 0.85 1.25 
6.25 8.32 2.38 0.58 5.24 5.00 16.6 6.26 0.74 1.97 
12.5 6.08 5.30 0.66 2.62 10.0 7.05 0.79 0.68 4.64 
Concurrent Treatment 0.00 21.8 4.87 1.01 - 0.00 25.0 6.98 0.94 1.06 
0.42 9.48 5.70 0.46 63.1 0.50 19.0 2.07 0.74 1.39 
2.10 9.22 1.26 0.51 12.6 2.50 8.27 0.55 0.43 3.20 
4.20 4.17 2.22 0.35 6.31 5.00 2.60 1.22 0.33 10.2 
21.0 0.36 0.15 0.81 1.26 
Platinum Pre-sensitization 0.00 50.0 28.7 0.96 - 0.00 27.8 5.09 1.05 0.95 
1.20 20.6 8.03 0.44 22.1 0.25 21.4 3.73 0.81 1.24 
6.00 12.5 4.31 0.47 4.41 1.25 18.2 5.18 0.71 1.45 
12.0 5.77 1.76 0.56 2.21 2.50 16,7 1.84 0.68 1.59 
12.5 4.80 1.06 0.42 5.51 
25.0 1.72 0.96 0.54 15.4 
Abbreviation: Combination Index (CI), Dose Reduction Index (DRI). DemethylCantharidin (DMC), Platinum (Pt), 
Standard Deviation (SD) 
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Appendix VI b. i) Isobolograms for Hep G2 ([Pt(DMC)(7?,i?-DACH)] and 
Oxaliplatin), x-axis is the concentration of platinum drugs in |JM, 
y-axis is the concentration of DMC in |JM. The enlarged dot 
indicates the most effective drug combinations with the data shown 
in bracket (platinum dose, DMC dose). 
Piatinum Pretreatment Concurrent Treatment DMC Pretreatment 
g • Antagonism 
8 • • • • • • Additive Effect 
^ ••• • Synergism 
• • x ^ ^ • • 春 D M C Dose Fixed 
• * 、 • • 〇 Platinum Dose Fixed 
〜 . . Line of Additivity 
Platinum Dose 
£ [ 
. (0.22’ 30.0) . (0.43, 2.00) . (0.40, 7.83) 
o i fPt(DIVICK/?./?-DACH) 
‘ ； ； 
8 1 • i 
I ^  [ fx 
0) § ^ ' , o 
O ° ； (0.20,7.50) : (0.60, 2.03) ： (1.20,2.64) 
O § \ Oxaliplatin 
S d t 
Q H • • 
_ \ r\：—— 
§ Lja<<:-i_I I_I_I I_I__I_I_I_Ls^_I_I I_I_I_I_I_I_ _<___I_I_1—fi_I_0_I_I_‘ 丫、. 
°0.00 5.00 10.00 5.00 10.00 5.00 10.00 
Platinum Dose {[iM) 
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Appendix VIII b. ii) Raw Data for SK-Hepl CisR ([Pt(DMC)(i^,/?-DACH)] and 
Oxaliplatin) Raw Data for Hep G2 *** DMC SD CI pt DRI pt SD CI pt DRI 
^ (Fixed) (Fixed) 
pM mM pM pM pM |JM 
[Pt(DMC)(R,R-DACH)】 
DMC Pre-sensitization 0.00 21.9 7.83 1.02 - 0.00 4.80 1.02 1.02 0 . 9 8 
0.04 14.6 6.61 0.69 118 0.75 3.90 1.50 0.86 1.21 
0.20 10.6 2.80 0.54 23,6 3.75 1.44 0.67 0.48 3.28 
0.40 7.83 2.20 0.45 11.8 7.50 0.86 0.18 0.53 5.48 
2.00 1.53 0.23 0.49 2.36 
Concurrent Treatment 0.00 19.9 4.62 0.93 - 0.00 1.14 0.25 1.02 0 . 9 8 
0.03 14.4 1.25 0.70 37.5 0.20 0.91 0.29 0.82 1 2 4 
0.15 13.3 1.11 0.75 7.49 1.00 0.59 0.20 0,57 1力1 
2.00 0.43 0.17 0.47 2.64 
10.0 0.32 0.08 0.75 3 .51 
Platinum Pre-sensitization 0.00 52.0 7.58 1.00 - 0.00 1.15 0.13 1.03 0.97 
0.08 40.1 8.41 0.84 14.0 3.00 1.12 0.25 1.05 1:00 
0.40 24.4 5.99 0.82 2.81 15.0 0.67 0.17 0.88 1 6 8 
0.80 13.37 5.62 0.97 1.40 30.0 0.22 0.10 0.77 5^22 
Oxaliplatin “ 
DMC Pre-sensitization 0.00 20.2 6.18 0.94 - 0.00 12.0 3.92 1.08 0 93 
0.12 9.92 1.49 0.47 92.3 0.75 3.83 0.04 0.38 2*89 
0.60 4.83 0.24 0.28 18.5 3.75 1.35 0.47 0.30 8.18 
1.20 2.64 0.65 0.23 9.23 7.50 0.47 0.26 0.39 2 3 . 4 
6.00 0.78 0.49 0.58 1.85 
12.0 0.37 0.34 1.10 0.92 
Concurrent Treatment 0.00 20.6 3.02 0.96 - 0.00 1.48 0.63 1.02 0 . 9 8 
0.45 5.61 1.67 0.57 3.23 0.20 1.66 0.71 1.15 0^88 
1.02 1.00 0.21 0.74 1 :45 
2.03 0.60 0.31 0.51 2 4 3 
10.2 0.39 0.11 0.74 3 :76 
20.3 0.16 0.02 1.05 9 . 3 7 
Platinum Pre-sensitization 0.00 55.6 13.5 1.07 - 0.00 1.45 1.18 1.00 1 q q 
0.07 34.4 15.2 0.71 19.4 0.75 0.79 0.62 0.56 1.84 
0.37 5.11 1.76 0.36 3.88 3.75 0.55 0.25 0.45 2.66 
7.50 0.20 0.06 0.28 7 . 1 3 
Abbreviation: Combination Index (CI), Dose Reduction Index (DRI), Demethylcantharidin (DMC), Platinum (Pt), 
Standard Deviation (SD) 
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Appendix VII a. i) Isobolograms for SK-Hepl (Cisplatin, [Pt(DMC)(NH3)2] and 
[Pt(DMC)(CH3NH2)2])，X-axis is the concentration of platinum 
drugs in |JM, y-axis is the concentration of D M C in (JM. The 
enlarged dot indicates the most effective drug combinations with 
the data shown in bracket (platinum dose, D M C dose). 
Platinum Pretreatment Concurrent Treatment DMC Pretreatment 
^ • Antagonism 
g • • • • • Additive Effect 
o V . ••• • Synergism 
乏• • 
• * _ • ⑩ D M C Dose Fixed 
* *、 • • • 〇 Platinum Dose Fixed 
. , Line of Additivity 
Platinum Dose 
§ i : : 
° i ( 0 . 2 0 , 4 . 3 3 ) . (0.30, 3.97) • ( 2 . 8 1 , 5 . 1 5 ) 
i i ^ 
§ —ITVWI•—I I I I I I I I I i^Li I I—I—I—I—I—I—I—t—I—I—I—I—I—I I I • . . 
§ • 
9 I 
^ ？ 1 (1.40, 1.45) (0.35.4.61) . (3.20,3.45) 
f \ ； L 
I 8 i … 
8 K • . 
° 
？ A ( 2 . 3 5 , 1 . 5 0 ) . (2 .31.4 .40) . ( 7 . 6 6 , 1 . 5 0 ) 
o • \ \ f \ rPt(DMC)(CH.NH,), 
^ ^ . 一 . . . . . . t t 
§ ‘ ‘ ‘ I _ • _ A _ • _ • • • ‘ • I I L_L 1~I— 1~‘~I 1~U 
° 0 . 0 0 10.00 20.00 0.00 10.00 20.00 0.00 10.00 20.00 
Platinum Dose (|JM) 
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Appendix VII a. ii) Raw Data for SK-Hepl (Cisplatin, [Pt(DMC)(NH3)2] and 
[Pt(DMC)(CH3NH2)2]) 
Raw Data for SK-Hep1 ‘** DMC SD CI Pt DRI。城^ pt SD CI pt DRI 
r (Fixed) (Fixed) 
pM |jM pM pM M^ pM 
Cisplatin 
DMC Pre-sensitization 0.00 7.53 0.13 1.01 - 0.00 28.2 1.86 1.13 0.89 
0.56 6.50 0.79 0.90 44.5 0.30 25.2 3.00 1.05 0.99 
2.81 5.15 0.61 0.80 8.91 1.50 17.1 2.39 0.88 1.47 
5.62 4.67 0.58 0.85 4.45 3.00 10.3 2.62 0.81 2.44 
Concurrent Treatment 0.00 7.79 1.90 1.05 - 0.00 3.88 0.66 1.04 0.96 
0.30 3.97 1.60 0.61 12.4 0.20 2.78 0.04 0.77 1.34 
1.50 1.63 0.26 0.62 2.48 1.00 1.92 0.40 0.65 1.93 
3.00 0.51 0.26 0.87 1.24 2.00 1.29 0.10 0.62 2.89 
Platinum Pre-sensitization 0.00 12.4 5.81 1.10 - 0.00 3.79 0.62 1.02 0.98 
0.20 4.33 1.09 0.44 19.1 0.12 4.83 0.88 1.31 0.77 
0.98 2.40 0.65 0.48 3.82 0.62 2.20 0.47 0.65 1.69 
1.95 1.27 0.38 0.64 1.91 1.25 2.44 0.53 0.77 1.53 
6.25 0.21 0.07 0.61 17.4 
【Pt(DMC)(NH3)2】 
DMC Pre-sensitization 0.00 7.58 1.47 1.02 - 0.00 24.3 7.38 0.98 1.02 
0.64 5.13 1.94 0.71 38.6 0.72 16.4 5.72 0.76 1.51 
3.20 3.45 2.42 0.59 7.72 3.60 3.45 2.42 0.62 7.17 
6.40 2.88 0.19 0,65 3.86 7.20 0.39 0.18 0.98 63.8 
Concurrent Treatment 0.00 7.75 1.78 1.04 - 0.00 3.11 0.58 0.99 1.01 
0.17 5.27 0.50 0.76 18.0 0.40 2.94 0.38 0.99 1.07 
0.35 4.61 0.86 0.73 9.00 0.80 2.40 0.35 0.87 1.31 
1.75 1.94 0.33 0.82 1.80 4.00 0.98 0.22 0.85 3.21 
Platinum Pre-sensitization 0.00 10.9 2.29 0.97 - 0.00 3.17 0.29 1.01 0.99 
0.28 7.21 1.43 0.73 11.2 0.80 1.70 0.27 0.61 1.85 
1.40 1.45 0.47 0.57 2.25 4.00 0.82 0.12 0.62 3.85 
2.79 0.59 0.26 0.94 1.12 8.00 0.31 0.06 0.81 10.2 
[Pt(DMC)(CH3NH2)2] “ 
DMC Pre-sensitization 0.00 7.28 0.31 0.98 - 0.00 12.0 1.66 0.97 1.04 
0.37 6.79 0.73 0.94 33.3 0.30 13.5 1.89 1.12 0.92 
1.87 5.86 0.85 0.94 6.66 1.50 7.66 1.16 0.82 1.63 
3.75 4.52 0.32 0.91 3.33 3.00 5.97 1.22 0.88 2.09 
Concurrent Treatment 0.00 7,32 0.61 0.98 - 0.00 8.71 0.40 1.01 0.99 
0.45 6.17 0.42 0.88 19.27 0.40 8.38 0.59 1.02 1.03 
2.31 4.40 0.66 0.86 3.75 2.00 5.21 1.00 0.87 1.66 
4.61 2.86 0.55 0.92 1.87 4.00 2.81 0.91 0.86 3.07 
Platinum Pre-sensitization 0.00 10.1 1.26 0.90 - 0.00 8.74 2.59 1.01 0.99 
0.20 7.75 1.04 0.71 43.2 0.15 7.26 0.87 0.85 1.19 
1.00 3.35 0.52 0.41 8.64 0.75 3.62 0.66 0.49 2.38 
2.00 2.71 0.43 0.47 4.32 1.50 2.35 0.67 0.41 3.68 
7.50 0.34 0.10 0.71 25.1 
Abbreviation: Combination Index (CI), Dose Reduction Index (DRI), DemethylCantharidin (DMC), Platinum (Pt), 
Standard Deviation (SD) 
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Appendix VII b. i) Isobolograms for SK-Hepl ([Pt(DMC)(足i^DACH)] and 
Oxaliplatin), x-axis is the concentration of platinum drugs in |JM, 
y-axis is the concentration of DMC in \ jM . The enlarged dot 
indicates the most effective drug combinations with the data shown 
in bracket (platinum dose, DMC dose). 
Platinum Pretreatment Concurrent Treatment DMC Pretreatment 
^ • Antagonism 
8 . • • • • • Additive Effect 
y ••••• Synergism 
^ 圓 D M C Dose Fixed 
•*•• ^ ^ D O O Platinum Dose Fixed 
• . , . . . • Line of Additivity 
Platinum Dose 
g 
§ : : 
° W (1.00, 1.50) (0.73,1.00) • (0.15,6.27) 
-\ t -
\ t 
§ \ V、(DMC”/;?•斤-pj^^H) 
1 : : \ … : ： ^ ^ . 
® 3 iWiW I I_I__I_I_I_I_I_I_I_I__I I I_I__I_I__I_I__I_I__I_II_I 1_I__I_I__• 1L 
o Q i • 
Q 8 I 
2 ° 1 (0.79, 1.50) (0.10, 5.86) - (1.40, 3.04) 
M I K 
g \ 3 \ Oxaliplatin 
^ i f k — 
o L j t T _ i _ _ I _ I _ _ 1 _ I _ I _ I _ I _ 1 _ I _ I _ I _ I _ _ _ _ I _ I _ I _ _ I _ _ I _ I _ I _ I _ I _ _ I _ i _ j _ _ I _ I _ I _ _ I _ I _ _ _ I _ I _ _ I _ I • 
°0.00 5.00 10.00 5.00 10.00 5.00 10.00 15.00 
Platinum Dose (pM) 
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Appendix IV b. ii) Raw Data for HCTl 160xaR ([Pt(DMC)(i?,i^-DACH)] and 
Oxaliplatin) 
Raw Data for SK-Hep1 DMC SD CI pt DRI pt SD CI pt DRI 
(Fixed) (Fixed) 
MM MM MM pM MM pM 
[Pt(DMC)(R,/?.DACH)] 
DMC Pre-sensitization 0.00 7.62 0.44 1.02 - 0.00 14.4 2.75 1.09 0.91 
0.15 6.27 1.01 0.85 87.9 0.40 14.1 1.71 1.12 0.94 
0.75 6.66 1.31 0.95 17.6 2.00 8.46 1.96 0.91 1.56 
1.50 6.10 1.21 0.93 8.79 4.00 5.32 1.99 0.94 2.48 
7.50 2.87 0.62 0.95 1.76 
Concurrent Treatment 0.00 8.16 3.34 1.10 - 0.00 2.14 0.78 0.97 1.03 
0.07 4.79 1.58 0.68 29.6 0.20 1.73 0.23 0.81 1.28 
0.37 2.99 0.79 0.57 5.91 1.00 0.73 0.21 0.46 3.04 
0.75 1.19 0.29 0.50 2,96 2.00 0.44 0.11 0.47 5.00 
Platinum Pre-sensitization 0.00 11.8 1.36 1.05 - O.OO 2.38 0.46 1.07 0.93 
0.15 9.42 1.26 0.91 14.8 0.30 1.38 0.23 0.65 1.61 
1.50 0.19 0.25 0.69 1.48 1.50 1.00 0.27 0.59 2.21 
0.00 0.00 0.00 0.00 0.00 3.00 0.86 0.14 0.66 2.57 
Oxaliplatin “ 
DMC Pre-sensitization 0.00 7.24 0,96 0.97 - 0.00 8.61 2.30 1.11 0.90 
0.14 5.66 1.20 0.78 57.0 0.40 6.55 0.87 0.89 1.19 
0.70 4.67 1.26 0.72 11.1 2.00 2.90 0.57 0.64 2.69 
1.40 3.04 0.56 0.59 5.55 4.00 1.27 0.04 0.70 6.13 
7.04 0.40 0,20 0.96 1.11 
Concurrent Treatment 0.00 7.14 0.92 0.96 - 0.00 1.60 0.26 1.08 0.92 
0.10 5,86 1.60 0.85 15.3 0.40 1.25 0.19 0.90 1.18 
0.50 4.38 0.67 0.93 2.97 2.00 1.15 0.24 1.05 1.28 
0.99 2.13 0.37 0.96 1.48 4.00 0.66 0.12 0.99 2.22 
Platinum Pre-sensitization 0.00 11.2 0.82 1.00 - 1.39 0.00 0.16 0.95 1.06 
0.06 10.5 0.87 0.97 24.6 1.05 0.15 0,16 0.73 1.40 
0.30 7.66 0.52 0.88 4.92 1.03 0.75 0.20 0.76 1.44 
0.60 3.44 1.81 0.71 2.46 0.79 1.50 0.12 0.67 1.86 
0.33 7.50 0.00 0.89 4.41 
Abbreviation: Combination Index (CI), Dose Reduction Index (DRI), Demethylcantharidin (DMC), Platinum (Pt), 
Standard Deviation (SD) 
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Appendix VIII a. i) Isobolograms for SK-Hepl CisR (Cisplatin, [Pt(DMC)(NH3)2] and 
[Pt(DMC)(CH3NH2)2])，X-axis is the concentration of platinum 
drugs in pM, y-axis is the concentration of D M C in \M. The 
enlarged dot indicates the most effective drug combinations with 
the data shown in bracket (platinum dose, D M C dose). 
Platinum Pretreatment Concurrent Treatment DMC Pretreatment 
识丄 • Antagonism 
“ f • • • • • Additive Effect 
y : ••••• Synergism 
* • 釅•癱 D M C Dose Fixed 
• • 〇 Platinum Dose Fixed 
• 卞 , • Line of Additivity 
Platinum Dose 
q iv 
° - \ (27.4,2.00) . (9.77,2.25) • (21.5,5.00) 
i ^ ： ^ - 塾 
§ __. . ._.__. _ . . . .__•__> ._,_._-o. •• . 
d ‘ 
o I • • 
一 ？ \ (10.0, 15.4) • (7.00. 7.27) • (10.4. '7:00) 
i 4 
g O J [Pt(DMC)(NH,), 
i 胃气. \ K 
、：i , i : � \ I A , 
B l\ : : 
° A (4.42. 10.0) . (7.97,1.00) • (11.3, 5.02) 
o [ \ ； I rPt(DMC)(CH,NH,), 
8 ‘ \ - - - ^ - K - -
§ _ % • C • • I — I _ _ _ I 命 ‘ I I I I I l ~ ： _ I I L — I 1 1 1 ~ 
°0 .00 50.00 50.00 10U. 50.00 100.00 
Platinum Dose (pM) 
146 
Appendix VIII a. ii)Raw Data for SK-Hepl CisR (Cisplatin, [Pt(DMC)_3)2] and 
[Pt(DMC)(CH3NH2)2]) 
Raw Data forSK-Hep1CisR 广*、DMC SD CI Pt DRI Pt SD CI Pt DRI 
(Fixed) (Fixsd) 
(JM HM mM MM |JM MM 
Cisplatin 
DMC Pre-sensitization 0.00 20.2 9.16 0.92 - 0.00 106 6.15 1.01 0.99 
0.90 17.4 1.38 0.80 117 0.10 104 18.0 0.99 1.02 
4.50 14.1 0.27 0.68 23.4 0.50 84.3 20.1 0.82 1.25 
9.00 9.09 1.67 0.50 11.7 1.00 62.6 5.31 0.64 1.68 
45.0 1.79 0.16 0.51 2.34 5.00 21.5 6.52 0.43 4.89 
90.0 0.64 0.17 0.89 1.17 10.0 6.91 1.72 0.52 15.2 
Concurrent Treatment 0.00 21.7 5.01 0.99 - 0.00 54.3 9.33 0.99 1.02 
0.75 17.0 2.61 0.79 73.4 0.45 18.0 3.06 0.35 3 0 6 
3.75 9.46 3.73 0.50 14.7 2.25 9.77 5.75 0.28 5 .64 
7.50 3.59 0.93 0.30 7.34 4.50 4.63 0.84 0.29 11 9 
37.5 0.19 0.04 0.69 1.47 
Platinum Pre-sensitization 0.00 40.3 20.7 0.91 - 0.00 57.0 29.5 1.03 0.97 
0.30 33.2 10.3 0.76 184 0.20 36.2 9.40 0.66 1 5 2 
1.50 31.7 0.24 0.74 36.7 1.00 31.6 4.99 0.60 1 7 4 
3.00 29.4 24.9 0.72 18.4 2.00 27.4 8.01 0.54 2^01 
15.0 17.8 11.5 0.68 3.67 10.0 20.0 0.41 0.59 2 .75 
30.0 1.41 0.26 0.58 1.84 20.0 11.8 4.43 0.67 � 6 7 
[Pt(DMC)(NH3)J 
DMC Pre-sensitization 0.00 21.5 8.65 0.98 - 0.00 27.5 3.80 1.00 1.00 
1.40 16.8 3.82 0.81 19.6 1.40 22.1 4.01 0.87 1:24 
7.00 12.0 0.85 0.80 3.92 7.00 10.4 0.65 0.70 2.63 
14.0 5.76 0.53 0.77 1.96 14.0 3.08 0.66 0.75 8.91 
Concurrent Treatment 0.00 22.6 0.00 1.03 - 0.00 19.0 5.81 0.97 1.03 
1.40 18.7 0.00 0.92 14.0 0.20 18.3 1.38 0.94 1 0 7 
7.00 7.27 0.00 0.69 2.79 1.00 15.8 0.19 0.85 1.24 
14.0 1.38 0.00 0.78 1.40 2.00 14.4 0.42 0.83 1.36 
10.0 5.04 0.47 0.71 3.88 
20.0 1.21 0.12 0.97 16.1 
Platinum Pre-sensitization 0.00 43.7 1.36 0.99 - 0.00 20.7 2.01 1.06 0,94 
I.00 43.6 2.90 1.04 19.5 0.54 18.3 3.42 0.95 1.07 
5.00 31.4 5.21 0.97 3.91 2.70 17.9 1.52 0.98 I.09 
10.0 15.4 3.32 0.86 1.95 5.40 16.5 3.33 0.96 I .19 
27.0 7.15 0.27 0.98 2 .73 
[Pt(DMC)(CH3NH2)2] 
DMC Pre-sensitization 0.00 20.2 9.16 0.92 - 0.00 43.7 1.65 1.05 0 .96 
2.25 15.3 0.75 0.75 18.6 0.10 35.5 9.06 0.85 I.IQ 
I I .2 5.02 0.26 0,50 3.71 0.50 30.9 3.04 0.76 1 .35 
22.5 2.86 0.65 0.67 1.86 1.00 28.2 5.75 0.72 1.48 
Concurrent Treatment 0.00 21.7 5.01 0.99 - 0.00 28.5 6.67 1.15 0 .87 
3.75 5.57 0.50 0.41 6.57 0.10 16.8 7.48 0.69 1.46 
18.7 0.25 0.10 0.77 1.31 0.50 10.2 2.62 0.44 2.41 
1.00 7.97 2.36 0.37 3 .09 
5.00 4.73 2.21 0.42 5.21 
10.0 1.08 0.30 0.50 22 .8 
Platinum Pre-sensitization 0.00 47.6 9.63 1.08 - 0.00 24.6 4.78 1.00 1.00 
0.75 30.4 14.4 0.72 32.9 0.20 16.7 3.30 0.68 1 .43 
3.75 11.4 4.99 0.41 6.57 1.00 14.2 5.37 0.60 I .73 
2.00 9.86 1.99 0.45 2 .50 
10.0 4.42 1.56 0.41 5 .57 
20.0 1.01 0.11 0.49 24 .3 
Abbreviation: Combination Index (CI), Dose Reduction Index (DRI), DemethylCantharidin (DMC), Platinum (Pt), 
Standard Deviation (SD) 
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Appendix VIII b. i) Isobolograms for SK-HeplCisR ([Pt(DMC)(7?,/?-DACH)] and 
Oxaliplatin), x-axis is the concentration of platinum drugs in JJM, 
y-axis is the concentration of DMC in nM. The enlarged dot 
indicates the most effective drug combinations with the data shown 
in bracket (platinum dose, DMC dose). 
Platinum Pretreatment Concurrent Treatment DMC Pretreatment 
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g • • • • • Additive Effect 
o V . ••• • Synergism 
IS • • 
� 
** 鼸 D M C Dose Fixed 
*••** • • 〇 Platinum Dose Fixed 
• , I Line of Additivity 
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8 i [ [ ZII 
？ 〕\  (0.96,6.87) . (1.00,4.50) • (4.15, 5.00) 
• \ • • 
• \ • • 
§ ；..i ；^  
s 8 , . 」 •.二 
^ d J 
O 1 [ : : 
S ^ I (0.38, 10.0) (0.17,4.50) (6.29. 1.00) 
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s ‘ i 
P 卜 \ 
o ‘ _____ I •_•__•••• • iL^i 111111111111111 — 1 1 1 1 1 fcui 11' • ' 1Q 1 
•0.00 5.00 10.00 15.00 5.00 10.00 15.00 5.00 10.00 15.00 20.00 
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Appendix VIII b. ii) Raw Data for SK-Hepl CisR ([Pt(DMC)(i^,/?-DACH)] and 
Oxaliplatin) 
Raw Data for SK-Hep1CisF DMC SD CI Pt DRI Pt SD CI Pt DRI 
(Fixed) (Fixed) 
MM MM MM pM pM jjM 
[Pt(DMC)(R,/?.DACH)] 
DMC Pre-sensit izat ion 0.00 20.2 4.22 0.92 - 0.00 17.3 3.71 1.06 0 .94 
0.22 16.4 7,61 0.76 72.4 0.10 15.9 4.37 0.98 1 .03 
1.12 13.2 5.15 0.67 14.5 0.50 12.7 3.21 0.80 1.28 
2.25 8.09 1.65 0.51 7.24 1.00 11.2 1.55 0.73 1.46 
5.00 4.15 2.34 0.48 3 .93 
10,0 1.37 0.10 0.54 1 1 . 8 7 
Concurrent Treatment 0.00 20.2 4.20 0.92 - 0.00 4.30 0.91 0.98 1 .02 
0.15 13.5 2.66 0.65 29.1 0.45 3.17 0.49 0.75 1.38 
0.75 7.92 2.07 0.53 5.82 2.25 2.91 0.03 0.77 1 .50 
1.50 3.17 0.81 0.49 2.91 4.50 1.00 0.11 0.43 4 .36 
Platinum Pre-sensit izat ion 0.00 44.1 7.88 1.00 - 0.00 4.63 0.39 1.06 0 .94 
0.04 41.6 5.92 0.95 116 0.14 3.10 0.25 0.71 1 4 1 
0.19 36.8 13.83 0.88 23.3 0.69 2.72 0.20 0.64 1.60 
0.37 19.3 6.74 0.52 11.6 1.37 1.71 0.22 0.42 2 . 5 5 
1.87 2.06 0.70 0.48 2.33 6.87 0.96 0.24 0.37 4 .56 
3.75 0.31 0.10 0.87 1.16 13.7 0.53 0.14 0.43 8 .17 
Oxaliplatin ‘ ‘ 
DMC Pre-sensit ization 0.00 21.67 14.1 0.99 - 0.00 17.2 4.77 0.96 1 .04 
0.15 15.51 7.28 0.71 120 0.10 16.6 4.64 0.93 r 0 8 
0.75 13.46 7.88 0.65 23.9 0.50 6.96 1.03 0.41 2 . 5 8 
1.50 11.26 2.99 0.60 12.0 1.00 6.29 1.35 0.40 2 . 8 5 
7.50 0.89 0.05 0.46 2.39 5.00 4.28 1.98 0.47 4 . 2 0 
15.0 0.21 0.10 0.84 1.20 10.0 2.02 0.15 0.57 8 . 8 8 
Concurrent Treatment 0.00 20.2 4.20 0.92 - 0.00 1.40 0.63 0.91 1 .09 
0.04 15.8 1.41 0.75 34.1 0.45 0.52 0.12 0.36 2^96 
0.22 4.54 2.60 0.35 6.82 2.25 0.38 0.04 0.35 4 . 0 7 
0.45 1.41 0.44 0.36 3.41 4.50 0.17 0.02 0.31 9 . 1 7 
Platinum Pre-sensit ization 0.00 48.1 15.2 1.09 - 0.00 1.52 0.28 0.99 i . o i 
0.00 33.2 1.01 0.75 341 0.20 0.88 0.33 0,58 1.75 
0.02 29.4 11.2 0.68 68.2 1.00 0.86 0.69 0.58 I.79 
0.04 25.3 1.08 0.60 34.1 2.00 0.67 0.06 0.48 2.29 
0.22 17.3 5.91 0.54 6.82 10.0 0.38 0.04 0.47 4.07 
0.45 9.68 2.82 0.51 3.41 20.0 0.15 0.03 0.55 10.4 
Abbreviation: Combination Index (CI), Dose Reduction Index (DRI), DemethyiCantharidin (DMC), Platinum (Pt), 
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